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Neutrophils, the most abundant leukocyte arrive at the site of infections to eliminate 
pathogens, particularly by using reactive oxygen species (ROS). They contain the 
antioxidant glutathione (GSH) to maintain homeostasis and combat ROS induced 
intracellular damage. Intracellular GSH is essential for a number of homeostatic and 
cellular processes, including chemotaxis and is the main intracellular redox buffer. 
During oxidative stress, protein modification by glutathionylation helps defend against 
oxidative damage.  
The aim of this work was to investigate the role of redox balance in the aberrant 
chemotactic phenotype observed in neutrophils, particularly from periodontitis 
patients.   
In healthy neutrophils, GSH modulating compounds (buthionine sulfoximine, N-
acetylcysteine, carmustine and 1-chloro, 2-4 dinitrobenzene) were used to change 
GSH levels: showing that decreased GSH was associated with a decreased 
chemotactic ability. In periodontitis patients there was less GSH in neutrophils in 
comparison to healthy donors, but it increased after successful non-surgical treatment. 
A similar pattern was observed for neutrophil chemotaxis. This demonstrated a link 
between these two factors in the same cells for the first time.  Proteomic analysis of 
extracts from patient and control neutrophils demonstrated modulation of glutathione 
regulation in periodontitis patients. 
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Chronic periodontitis is a dental disease characterized by non-resolving inflammation 
which leads to host mediated tissue damage and bone loss around the teeth (Hasturk 
and Kantarci, 2015). It is initiated by the biofilm but exacerbated by the host response 
which leads to tissue and bone destruction (Graves and Cochran, 2003). Among the 
symptoms of periodontitis are redness and bleeding gums, swollen gums, loose gums 
and teeth, pain on biting as well as bad breath. It is a common infection affecting 11% 
of the population in its most severe form and over 50% of people over the age of 65 
years in any form (Nazir, 2017). The human oral tissues are always exposed to 
potential and harmful microorganisms and to combat the infections in this area, 
leucocytes are attracted to and infiltrate into the tissues from the blood stream in 
response to chemoattractants (Gamonal et al., 2001). A strong neutrophil tissue 
infiltrate is a characteristic of this disease (Van Dyke, 2007). 
Chronic periodontitis can also exert a wide range of systemic effects. A study by Nicu 
et al., (2009) hypothesized that stimulation by periodontal pathogens has shown 
platelets and leucocytes to be more sensitive than normal cells. In previous studies, it 
has been shown that patients with periodontal infection have a higher white blood cell 
and platelet count compared to healthy controls (Al-Rasheed, 2012). Activated 
platelets regulate chemokine release by the monocytes in inflammatory lesions 
(Weyrich et al., 1996). A study found that activated platelets and leucocytes might 
cause an increase in atherothrombotic activity and eventually leads to atherosclerosis 
and coronary artery disease (Zeviani et al., 2009), therefore, treatment of periodontitis 
may be beneficial in control of atherosclerosis because control of periodontitis 
significantly decreases serum mediators and markers of acute phase response 







Periodontal disease is a chronic inflammatory disease and has been associated with 
other diseases such as rheumatoid arthritis and chronic kidney disease. Rheumatoid 
arthritis (RA) is a chronic inflammatory joint disease which causes damage to the bone 
and cartilage (Muller, 2018). There are a number of studies that have suggested an 
epidemiological, serological and clinical association between RA and periodontitis, 
where the bi-directionality in that RA affects manifestation of periodontitis and contrary, 
periodontitis is a risk factor for RA  (de Pablo et al., 2009; Potempa et al., 2017). There 
are suggestions that periodontitis could be the causal factor in the initiation and 
maintenance of the inflammatory response that occurs in RA (de Pablo et al., 2009). 
Citrullination has played a role in the development of rheumatoid arthritis and the 
recognition that oral bacteria and inflammation may play important roles (Bingham and 
Moni, 2013). There was a discovery that Porphyromonas gingivalis which is involved 
in the development of periodontal disease has a peptidylarginine deiminase enzyme 
which is capable of citrullination peptide has said to be the mechanistic link between 
periodontal disease and rheumatoid arthritis (Bingham and Moni, 2013).  
Periodontitis has said to be a potential risk for chronic kidney disease. Periodontitis 
increased the inflammatory burden of this chronic kidney disease where pathogens 
that cause the destruction of periodontal tissues and entry of this pathogen will go in 
systemic circulation causing increased systemic inflammation (Wahid et al., 2013). 
There are also studies mentioned that chronic kidney disease affects teeth, oral 
mucosa, periodontium and salivary glands which leads to negative effect of the oral 
hygiene and periodontal status of the patient (Summers et al., 2007).  
Periodontitis has been associated with other systemic disease including respiratory 
diseases, cardiovascular disease and pre-term labour (Ohyama et al., 2009). In 
addition, periodontitis has been a potential risk for increased morbidity and mortality 
for diabetes and complications of pregnancy (Fowler et al., 2001). One of the possible 
mechanisms linking periodontitis with other systemic disease is that the spread of 
infection from the oral cavity caused by immunological injury induced by oral 






Figure 1.1 shows structure of a normal tooth and a tooth that has periodontitis disease. 
Irreversible destruction of the bone and gum holding the tooth are the causes of 
periodontitis shown in the figure.  
 
Figure 1.1: Structure of normal tooth and tooth that has periodontitis. Image from 
shutterstock.com.  
1.2 Neutrophils 
Neutrophils are the most abundant white blood cells, or leucocytes, they are short-
lived, do not divide and cannot easily be genetically modified (Dale et al., 
2008),(Bishop et al., 1968)(Cartwright et al., 1964). They are essential for immune 
defence and contain various antimicrobial proteins and peptides.  
Along with other cells, such as basophils and eosinophils, neutrophils are members of 
the granulocyte family of leucocytes. Neutrophils have the fastest response of towards 
a site of infection of injury. At the site of infection detect foreign particles such as 
bacteria and viruses via pathogen associated molecular patterns (PAMP) or signals 
from damaged tissues, such as adenosine triphosphate (ATP), damaged associated 





of macrophages and endothelial cells after activation of pathogen recognition receptor 
(PRR) such as Toll-like receptors. Then, these endothelial cells release 
chemoattractants to attract circulating neutrophils in the blood stream toward the 
vessel wall.  The rolling neutrophils are brought into contact with the endothelial cells, 
so chemokines can further activate neutrophils and other pro-inflammatory agents on 
the surface of the endothelial cells (Sadik et al., 2011). Selectin ligand in the neutrophil 
binds to E-selectin and P-selectin, meanwhile β2 integrin binds to intercellular 
adhesion molecule 1 (ICAM-1) as in figure 1.2. Activated neutrophils undergo a cell 
shape change from round to flat and highly polarized (Filippi, 2016). This shape 
enables the cell to migrate on the endothelial surface to cross the endothelial cells that 
lines the blood vessel. This process is called diapedesis. After passing the endothelial 
barrier, neutrophils must cross the pericyte layer in the basal membrane to enter the 
inflamed tissues. There are two ways that neutrophils can cross the endothelial cells, 
by transcellularly, where the cells pass through the endothelial cells themselves (Feng 
et al., 1998), or paracellularly, where cells travel between endothelial cells in amoeboid 
fashion (Schmidt et al., 2011). For transendothelial migration (TEM) (Muller, 2013) or 
diapedesis, the neutrophil forms actin-rich podosomes that indent the endothelium, 
then, actin-enriched projections are formed by the endothelium which leads to 
formation of ‘transmigratory cup’ around the neutrophil (Filippi, 2016). For paracellular 
migration, neutrophil crawls along the endothelial cell surface to the intercellular 
junctions, which then lamellopodia extends between endothelial cells to disrupt the 
intercellular junction, followed by translocation of the cell through the inter-endothelial 
junctions (Schmidt et al., 2011). They then migrate through the interstitial tissue (Ley 
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1.3 Neutrophil granules  
Neutrophils are granulocytes and as such contain high numbers of granules, which 
contain proteins and reactive substances used in the killing of microbes. The granules 
are classified by their stage of formation in the bone marrow. There are several types 
of granules that neutrophils contain which are azurophilic (primary) granules, specific 
(secondary) granules, gelatinase-rich (tertiary) granules and secretory vesicles. 
During degranulation, neutrophil granules containing antimicrobial substances are 
delivered to the phagosome or the exterior of the cell (Faurschou and Borregaard, 
2003). Exocytosis is the effect of fusion of granule membrane with the plasma 
membrane and integration of granule membrane into the plasma membrane. 
Therefore, membrane proteins in the membrane granules transfer to the surface 
membrane and provide the neutrophil with new receptors and other functional proteins 
(Borregaard and Cowland, 1997). When neutrophil is in rolling contact with activated 
endothelium, secretory vesicles are mobilized which is mediated by selectins and their 
ligands (Borregaard and Cowland, 1997). Incorporation of the plasma membrane of 
secretory vesicles causes firm adhesion of the neutrophil to the endothelium. 
Mobilization of specific granules to the surface membrane could intensify phagocytic 
capacity of the neutrophils. In the phagosome, the fusion of azurophil and specific 
granules could bring conditions for independent bacterial activity (Borregaard and 










1.4 Neutrophil NETs (neutrophil extracellular traps) 
Neutrophils can release neutrophil extracellular traps (NETs) to control microbial 
infections. NETs are decondensed nuclear chromatin which makes a web-like 
structure that consist of chromatin backbones, histones and antimicrobial proteins 
(Manda et al., 2014). NETs are formed in response to a range of pathogens, including 
bacteria, viruses, fungi, and protozoa as well as host-derived mediators. NETs act to 
contain and destroy pathogenic organisms. NETs offer fundamental defence strategy 
to prevent infiltration of bacteria that is important for health and are produced in 
response to bacteria stimuli including Gram-negative and Gram-positive bacteria 
(Kaplan and Radic, 2012).  
1.5 Production of ROS, NADPH, other mechanisms  
One of the roles of the neutrophil is the uptake and killing of invading microbes (Stabel 
et al., 2002). The physiological function of phagocytes is the killing of microbes. The 
general aspects of the process of phagocytosis are that the contents of neutrophil 
granules degrade microbes ingested by the neutrophils (Dale, Boxer and Liles, 2008). 
A respiratory burst, which is also known as an increment in neutrophil oxygen 
consumption, occurs during phagocytosis (Dahlgren and Karlsson, 1999). 
Myeloperoxidase (MPO) released from granules during phagocytosis generates 
hypochlorous acid (HOCI), a potent antimicrobial substance (Klebanoff, 1968); 
hydrogen peroxide (H2O2) and other reactive oxygen species are produced via 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (Babior et al., 1976). 
Figure 1.3 shows the diagram of MPO-H2O2-chloride antimicrobial system where 
NADPH oxidase causes the generation of H2O2 and other ROS. Then, MPO combines 
H2O2 and chloride to generate HOCI as an antibacterial substance within the 
phagosome (Klebanoff, 1968). Phagocytosis with generation of reactive oxygen 
species and hypochlorous acid is still the killing mechanism for most pathogens even 
though phagocytes have other microbial mechanism such as antimicrobial peptides 





In regulation of neutrophil activation and chemotaxis, CXC chemokines play a central 
role (Doroshenko et al., 2002). Chemotactic cytokines and chemokines cause the 
migration and movement of neutrophils. Chemokines are small chemotactic proteins, 
for example interleukin-8 (CXC8). Chemokine receptor 1 (CXCR1) has high affinity for 
interleukin-8 and low affinity in other chemokines  whereas chemokine receptor type 
2 (CXCR2) has a high affinity for all CXC chemokines that contains N-terminal Glu-
Leu-Arg motif (Schumacher et al., 1992). Exploration of the effect of phagocytic stimuli 
in human neutrophils on the expression of CXCR1 and CXCR2 of interleukin 8 
receptors found that levels of CXCR1 and CXCR2 were constant during phagocytic 
stimulation of neutrophil. However, after phagocytosis, expression of CXCR1 and 
CXCR2 was down-regulated and Ca++ responses were reduced to ligands, interleukin-
8 and neutrophil activating peptide 2. Therefore, this study suggested that down-
regulation of CXCR expression may reduce the responsiveness of phagocytosing 
neutrophils to CXC chemokines (Doroshenko et al., 2002). It is already known that 














Figure 1.3: The MPO-H2O2-chloride antimicrobial system. NADPH represents reduced nicotinamide adenine dinucleotide 





1.6 Neutrophil ROS and NET production and degranulation in periodontitis  
Neutrophil homeostasis is required for periodontal health as they protect the 
periodontal tissues from damage and they are commonly found in the gingival crevice 
and epithelium area (Hajishengallis and Hajishengallis, 2014). By killing various 
pathogenic bacteria either by non-oxidative or oxidative means in an intracellular or 
extracellular environment, neutrophils are able to protect the host tissue.  
It is hypothesized that protease inhibitors present in biological fluids can be inactivated 
by reactive forms of oxygen that were produced in vivo in localized aggressive 
periodontitis (LAP) patients (Bhansali et al., 2013). Meanwhile, neutrophil-produced 
matrix metalloproteinases (MMPs) can be activated by reactive oxygen species 
(Bhansali et al., 2013). It is possible that reactive forms of oxygen produced by 
neutrophils are particularly important factors causing tissue damage in periodontitis 
(Bhansali et al., 2013). A phenomenon that is associated with periodontitis is the 
determinant of oxidative stress which is the rate of reactive oxygen species (ROS) 
(Dias et al., 2011; Matthews et al., 2007). A study done by Chapple and Matthews, 
suggested a dual role for neutrophils in the production of oxidative tissue damage, 
involving a potentially reversible Fcɤ-receptor-mediated hyperactivity and a 
constitutional hyperactivity relative to baseline oxygen radical release (Matthews et 
al., 2007).  
NETs release is elevated in periodontal pockets of periodontitis (Hirschfeld et al., 
2017). The manifestation of periodontitis disease in not merely oral but systemic as 
peripherally isolated neutrophils display aberrant ROS production, chemotaxis, 
cytokine production and altered transcription activity (Matthews et al., 2007a; 
Matthews et al., 2007b; Roberts et al., 2015). From our previous group, a study 
completed by (Ling et al., 2016) reported that neutrophils from chronic periodontitis 
patients released more superoxide compared to control group before periodontal 
treatment and the superoxide release was reduced to control cell levels after 
treatment. It was also reported that there is a positive relationship between neutrophil 
superoxide release and plasma C-reactive protein (CRPA) which shows that CRP has 
a protective role in reducing inflammation. It is hypothesised that defects in the 





by (Van Dyke et al., 1980) indicate that there was impairment of neutrophil chemotactic 
ability on LAP patients due to cell-associated defect which suggests that neutrophils 
plays a protective role against periodontal infection.   
Periodontal disease is characterized by involvement of chemokines for recruitment of 
neutrophils. CXC chemokine ligand 16 (CXCL16) is produced by human gingival 
fibroblast (HGF) and its receptor, CXCR6 are expressed at the messenger RNA 
(mRNA) and protein levels may be involved in neutrophil migration into periodontal 
disease inflamed tissues (Hosokawa et al., 2007). 
1.7 Neutrophil chemotaxis 
Chemotaxis is a process where white blood cells are attracted to chemical factors 
released at the site of infection by directed cell motility. When an infection occurs, 
chemical factors are released that attract white blood cells to the site of infection. The 
attraction of white blood cells is called chemotaxis. The primary white cells attracted 
are neutrophils and macrophages. Both cells phagocytize the invader. Chemotaxis is 
a directional movement of cells through a concentrated gradient of a chemoattractant. 
Chemotaxis is a dynamic process that requires cell polarization, directional sensing, 
cell adhesion and motility and is a process where cells interact with the 
chemoattractant, transmit signal across plasma membrane and therefore, localize the 
response (Janetopoulos and Firtel, 2008).  
Factors that cause the directional cell movement are identified as chemoattractants. 
Chemoattractants such as interleukin-8 (CXCL8) and N-formylmethionyl-leucyl-
phenylalanine (fMLP) attract neutrophils to the site of infection. fMLP is a bacteria-
derived product, causes the strongest migration and fastest directional movement 
whereas chemokine CXCL8 is a weak chemoattractant compared to fMLP and causes 
a lesser amount of migration. fMLP can be detected by G protein-coupled receptors 
(GPCRs), and chemokines such as CXCR1: these chemoattractants activate 
signalling cascades via receptor binding to initiate movement. Receptors can be 
recycled back to the membrane for degradation (Samanta et al., 1990). In chemotaxis, 





processes which are cell polarization, directional sensing, cell adhesion and motility 
(Janetopoulos and Firtel, 2008; Kolaczkowska and Kubes, 2013).  
Formation of new pseudopods at the leading edge and retraction at the posterior edge 
of the cells occurs when chemoattractant is detected (Andrew and Insall, 2007). 
Reactive oxygen species (ROS) produced by NADPH oxidases are generated by 
chemoattractant stimulation and play a role in signal transduction of cell movement 
(Dickinson et al., 2012). ROS derived from NADPH oxidase maintain neutrophil 
pseudopod formation and chemotactic behaviour through actin glutathionylation and 
polymerisation (Sakai et al., 2012). It has been shown that when NADPH oxidase is 
inhibited, chemotaxis inefficiency can occur among neutrophils from healthy donors 
which are exposed to a chemoattractant (Sakai et al., 2012).  Similarly, (Niethammer 
et al., 2009) showed that hydrogen peroxide (H202) can permeate the plasma 
membrane and allows directional cell motility towards the chemotactic gradient. 
Hydrogen peroxide is a secondary messenger that mediates its effects through 
oxidation of cysteine thiols. Fluorescence imaging microscopy has been used to show 
that motile cells generate H202 at membranes and cell protrusions (Cameron et al., 
2015). H202 inhibits cofilin, part of the cytoskeletal machinery, activity through oxidation 
of cysteines and helps with cell motility which indicates that H202 contributes to 
polarized cell motility through cofilin inhibition (Cameron et al., 2015). 
1.8 Measuring chemotaxis 
Chemotaxis can be analysed by direct or indirect chambers. Direct visualization 
chambers, for example the Insall Chamber are used for measuring and analysing 
chemotactic responses as they allow analysis of cell behaviour during the process of 
chemotaxis by video microscopy. This assay can directly visualize the process of cell 
motility (Muinonen-Martin et al., 2013), and allows consistent oriented gradients and 
use of standard thickness coverslips for aberration free microscopy and short working 
distance objectives.  
 
An indirect chamber example is the Transwell Boyden Chamber assay, where 
chemoattractant gradients are put in a 96-well plate and neutrophil cells on the filter 





Chamber assay is based on a chamber of two liquid-filled compartments separated by 
a microporous membrane (filter). In this assay, cells are placed in the upper 
compartment and allowed to migrate through the pores of the membrane to the lower 
compartment where chemoattractant such as fMLP, are present. The number of cells 
that have migrated to the lower compartment is determined. A potential involvement 
of an intracellular signalling pathway or cell surface protein in cell motility can also be 
examined using this assay (Chen, 2005) by manipulating the cells with inhibitors. For 
example, research done using neutrophil cells incubated with different concentrations 
of non-steroidal anti-inflammatory drugs (NSAIDs) on chemotaxis found that migration 
was inhibited in response to interleukin-8 (Bertolotto et al., 2014).  
1.9  Neutrophil chemotaxis in periodontitis 
In the gingival tissues of dental plaque, an inflammatory infiltrate is usually present 
with lymphocytes and neutrophils comprising most of the infiltrate. Neutrophil cell 
migration to the inflammation area maybe in response to chemotactic substances 
released by the bacteria or complement system activated by bacteria antigens that 
produce chemotactic factors (Mergenhagen et al., 1970).  
Impaired neutrophil chemotaxis seems to be one of the risk factors in the development 
of periodontal disease. The Insall and Boyden Chamber assays have been used to 
study neutrophil chemotaxis in chronic periodontitis. A study using the Insall Chamber 
on chemotaxis reported that speed, velocity and chemotactic accuracy was 
significantly reduced in chronic periodontitis patients compared to healthy controls for 
Interleukin-8 and fMLP chemoattractant (Roberts et al., 2015). A study done by (Van 
Dyke et al., 1980) showed that localized aggressive periodontitis (LAP) patients have 







1.10 Introduction to antioxidants in the body  
Reactive oxygen species (ROS) can be beneficial when in controlled situations but 
when rampant will cause damage to the body. Low levels of ROS refer to redox biology 
that activates signalling pathways while high levels of ROS refer to oxidative stress 
which can incur damage to lipids, protein and deoxyribonucleic acid (DNA) (Schieber 
et al., 2014). Oxidative stress is an imbalance between oxidants and antioxidants 
within a cell, tissue or organism. Cell damage can result if the imbalance is severe 
enough. This imbalance can be an effect of increased production of ROS and/or 
depletion of antioxidants. Free radicals found in living organisms, originate from 
reactive oxygen species (ROS) or reactive nitrogen species (RNS) (Cooper et al., 
2002; Fisher-Wellman & Bloomer, 2009). Overproduction of free radicals may cause 
oxidative damage to biomolecules, which, if severe, can cause toxic and may lead to 
cell death. Free radicals can attack lipids, proteins and nucleic acids (Beckman and 
Ames, 1998). Oxidative stress due to imbalance between antioxidants and oxidants 
may lead to disruption of redox signalling and/or molecular damage. There is a 
physiological system to balance this potential for damage via antioxidants. Therefore, 
an antioxidant system needs to be in place to maintain a well-balanced production and 
elimination of ROS. There are enzymatic ways of removing oxidants such as catalase, 
superoxide dismutase (SOD) and also non-enzymatic ways of balancing ROS which 
are small molecule antioxidants such as vitamins and glutathione. They can be 
hydrophilic and hydrophobic to allow for control of different compartments, for 
example, lipid membranes and cytosol or aqueous compartments. Many antioxidants 
in circulation are found intracellularly. Antioxidants are important as they can eliminate 
reactive oxygen species (ROS) from the body. In many human diseases, a higher 
amount of ROS plays a pivotal role, and this may damage the body’s cells. In a 
previous study, it was found that there is overproduction of ROS and lower levels of 
glutathione in periodontitis patients (Dias et al., 2013). This caused oxidative stress 
because of imbalance of ROS and antioxidants in periodontitis patients. 
An ideal antioxidant is the one that can absorb and quench free radicals at 
physiologically relevant levels. Glutathione peroxidase, catalase and superoxide 
dismutase are considered the most efficient enzymatic antioxidants (Matés et al., 





natural flavonoids and other compounds (McCall and Frei, 1999). Thiols and vitamins 
like E and C are example of antioxidants that can inhibit the oxidation process. It is 
important to have antioxidants as it prevents or slows down the oxidative damage 
throughout the body.  
1.11 Glutathione  
Glutathione (GSH) acts as the primary antioxidant against free radicals produced by 
toxic chemicals (Masella et al., 2005). It is considered the most important of our body’s 
antioxidant, especially since it is found in every cell of the body. It is also essential for 
a number of homeostatic and cellular processes including chemotaxis and is the main 
intracellular redox buffer. Glutathione is an antioxidant that neutralizes free radicals 
due to the high electron-donating capacity of its sulfhydryl-group (-SH) group and 
prevents damage to important cellular components. GSH is also involved in a 
multitude of cellular functions such as protein synthesis.  
GSH exists in the form of thiol-reduced and disulphide-oxidized (GSSG) (Kaplowitz et 
al., 1985). The structure of GSH in figure 1.4. Glutathione (ɤ-l-glutamyl-l-
cysteinylglycine, GSH) is a ubiquitous tripeptide in mammalian systems, where its 
intracellular concentration can be as high as 10mM (Appenzeller-Herzog, 2011). 
Amino acid homocysteine is produced in the body through the metabolism of amino 
acid methionine. For GSH creation homocysteine is the broken down into amino acid 
cysteine. Cysteine is needed by cells to make intracellular glutathione where it is 
combined with glutamate by gamma- glutamyl cysteine synthase, this product is then 
combined with glycine by glutamate synthetase to form the tripeptide. Glutathione is 
the most abundant low molecular weight peptide in eukaryotic cells (Johansson et al., 
2014), acts as a nucleophilic scavenger, protecting the cells by functioning as an 
antioxidant and by detoxifying electrophilic species (Johansson et al., 2014). It acts as 
an antioxidant by interacting with ROS and electrophiles. GSH acts with other redox-
active compounds such as nicotinamide adenine dinucleotide phosphate (NADPH) to 
regulate and maintain cellular redox status (Jones et al., 2011). Glutathione also 
functions as reserve form of cysteine, stores and transports nitric acid, participates in 





transcription factors such as in redox signalling and detoxification of endogenous 
compounds and xenobiotics (Lushchak, 2012). 
Cellular GSH can be found in amount of 80-85% in cytosol, about 10-15% in the 
mitochondria and in the endoplasmic reticulum, there is small percentage of GSH 
(Hwang et al., 1992; Meredith and Reed, 1982). The liver plays a role in the 
homeostasis of GSH where most of the plasma GSH originates (Ookhtens and 
Kaplowitz, 1998). 
In figure 1.5, is a diagram of GSH redox cycle. The primary function of glutathione is 
maintenance of intracellular redox homeostasis as this redox cycle can protect 
endothelial cells against oxidative stress. Through the action of GSH peroxidase 
(GPx)-catalysed reactions, the antioxidant function of GSH is achieved: the reduction 
of hydrogen peroxide and lipid peroxide while GSH is oxidized to GSSG. The GSSG 
is then reduced back to GSH by GSSG reductase forming a redox cycle. GSSG 
accumulates inside the cell and the ratio of GSH/GSSG is a good measure of oxidative 
stress  (Dro, 2002). GSH also plays a key role in protein redox signalling. GSH are 






 Figure 1.4: Structure of the tripeptide reduced glutathione (GSH: L-g-glutamyl-L-cysteinyl-glycine).  
Structure from Pubchem Open Chemistry database 

























Glutathione is responsible to maintain redox balance by directly or indirectly reacting 
with ROS and is involved in detoxification of electrophiles. Certain phytochemicals 
may effect GSH action on ROS and electrophiles by directly interacting with ROS and 
electrophiles or by upregulating defensive enzymes. Level of intra and extracellular 
GSH is determined by balance between its production, consumption and 
transportation.  Efforts have been done to decrease or increase GSH levels in 
organisms. In the redox cycle, cellular GSH can be depleted by increasing GSH 
oxidation to oxidized glutathione (GSSG), by inhibition of biosynthesis, or by 
inactivation of genes encoding the enzymes of GSH synthesis. GSH levels can also 
be inhibited by key enzyme of GSH biosynthesis and by externally added 
electrophiles. Increment of GSH levels could be done by cysteine in the form of 
different esters. Any modification of a parameter may give different results in diverse 
processes. For example, the increment of GSH level through supplementation of its 
esters can increase defence mechanisms.  
Catalase, or the glutathione peroxidase-glutathione reductase system may detoxify 
hydrogen peroxide (H2O2) in cells (figure 1.2). In this glutathione redox cycle, oxidation 
of reduced glutathione by H2O2 is catalysed by glutathione peroxidase. It is then 
reconverted by glutathione reductase to form reduced glutathione. At several points in 
vitro, this glutathione redox cycle will be disrupted (Alton, 1983). Carmustine (BCNU) 
is a selective inhibitor for glutathione reductase (Kehrer, 1983). Reduced glutathione 
can be depleted by formation of a thioether conjugate such as 1-chloro-2,4-
dinitrobenzene (CDNB) which is catalysed by endogenous glutathione-s-transferase 
(Sherratt and Hayes, 2002). Buthionine sulfoximine (BSO) is a selective inhibitor of Ɣ-
glutamyl-cysteine synthetase and may inhibit glutathione biosynthesis (Alton, 1983, 
Griffith, 1982). The glutathione redox cycle is disrupted at several points to modulate 
oxidant injury to endothelial cells in culture. Carmustine (BCNU) is a selective inhibitor 
of glutathione reductase and CDNB depleted cellular stores of reduced glutathione 
and BSO inhibits glutathione synthesis (Harlan at al., 1984). 
Post-translational modification (PTMs) is a chemical modification in which properties 
of protein are altered after its translation, for example by addition of a modifying group 
to one or more amino acids or by proteolytic cleavage. Besides that, PTMs are also 





stability, activity and functions of the proteins. Oxidative modification is an exposure 
of some protein thiols to oxidising reagents through variety of mechanisms that 
involves ROS, nitric oxide or glutathione  (Birben et al., 2012). Protein glutathionylation 
is a modification that can modify protein characteristics and functions. Many proteins 
contain free thiols that could be modified by the reversible formation of mixed 
disulphides with glutathione. This modification occurs when the protein thiol group 
goes through oxidation in response to ROS and reaction with GSH to form protein-
glutathione mixed disulphide adducts (PSSG). At cellular signalling, this modification 
may serve to transduce oxidative stimuli into functional response and as an adaptive 
response to protect thiol groups in protein (Shao et al., 2012) as thiol groups in reactive 
sites may be modified thereby inhibiting enzymatic activity and influencing signalling 
cascades.  
1.12  Glutathione in periodontitis  
Glutathione is considered an important redox regulator that controls inflammatory 
process and damage to the periodontium. There are therapeutic considerations for the 
use of glutathione in management of periodontitis for limiting the tissue damaged 
caused by oxidative stress (Bains and Bains, 2015). Oxidative stress is involved in 
many chronic inflammatory disease, such as periodontitis (Kumar et al., 2017), 
diabetes mellitus (Asmat et al., 2016) and atherosclerosis (Vogiatzi et al., 2009), and 
it is key to understanding underlying mechanisms that new therapies might be 
developed. 
Intracellular glutathione is essential for a number of homeostatic and cellular 
processes, including chemotaxis (Sakai et al., 2012).  Neutrophils from periodontitis 
patients have decreased intracellular glutathione (Dias et al., 2013). Previously (Dias 
et al., 2013) have demonstrated that incubation of neutrophils, isolated from 
periodontitis patients, with sulforaphane increases intracellular glutathione.  
In gingival crevicular fluid (GCF), neutrophils are considered significant contributors 
for the high concentrations of glutathione. This maybe the result of increased synthesis 
by cells of the periodontal tissues, or of active release mechanisms or of passive 





Matthews, 2007). A study by (Chapple et al., 2002) observed that glutathione 
concentrations are reduced in chronic periodontal diseases compared to control in 
GCF. These lower concentrations of glutathione could be due to several factors 
resulting in decreased synthesis and/or enhanced local degradation which may involve 
defect in Ɣ-glutamyl pathway of glutathione synthesis. Then, a study (Grant et al., 
2010) showed improvement in glutathione concentrations in GCF following periodontal 
therapy. 
1.13 Mass spectrometry  
Mass spectrometry is a powerful technique that has transformed the detection of 
proteins in biology (Haag, 2016): through development of methods and 
instrumentation. Mass spectrometers consist of the ionisation source and the mass 
analyser. 
The ionization source of a mass spectrometer introduces charges to the molecules of 
interest in the sample. Types of ionisation are electrospray ionisation (ESI) and matrix 
assisted laser desorption (MALDI). For ESI, protein sample flows through a capillary 
where voltage is applied and generates ionised droplets. These ionised droplets are 
vaporised, and ions are drawn into the mass spectrometry source. MALDI converts 
non-volatile macromolecules into ionized molecules by using short intense pulses of 
laser light to induce the formation of intact gaseous ions. After ionization, ions are 
accelerated in the ion source to a fixed kinetic energy.  
In mass spectrometry, a mass analyser is used for the determination of mass-to-
charge ratio (m/z) of the ions. There are various kinds of mass analysers used in mass 
spectrometry such as quadrupole, time of flight (ToF) and orbitrap. A quadrupole mass 
analyser is a bundle of parallel rods that enables ions to move between the rods, 
allowing for selection of ions. Meanwhile, ToF measures time taken for ion to reach 
the detector where lighter and more charged ions will reach the detector faster. The 
orbitrap detects ions in a circular motion. In figure 1.6, C-trap is used to inject ions into 
orbitrap and they spread into oscillating rings that induce current detected by the 
amplifier  (Zubarev and Makarov, 2013). Oscillations from detected signal used to 






Figure 1.6: Cross-section of the C-trap and orbitrap analyser. In the orbitrap analyser, 
ions enter during the voltage ramp and form rings that induce current detected by the 
amplifier. Image taken from Thermo Fisher Scientific.  
There are various types of fragmentation in mass spectrometry for protein detection, 
for example: collision-induces dissociation (CID) and electron-transfer dissociation 
(ETD). CID results in kinetic energy converting into internal energy from collision of 
the peptide with a neutral gas to cause fragmentation along the backbone of the 
peptide (Brodbelt, 2016). Fragment ions generated are recorded along with the parent 
ion mass and computationally these can be reconciled for sequencing of the peptide 
amino acid constituents. In ETD, generation of a radical occurs (Hauser et al., 2008) 
because of rapid neutralization of the charged site by an electron due to electron reacts 
with positively charged peptides (Kim and Pandey, 2012). The fragmentation is more 
likely to remove side groups and thus it is a useful technique to gather data on peptide 
modifications. 
High performance of liquid chromatography (HPLC) is molecular fractionation of small 
and large molecules of various polarities (Ho et al., 2003). Electrospray ionization is 
able to couple liquid chromatography (LC) with mass spectrometry. The LC column 





chromatography is used because of availabilities of various mobile and stationary 
phases where there is coupling of this technique with sample preparation and 
detection units (Singh et al., 2011).  
Quantitative protein measurements by mass spectrometry have been widely used in 
research settings, thus, have evolved dramatically over the last decade (Hale 2013). 
There are different techniques that are carried out which can be divided into labelled 
and labelled free techniques. Many reagents that are enriched with stable isotopes to 
introduce mass tags of interest for protein quantification involve labelling proteins with 
reagents (Gygi et al., 1999) but there are also techniques which are label free.   
Label free technique is to determine amount of protein in two or more biological 
samples, but it does not use a stable isotope that basically binds and label the proteins 
like other protein quantification methods. This technique has the advantage of having 
no limit number of samples or experimental conditions that can be compared, 
however, they rely on the performance of the liquid chromatography system or the 
mass spectrometer to accurately identify the peptide and its quantity. Methods for 
protein quantification in cell culture systems have been developed, for example stable 
isotope labelling with amino acids in cell culture (SILAC) (Ong et al., 2002). This 
method utilises combinations of isotope labelled arginine and lysine to give rise to 
three different masses that can be detected within a mass spectrometry instrument. 
This SILAC method is for the incorporation of stable isotope-labelled amino acids into 
a cellular protein pool and relies on the ‘light’ or ‘heavy’ form of amino acid into the 
proteins (Lanucara and Eyers, 2011). Every sample that used this method is labelled 
before any kind of treatment occurs at protein level to minimise errors associated with 
processing samples within the work flow. For example, gingival fibroblasts would be 
labelled prior to challenge with oral pathogens. However, SILAC is limited to three 
channels compared with the peptide labelling techniques. There are other techniques 
that can do peptide labelling up to 11 channels which allows for comparison of more 
samples, experimental conditions or replicates of individual conditions within one 
experiment, which may reduce variability. These techniques include tandem mass 
tags (TMT), isobaric tags for relative and absolute quantitation (iTRAQ) and isotope-
coded affinity tag (ICAT). In TMT, the protein samples are labelled separately with 





experiment and then, pooled into one sample to run on the mass spectrometer. Only 
ions picked for MS/MS fragmentation are quantified.    
To aid with protein identification there are also enrichment strategies available. 
Antibodies of specific chemistries can be used to isolate proteins of interest. 
Glycoprotein enrichment is one example using column/resin enrichment  (Zhu et al., 






1.14  Project aims 
In this research it was hypothesized that modulation of glutathione would alter the 
ability of neutrophils to chemotax. Thus, the overall aim of the work was to further 
understand the role of redox balance in the aberrant chemotactic phenotype observed 
in neutrophils, particularly from periodontitis patients. This will be answered by 
addressing the following objectives: 
 
i. To assess glutathione modulating compounds on altering glutathione 
level in chemotactic behaviour of neutrophil cells using functional 
neutrophil assays.  
 
ii. To optimise neutrophil preparation and separation for proteomics.  
 
iii. To assess protein glutathionylation of haemoglobin using glutathione 
model protein in Orbitrap-based mass spectrometry.  
 































GENERAL MATERIALS AND METHODS 
2.1 Study volunteer donors 
2.1.1 Selection of healthy volunteers 
All volunteers for blood sample donations were obtained from staff and students 
recruited from The School of Dentistry. All participants were non-smokers and were 
not taking any medication. Ethical approval was obtained from the Birmingham Dental 
Hospital and University of Birmingham. Reference for the ethical approval is 
14/SW/1148.   
2.1.1 Periodontitis study – volunteer selection 
Periodontitis patients were recruited from the Periodontology clinic within the 
Birmingham Dental Hospital. Gender and age matched healthy controls were recruited 
as stated in 2.1.1. Ethical approval for the study was approved (Reference: 
14/SW/1148) and all 4 volunteers provided written informed consent. Exclusion criteria 
for both patient and control subjects included pregnancy, smoking and use of vitamin 
supplements.  
2.2 Neutrophil isolation 
Neutrophils were isolated from whole blood collected by venepuncture. The method 
used was based on that of Matthews et al., 2007. Venous blood samples were 
collected in lithium heparin vacutainers (Greiner, Bio-One, Kremsmunster, Austria); 
the amount of blood collected was approximately 24ml and did not exceed maximum 






2.2.1 Reagents for neutrophil isolation 
2.2.1.1 Percoll gradients 
Percoll (1.13g/ml, 8 ml) (GE Healthcare, Buckinghamshire, United Kingdom) was used 
to make up two densities of 1.079g/ml and 1.098g/ml as shown in table 2.1. The 
1.098g/ml Percoll density (8 ml) was layered under 1.079g/ml density (8 ml) in a 
centrifuge tube. These solutions were stored at 4°C prior to use. Sodium chloride 
(NaCl) (Sigma Aldrich, Dorset, United Kingdom) at a concentration of 1.5M was used 
as a component for the Percoll gradient. About 3.5ml NaCl was mixed with distilled 
water and Percoll to form the gradients.  
Component 1.079g/ml density 1.0987g/ml density 
Percoll 19.708ml 24.823ml 
Water 11.792ml 6.677ml 
NaCl (1.5M) 3.5ml 3.5ml 
Table 2.1: Composition of Percoll gradients for neutrophil isolation 
2.2.1.2 Lysis buffer 
Lysis buffer was made by adding ammonium chloride (NH4Cl) (8.3g; Sigma, A9434) 
(Sigma Aldrich), potassium bicarbonate (KHCO3) (1g; Sigma, P9144) (Sigma Aldrich), 
Disodium ethylenediaminetetraacetic acid dihydrate (Na2 EDTA 2H2O) (0.04g; Sigma, 
E5134) (Sigma Aldrich) and bovine serum albumin (2.5g; BSA; Sigma, A4530) (Sigma 
Aldrich) sequentially to 1 litre of distilled water and stored 4°C prior to use for about 1 





2.2.1.3 Phosphate buffered saline (PBS) 
PBS was made by adding 7.75g sodium chloride (NaCl) (Sigma Aldrich), 0.2g 
potassium phosphate monobasic (KH2PO4) (Sigma Aldrich) and 1.5g potassium 
phosphate dibasic (K2HPO4) (Sigma Aldrich) to a 1 litre distilled water. The solution 
was then autoclaved and stored at 4°C prior to use.  
2.2.1.4 Glucose supplemented phosphate buffered saline (gPBS) 
gPBS was made by adding up 1.8g glucose (Sigma-Aldrich), 0.15g calcium chloride  
(CaCl2) (Sigma-Aldrich) and 1.5ml magnesium chloride (MgCl2) (Sigma-Aldrich) to 1 
litre of PBS. The salts were mixed and dissolved before adding the next one and the 
solution was stored to 4°C prior to use for about 1 week.  
2.3 Neutrophil isolation method 
Whole blood (8ml) was layered at the top of the Percoll gradients (methods section 
2.2.1.1). The tubes were then centrifuged for 8 minutes at 150g, then followed by 10 
minutes at 1200g. After centrifugation, five layers formed that consist of plasma at the 
top, followed by monocyte and lymphocyte layer, Percoll layer and red blood cell layer 
as shown in Figure 2.1. 
 






Figure 2.1 : Layers of blood components in Percoll after density centrifugation showing 
a distinct neutrophil layer from other leukocytes.  
The neutrophil layer sat above the red blood cell layer. By using a Pasteur pipette 
(Appleton Woods, Birmingham, United Kingdom), plasma, monocyte, lymphocyte and 
Percoll layers was removed by manual aspiration. The neutrophil layer above red 
blood cell layer was then removed by gentle aspiration using a Pasteur pipette and 
was added to 50ml centrifuge tube (Sigma-Aldrich) containing lysis buffer (30ml) 
(methods section 2.2.1.2). The tube was then inverted several times and left at room 
temperature for 10 minutes to allow for erythrocyte lysis. After that, the cells were 
centrifuged at 350g for 6 minutes. The supernatant was discarded, and the cell pellet 
was resuspended in lysis buffer (4ml), incubated for 5 min at room temperature as 
before, prior to re-centrifugation. The supernatant was removed, and the cell pellet 
was suspended in PBS (4ml) and centrifuged again to remove any remaining lysis 
buffer. The supernatant was removed, and cells were suspended in PBS (3ml). The 
neutrophil cells were counted using a haemocytometer (Neubaeur, Reichart, Hausser 
Scientific, Horsham, United Kingdom) (methods section 2.4.1) and automated Luna 
cell counter (methods section 2.4.2). Neutrophils were then resuspended at 





2.4 Neutrophil viability using trypan blue and Luna cell counter 
2.4.1 Trypan Blue 
The cells were counted using a haemocytometer (Neubaeur, Reichart, Hausser 
Scientific) as shown in figure 2.2. The viability of the cells was checked using trypan 
blue dye exclusion (Sigma-Aldrich). Cells were mixed with trypan blue at a ratio of 1:1 
and this mixture was added to the haemocytometer. Cell count and cell viability was 
visualized using a light microscope (Leitz Laborluxs, Ontario, Canada). Cells 
confirmed visually as blue were counted as dead cells. The small squares in red were 
counted. Each square has volume: 0.2 x 0.2 (width) x 0.1 (depth) = 0.004mm3. The 






Figure 2.2 : Haemocytometer. Cells observed in the 9 small squares highlighted in 
red were used in the calculation of cell concentration.  
 
1 cm 
Calculation of number of cells per ml : 
- Cell count /9 x 25 = no. of cells in the entire grid. 






2.4.2 Luna automated cell counter 
Neutrophil cells were also counted using Luna automated cell counter (Logos 
Biosystems, East Sussex, United Kingdom). This Luna cell counter produced total, 
live and dead cell counts. For each cell count, the live cells were identified with green 
circles and the dead cells were identified with red circles.  
Luna reusable slides were used for cell counting. Sample (10µl) was mixed with trypan 
blue stain (10µl 0.4%). This mixture was put into the Luna counting slides and the slide 
was inserted Into the Luna counter instrument until a click sound was heard. The focus 
knob on the slide of the instrument used to adjust focus on the cells. Cells that are live 
had dark edges and bright surface while cells that are dead had a dark blue colour. 
Results was then viewed and saved.   
2.5 Boyden chamber: QCM chemotaxis 3µm 96-well cell migration assay  
 
Figure 2.3: QCM chemotaxis assay (3µm). The letter label represents; A; lid, B; cell 
migration chamber plate, C; 96-well feeder tray, D; base. The cell migration chamber 
plate was used for cells and the 96-well feeder tray was used for chemoattractant. 







QCM chemotaxis assay (Merck Milipore, Hertfordshire, United Kingdom) is a Boyden 
chamber for high throughput chemotaxis assay. The method was based on 
manufacturer’s protocol and the manufacturer provided all solutions described. For 
this assay, fMLP and IL8 chemoattractant (150µl, concentration as described in 
results) in gBPS was added to the wells of the feeder tray (figure 2.4, label C) in the 
lower chamber. In the upper chamber, cells (2 x 104 or 2 x 105) were places in 100µl 
RPMI. Plate was incubated for 1 hour at 37°C in a carbon dioxide (CO2) incubator that 
has 4-6% CO2. 
After incubation, the migration chamber plate was removed from the plate assembly 
and non-migrated cells were gently discarded from the top side of the insert by flipping 
out the remaining cell suspension. This migration chamber plate was then placed onto 
a new 96-well feeder tray (second feeder tray) containing prewarmed Cell Detachment 
Solution (150µl) in the wells. These plates were incubated for 30 minutes at 37°C. 
During incubation, the migration chamber plate was gently tilted back and forth several 
times so that cells were completely dislodged from underside.  
From the first feeder tray, 75µl of the solution (cells that migrated through the 
membrane and into the chemoattractant in the lower chamber) was transferred to a 
new 96-well black plate. Then, 75µl of the detachment solution from the second feeder 
tray (cells that migrated through the membrane and detached from the membrane by 
detachment buffer) was transferred to the same well in the 96-well black plate. 
The Dye Solution was prepared of CyQuant GR Dye and Lysis Buffer. The ratio of 
preparation was as follows: CyQuant GR Dye prepared by manufacturer 1:75 was 
diluted with 4X Lysis Buffer (For example, 4µl dye in 300µl of 4X Lysis Buffer). Lysis 
Buffer/Dye Solution (50µl) was added to each well in the black 96-well plate containing 
150µl of the migratory cells’ solution. This plate was incubated for 15 minutes at room 
temperature and then read with plate reader (Infinite 200 PRO, Tecan Life Sciences, 







2.6 GSH-Glo assay (Promega Corporation, Southampton, United Kingdom) 
2.6.1 GSH-Glo reagent (2X concentration) 
The reagents that are already contained in the assay kit were used to make up the 
GSH-Glo reagent (2X concentration):, Luciferin-NT substrate and Glutathione S-
Transferase were diluted 1:50 in GSH-Glo Reaction Buffer. The GSH-Glo reagent 2X 
was prepared immediately prior to use.  
2.6.2 Luciferin detection reagent 
The contents of a bottle of reconstitution buffer with esterase that was provided in the 
assay kit was transferred to the amber bottle of lyophilized luciferin detection reagent 
that was also in the assay kit. The solution was mixed by inversion until the substrate 
was dissolved.  
2.6.3 Method for GSH-Glo assay 
GSH-Glo assay used to measure the glutathione level in neutrophil cells. Neutrophil 
cells were in PBS at concentration of 1 x 105. In a 96-well plate, cells were dispensed 
at 50µl per well. Then, 50µl of prepared GSH-Glo reagent 2X was added per well. 
Plate was mixed briefly on a rocker (Stuart Gyro-rocker SSL3, Sigma-Aldrich, Dorset, 
United Kingdom) and incubated at room temperature for 30 minutes. Then the 
prepared luciferin detection reagent was added at 100µl per well to the 96-well plate. 
The plate was then mixed briefly on a rocker (Stuart Gyro-rocker SSL3, Sigma-Aldrich) 
and incubated at room temperature for 15 minutes. The luminescence was then 








2.7 GSH/GSSG-Glo assay 
GSH/GSSG-Glo assay was purchased from Promega Corporation used to measure 
total glutathione and oxidized glutathione (GSH:GSSH) in neutrophil cells.  
2.7.1 Total glutathione lysis reagent  
The volume for this reagent was 25µl per well in a 96-well plate. The reagents used 
was 1µl Luciferin-NT, 10µl passive lysis buffer and 14µl water. This reagent was 
prepared approximately 30 minutes before use.  
2.7.2 Oxidized glutathione lysis reagent 
The volume for this reagent was 25µl per well in a 96-well plate. The reagents used 
was 1µl Luciferin-NT, 0.5µl 25mM N-ethylmaleimide (NEM), 10µl 5X passive lysis 
buffer and 13.5µl water. The reagent was prepared approximately 30 minutes before 
use.  
2.7.3 Luciferin generation reagent component 
The volume for this luciferin generation reagent (100mM) was 50µl per well in a 96-
well plate. The reagents used were 1.25µl DTT, 3µl glutathione-S-transferase and 
45.75µl glutathione reaction buffer.  
2.7.4 Luciferin detection reagent 
The contents of a bottle of reconstitution buffer with esterase that was provided in the 
assay kit was transferred to the amber bottle of lyophilized luciferin detection reagent 
that was also in the assay kit. The solution was mixed by inversion until the substrate 
was dissolved.  
2.7.5 Method for GSH/GSSG-Glo assay 
GSH/GSSG-Glo assay used to measure the total glutathione and oxidized glutathione 
level in neutrophil cells. Neutrophil cells were in PBS at concentration of 1 x 105. In a 
96-well plate, cells were dispensed at 20µl per well. Then, 25µl of prepared total 
glutathione lysis reagent or oxidized glutathione lysis reagent was added per well. 





minutes and 50µl of luciferin generation reagent was added per well. Then, the plate 
was incubated at room temperature for 30 minutes. Then the prepared luciferin 
detection reagent was added at 100µl per well to the 96-well plate. The plate was then 
mixed briefly on a rocker (Stuart Gyro-rocker SSL3, Sigma-Aldrich) and incubated at 
room temperature for 15 minutes. The luminescence was then measured using a 
luminometer (Berthold Technologies). 
2.8 Preparation of whole cell protein extracts 
Neutrophil cells were prepared for protein extracts to determine protein contents. After 
neutrophil isolation from whole blood, cells were lysed with lysis buffer (10% sodium 
dodecyl sulphate (SDS) in 100mM triethylammonium bicarbonate (TEAB) 
(ThermoFisher Scientific, Paisley, United Kingdom). Cells were stored at -80°C until 
used for proteomics experiments. When it was ready, sample viscosity was reduced 
by shearing deoxyribonucleic acid (DNA) using a microtipsonicator Soniprep 150 
(MSE (UK) Ltd, London, United Kingdom) on ice for 10 seconds.  Then, lysate was 
centrifuged at 16,000 xg for 10 minutes at 4°C. The supernatant was then carefully 
separated and transferred into a new tube. Protein concentration of the supernatant 
was determined using the BCA Protein Assay (ThermoFisher Scientific). In this study, 
100µg of protein were harvested per condition. 
2.9 Protein determination using bicinchoninic acid (BCA) assay 
All protein measurements were made using the bicinchoninic acid assay (Smith et al., 
1985, purchased from Thermo Fisher Scientific), unless otherwise stated.  
Bicinchoninic acid reagent solution (Reagent A): containing bicinchoninic acid, sodium 
carbonate, sodium tartrate and sodium bicarbonate in sodium hydroxide (0.1M, 
pH11.25) (Sigma) 
Reagent B: Copper (II) sulphate pentahydrate solution: 4% (w/v) solution (Sigma).  






The standards were prepared using diluted albumin (BSA) (ThermoFisher Scientific). 
The contents of one Albumin Standard (BSA) ampule was diluted into several clean 
vials, using the same diluents as the samples. A set of diluted standards was prepared 
such as the table 2.2: 
 
Vial Volume of 
Diluent (µl) 





A 0 300 of stock 2000 
B 125 375 of stock 1500 
C 325 325 of stock 1000 
D 175 175 of vial B dilution 750 
E 325 325 of vial C dilution 500 
F 325 325 of vial E dilution 250 
G 325 325 of vial F dilution 125 
H 400 100 of vial G dilution 25 
I 400 0 0 = Blank 
 
Table 2.2: Preparation of Diluted Albumin (BSA) Standards 
Then, BCA working reagent (WR) was prepared. In preparation of this reagent, the 
following formula was used to determine the total volume of WR required: 
(# standards + # unknowns) x (# replicates) x (volume of WR per sample) = total 
volume WR required 
WR was prepared by mixing BCA Reagent A (BCA solution) (ThermoFisher Scientific) 
with BCA Reagent B (Copper II Sulphate Pentahydrate 4% solution) (ThermoFisher 
Scientific). The ratio was 50 parts of BCA Reagent A with 1 part of BCA Reagent B 
(50:1), Reagent A:B).  
Standards and samples (10µl) were pipetted in duplicate into separate wells of a 96 
well plate (Starlab, Milton Keynes, United Kingdom), WR (200µl) was added to each 
well and plate was mixed thoroughly on a plate shaker for 30 seconds. Plate was then 





temperature and absorbance was measured at 570nm in the plate reader (Infinite 200 
PRO, Tecan Life Sciences, Mannedorf, Switzerland). Protein concentration was 
determined through reference to a standard curve.  
2.10 Protein digestion in solution.  
After protein was determined, 100µg was transferred into a new tube and adjusted to 
a final volume of 100µl with 100mM TEAB (Thermo Fisher Scientific). 5µl of 100mM 
tris(2-carboxyethyl) phosphine hydrochloride (TCEP) (Sigma-Aldrich) was added and 
the sample was incubated at 55°C for 1 hour. Iodoacetamide (9mg) (Sigma-Aldrich) 
dissolved in TEAB (132ul, 100mM) to make up 375mM iodoacetamide. This solution 
was protected from light. Then, 5µl of this solution was added to the protein solution 
and it was incubated for 30 minutes protected from light at room temperature. After 
that, dithiothreitol (DTT, 5µl, 230mM) (Sigma-Aldrich) was added to quench any 
excess iodoacetamide and was incubated for 10-15 minutes at room temperature. 
For protein digestion, trypsin was used. Before usage, Trypsin Gold Storage Solution 
(Promega Corporation) (20µl) was added to the bottom of the trypsin glass vial 
containing 20µg and incubated for 5 minutes. Then, trypsin (2.5µl) was added to the 
reduced and alkylated protein (100µg). The sample was then digested overnight at 
37°C. The next day, sample was dried in a Speed Vac (Thermo Fisher Scientific). 
2.11 Macrotrap desalting  
Macrotrap desalting was used to desalt protein samples. Firstly, the trap was cleaned 
5-10 times using (100µl) of 90% Acetonitrile (ACN), 10% water (H20) and 0.1% 
Trifluoroacetic acid (TFA). Then, it was equilibrated 5-10 times using (100µl) of 2% 
ACN, 98% H20 and 0.1% TFA. The sample was then loaded with (100µl) of 2% ACN 
and 0.1% TFA. Salts were removed from the sample using (100µl) of 2% ACN, 98% 
H20 and 0.1% TFA. Next, the sample was eluted using (100µl) of 90% ACN, 10% H2O 





2.12 MicroBCA assay 
After digestion, MicroBCA assay was done to determine peptide concentration by a 
modified bicinchoninic acid assay. This method was based on Krishan et al., 2009. 
The digested proteins were resuspended in (100µl) of 7.2% Trifluoroacetic acid (TFA) 
(Sigma-Aldrich). Then, it was centrifuged at 10,000 xg for 20 minutes. The supernatant 
was taken and diluted 1 in 10 in 0.1M sodium hydroxide (NaOH) (Sigma-Aldrich) with 
1% sodium dodecyl sulphate (SDS) (Sigma-Aldrich). Using an Eppendorf thermomixer 
compact (Sigma-Aldrich), it was heated at 95°C for 5 minutes. Then, it was cooled 
down to room temperature. After that, (10µl) of the sample was transferred into a 
microplate well (Starlab, Milton Keynes, United Kingdom) and BSA assay was done 
as described in 2.9.  
2.13 Desalting using ZipTips  
For mass spectrometry, residual salts were removed from the extracted peptides using 
ZipTips (Merck Milipore). This method was done as described by the manufacturer. In 
this method, TFA (Sigma-Aldrich) was added to sample until 0.1% TFA was achieved. 
ZipTip was wetted with Acetonitrile (ACN) (Sigma-Aldrich) (10µl) and then equilibrated 
with TFA (10µl, 0.1% v/v). The 10µl sample was loaded, aspirated and dispensed 7-
10 times for maximum binding. The waste was retained. After that, the tip was washed 
with 0.1% TFA (10µl) (Sigma-Aldrich), aspirated and dispensed twice. Then, to remove 
all peptides, 10µl 0.1% Formic Acid (Sigma-Aldrich)/ 50% ACN (Sigma-Aldrich) was 
taken to elute, aspirated and dispensed 10 times. This sample was kept as desalted 
sample. Then, it was spun in vacuum centrifuge SpeedVac (ThermoFisher Scientific) 
and stored at -20 or -80°C.  
2.14 Western blot 






2.14.1 Tris-buffered saline (TBS) 
For 1L of TBS, 8g sodium chloride (NaCl) (Sigma-Aldrich), 0.2g potassium chloride 
(KCI) (Sigma-Aldrich) and, 3g Tris base (Sigma-Aldrich) was dissolved in distilled 
water and adjusted to pH 7.5.  
2.14.2 Tris buffered saline with Tween (TBST) for washes  
To make up TBST, Tween 20 (500µl, Sigma-Aldrich) was added per litre of TBS.  
2.14.3 Antibodies used in western blot 
No.  Antibody Concentration Manufacturer 
1. Anti-actin 1:5000 dilution Thermo Fisher 
Scientific 
2. Anti-glutathione (Anti-PSSG) 1:5000 dilution Thermo Fisher 
Scientific 
3. Secondary mouse antibody 1:10,000 dilution Thermo Fisher 
Scientific 







2.15 Protocol for western blot 
Mini-Protean TGX precast gels from Bio-Rad, Hertfordshire, United Kingdom with gel 
composition of 12% acrylamide were used. Before usage, the comb was removed by 
pulling it upward in one smooth motion. At the bottom of the gel cassette, the sealing 
green tape was removed by pulling it gently.  
Electrophoresis tank (Bio-Rad) were used. Two gel cassettes were put into it facing 
each other (front to front). Then, running buffer was added to the outer part and then 
added to the inner part of tank till overflowing. Protein ladder (ThermoFisher Scientific) 
4µl was loaded and sample (20µl) were loaded in separate wells. The tank lid was put 
on (black top on black) and (red top on red). Then, the tank was run at about 200V for 
approximately 40 minutes until the dye stain was approaching the bottom of the gel. 
   
2.15.1 Running buffer (10x concentration) 
Tris (30.3.g, Sigma-Aldrich) and glycine (144g, Sigma-Aldrich) were dissolved in 
900ml distilled water. Then, 10g of sodium dodecyl sulphate (SDS) (Sigma-Aldrich) 
was added and dissolved. The solution pH was adjusted to 8.3 and made up to 1L.  
2.15.2 Sample preparation 
Protein samples (20µg) were prepared by mixing 1:1 with Laemlli buffer (Sigma-
Aldrich) that consists 20% glycerol, 0.004% bromophenol blue and 0.125M Tris 
(Sigma-Aldrich). The resulting solution was heated to 95°C for 5min before separation 
by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE).  
2.15.3 Coomassie Blue Staining 
Instant Protein Stain (Expedeon, Cambridge, United Kingdom) was used for gel 
staining. Instant Protein Stain is a ready to use Coomassie protein stain for 
polyacrylamide gels. Gels were incubated in 100ml staining solution for 1 hour. Then 
the staining solution was removed, and the background was removed with water (2 x 






2.15.4 Membrane transfer 
For membrane transfer, nitrocellulose and transfer blot packs from Bio-Rad were used. 
The transfer runs at 25V, 2.5mA for 10 minutes.  
2.16 Strip Western blot membranes 
The western blot membrane was submerged in sodium hydroxide (0.4M) (Sigma-
Aldrich) on a rocker (Stuart Gyro-rocker SSL3, Sigma-Aldrich) for 15 minutes. The 
solution was discarded and replaced with TBS and put on the rocker for 10 minutes. 
This was repeated twice. Bovine serum albumin (BSA) (Sigma-Aldrich) 3% in TBS 
was prepared. The membrane was blocked with the BSA solution on a rocker (Stuart 
Gyro-rocker SSL3, Sigma-Aldrich) for one hour. Then, antibody 1:5000 (Thermo 
Fisher Scientific) was prepared, hence, the blot was put in the antibody overnight in 
the cold room (4°C). The blot was put in a black plate (Sigma-Aldrich) and washed 
with tris buffered saline with Tween (TBST) (Sigma-Aldrich) three times for 10 minutes 
each time. Then, the blot was incubated in anti-mouse secondary antibody labelled 
with infra-red label 800CW or 680RD (red or green dyes respectively) at 1:10,000 
dilution (Thermo Fisher Scientific) for 1 hour. Then, the blot was washed with TBST 
three times for 10 minutes each time. Then, the membrane blot was scanned using 
the Odyssey Licor scanner (Odyssey System, Wakefield, United States).  
2.17 Tryptic digestion for gels 
2.17.1 Ambic 
Ammonium bicarbonate (100mg) (Sigma-Aldrich) was dissolved in distilled water 
(50ml). 
2.17.2 Ambic:ACN 
Ammonium bicarbonate (100mg) (Sigma-Aldrich) was dissolved in distilled water 
(25ml) and acetonitrile (25ml) (Sigma-Aldrich). 
2.17.3 ACN:formic acid 
Acetonitrile (50ml) (Sigma-Aldrich) was mixed with formic acid (5ml) (Sigma-Aldrich) 






Trypsin (sequencing grade 12.5ng/µl from Promega Corporation). 
2.18 Protocol for tryptic digestion of gels  
Samples were separated by SDS-PAGE on ready gels (Bio-Rad) (methods section 
2.14) and the gels were stained with Instant Protein Stain Coomassie Blue (Expedeon, 
Cambridge, United Kingdom). Bands of interest were excised in a flow hood to prevent 
keratin contamination.  
Each gel sliced were diced into small pieces (~1mm2) and placed in a 500µl Eppendorf 
tube (ThermoFisher Scientific). ACN (100µl) (Sigma-Aldrich) was added and the tube 
was vortexed for 10 minutes. The supernatant was removed and transferred to a 
separate tube to be discarded. This dehydration and extraction of Coomassie stain 
was repeated 3 or 4 times. The pieces were then dried completely in a Speed Vac 
(ThermoFisher Scientific). The gel volume was estimated (in µl) and trypsin (Promega 
Corporation) solution was added to cover the gel pieces. The mixture was then 
vortexed for 10 minutes before incubating at 4°C for 30 minutes. The tube was briefly 
centrifuged, to sediment the gel pieces, before sealing with Parafilm (Sigma-Aldrich), 
to prevent evaporation, and incubated at 37°C overnight.  
To extract the peptides from the gel pieces, the tube was briefly vortexed and 
centrifuged. Liquid was removed to a fresh tube. Peptides were extracted by addition 
of 0.1% TFA in 60% acetonitrile of a volume to cover the gel pieces, 30min at 30°C.  
The liquid was removed to the same fresh tube and the procedure was repeated. The 
total liquid removed in the fresh tube was then dried by vacuum centrifuge before 
desalting (methods section 2.13). 
2.19 Mass spectrometry 
All mass spectrometry for proteomics was carried out at School of Biosciences, 
University of Birmingham with assistance from Dr Sabah Pasha (postdoctoral fellow) 





After protein samples digested as in methods section 2.10 and desalted through steps 
in methods section 2.12, peptides were loaded on to a 150 mm Acclaim PepMap100 
C18 column (ThermoFisher Scientific) in formic acid (0.1% v/v) (Sigma-Aldrich). 
Peptides were separated over a linear gradient from 3.2% to 44% mobile phase B 
(acetonitrile with formic acid (0.1% v/v) with a flow rate of 350 nL/min. The column was 
then washed with 90% mobile phase B before re-equilibrating at 3.2% mobile phase 
B. The column oven was heated to 35°C. The LC system was coupled to an Advion 
TriVersa NanoMate (Advion) which infused the peptides directly into an LTQ-Orbitrap 
Elite ETD (ThermoFisher Scientific). 
The mass spectrometer performed a full FT-MS scan (m/z 380-1800) and subsequent 
CID MS/MS scans of the 7 most abundant ions above an absolute signal intensity 
threshold of 5000 counts. Full scan mass spectra were recorded at a resolution of 
60,000 at m/z 400 and anterior cingulate gyrus (ACG) target of 1x106 (maximum 
injection time 1s). Precursor ions were fragmented in CID MS/MS with a normalized 
collision energy of 35% and an activation Q of 0.25. ACG target for CID MS/MS was 
1x105 (maximum injection time 50 ms). The width of the precursor isolation window 
was 2 m/z and only multiply-charged precursor ions were selected for MS/MS. Spectra 
were acquired for 56 minutes. A full Fourier-transform mass spectrometry (FT-MS) 
scan (m/z 380-1800) was performed with subsequent higher-energy collisional 
dissociation (HCD) MS/MS scans of the 7 most abundant ions that passed a minimum 
signal requirement of 5000 counts. The full FT-MS scans were recorded at 120,000 
resolution and ACG target of 1x106 (maximum injection time 1 s). Precursor ions were 
fragmented in HCD MS/MS with a normalized collision energy of 38% and an 
activation time of 0.1. ACG target for HCD MS/MS was 1x105 (maximum injection time 
50 ms). The width of the precursor isolation window was 2 m/z and only multiply-
charged precursor ions were selected for MS/MS. FT first mass value was reduced to 









2.20 Proteome discoverer software 
The data were analysed using Proteome Discoverer (version 1.4 and 2.1 Thermo 
Fisher Scientific). Data from each SCX and reverse phase column (C18) set were 
analysed together and each replicate searched independently. The database used 
was from Uniprot (Human database) (European Bioinformatics Institute, Cambridge, 
United Kingdom). The data were searched with the following settings: trypsin as the 
enzyme with a maximum of two missed cleavages, 10 ppm mass accuracy for the 
precursor ion, fragment ion mass tolerance was set at 0.8 Da, carbamidomethylation 
of cysteine and isobaric tags for relative and absolute quantitation (iTRAQ) addition to 
the N-terminus and lysine residues were set as fixed modifications, and 
phosphorylation of serine, threonine and tyrosine was set as a variable modification 
as was oxidation of methionine and TMT addition to lysine. The search results from 
each of the technical replicates were combined and proteins which were identified with 
two or more unique peptides were classed as identified. Only unique peptides were 
used for protein quantification (performed in Proteome Discoverer) and protein 














2.21 Software used in study 
Various software was used in this study. Below are the software used.  
2.21.1 Graph Pad Prism (GraphPad Software, San Diego, United States) 
This software was used to do data analysis, graphs and statistics, for example,  
Kolmogorov-Smirnov test to determine if the data fits a Gaussian distribution and One 
Way ANOVA with Tukey’s multiple comparison test for significant difference 
confirmation (p< 0.0001). 
2.21.2 Proteome Discoverer (ThermoFisher Scientific)  
This software was used to identify and quantify protein samples and for analysis of 
TMT labelled samples. Search engine used was SEQUEST.  
2.21.3 Protein-Prospector (University of California, San Francisco, United States)  
The Protein-Prospector software was used to in silico digest haemoglobin alpha and 
beta chain, with and without glutathione modification, to generate peak lists for 
identification of the proteins.  
2.21.4 UniProt (European Bioinformatics Institute) 
The Uniprot software provides a database for protein and its functional information.    
2.21.5 Xcalibur (ThermoFisher Scientific)  
All mass spectrum was put through the Xcalibur to identify the proteins in the neutrophil 
samples. For glutathione model protein, the mass spectra were deconvoluted using 



























Functional assays of neutrophils 
3.1 Introduction 
Neutrophil function is vital to proper execution of the innate immune system. These 
cells are first to arrive at a site of infection and carry out three functions: recruitment, 
response and resolution. Measurement of neutrophil chemotaxis has been done by a 
wide variety of methods including video microscopy (Muinonen-Martin et al 2010), 
movement of cells across membranes (Gomez-Lopez et al., 2011) and movement of 
cells under agarose (Chethana et al., 2012). Recruitment of neutrophils relies on 
chemotaxis of the cells to the location required. In periodontitis Roberts et al (2015) 
demonstrated that neutrophils were slower and had less directionality than neutrophils 
from donors without periodontitis.  Previously in our lab, chemotaxis of peripheral 
blood neutrophils has been determined by video microscopy using the Insall chamber 
(Roberts thesis 2016). The Insall chamber was developed for the study of 
Dictyostelium discoideum (Muinonen-Martin et al., 2010) and can record many details 
of the migrating organisms or cells being studied. This approach generates a large 
amount of information about the migrating cells as each cell is visualised across time 
and information can be gained about the direction of motion, the distance travelled 
and even the morphology of the cells. The method is time consuming, with each 
observation taking at least 20min. Therefore, it is slow and does not lend itself to 
measuring multiple conditions in parallel. At present in our laboratories the rate limiting 
factor is the accessibility to only one microscope that can record videos.  
Previous research had also demonstrated that the window of opportunity for the 
neutrophils was limited to 4h before their integrity was compromised in terms of ability 
to chemotax (Roberts thesis 2016). In this work it was desired to challenge isolated 
human primary neutrophils with a range of stimuli that might modulate intracellular 
glutathione (GSH). For this a higher throughput technique would be required for 
assessing chemotaxis. Thus, available Boyden chamber style assays were evaluated. 





from the Insall chamber.  It was vital to develop another higher throughput chemotactic 
technique to study multiple conditions of neutrophils. 
Additionally, neutrophil intracellular glutathione (GSH) has also been shown to be of 
importance to the functionality of neutrophils in their multiple abilities; a decrease in 
intracellular GSH was found in neutrophils isolated from periodontitis patients (Dias et 
al 2013). Thus, a key aim of this chapter was to determine if manipulation of 
intracellular GSH directly changed chemotactic properties of neutrophils isolated from 
healthy donors. Figure 3.1 shows compounds that intervene in the production of 
glutathione which was adapted from Harlan et al., (1984) study. The red labels points 
to inhibitors used to inhibit glutathione levels in glutathione redox cycle, thus 
manipulate the glutathione levels. The rationale of using these inhibitors is to see 
whether there are any effects on neutrophils chemotaxis after the glutathione levels 
were manipulated.   In the diagram, cellular glutathione can be depleted by inhibition 
of glutathione reductase by carmustine (BCNU). Reduced glutathione can also be 
depleted by formation of a thioester conjugate with 1-chloro-2,4-dinitrobenzene 
(CDNB) which is catalysed by endogenous glutathione-s-transferase. 
Buthioninesulfoximine (BSO) is a selective inhibitor of γ-glutamyl-cysteine synthetase 
and may inhibit glutathione biosynthesis (Alton, 1983). N-acetylcysteine (NAC) is an 
acetylated cysteine residue and causes increase of GSH level by providing a cysteine 
precursor. NAC has the ability to minimize negative effects thought to be associated 







Figure 3.1: Pharmacologic modification of the glutathione redox cycle in vitro. Adapted 
from Harlan et al., 1984. Abbreviations BCNU: carmustine or bis-
chloroethylnitrosourea; CDNB: 1-chloro2,4-dinitrobenzene; BSO: 






3.2 Materials and methods 
3.2.1 Real-Time Glo 
For neutrophil viability, Real Time Glo assay (Promega Corporation) was used. The 
method used for determination of time course for neutrophil experiment was that of 
the manufacturer’s protocol.  
Prior to starting the assay, MT cell viability substrate, NanoLuc enzyme and cell culture 
medium was equilibrated to 37°C. The neutrophil cells were plated at various cell 
densities (1 x 102 – 1 x 105) in a white walled 96 well plate.  For making the 2X 
RealTime-Glo reagent MT cell viability substrate (2 µl) and NanoLuc enzyme (2 µl) 
were added to prewarmed cell culture medium (996 µl) and vortexed to mix. 
An equal volume (40µl) of the prepared 2X Real Time-Glo reagent was added to the 
cells (40µ). Cells were incubated in a cell culture incubator at 37°C and 5% carbon 
dioxide (CO2). The luminescence of the sample was measured for 12 hours using a 
Tristar multimode reader from Berthold Technologies. 
3.2.2 Insall chamber 
The Insall chamber (Epigem Ltd, Redcar, UK) (figure 3.2) method was based on 
Muinonen-Martin et al., 2010. The Insall chamber was washed three times with 
Roswell Park Memorial Institute Medium (RPMI) (Sigma-Aldrich) prior to use. After the 
last wash a large droplet of RPMI was left on the chamber. Glass coverslips (22 mm) 
were submerged in 0.2M acid hydrochloric (HCl) (Sigma-Aldrich) in a Petri dish for 15 
minutes. Then, the coverslips were washed twice with reverse osmosis water. The 
coverslips were left to dry on filter paper before use. The coverslips were coated in 
bovine serum albumin (BSA, 7.5% in PBS, 400µl) (Sigma-Aldrich), ensuring an even 
coat was formed. Any excess was aspirated from the surface. Immediately. neutrophil 
cells (1 x 106 /ml, 400ul), suspended in RPMI (containing BSA 1.5ul/ml 7.5%), were 
added to the coverslip. The coverslip was left at room temperature for 20 minutes for 



















1. Coverslip with adhered 
neutrophils is inverted onto the 
microscope. 
3. The desired 
chemoattractant
/control is added 
to the chamber. 
4. The cells are 
visualised on the 
widest bridge area. 






2. Excess RPMI is aspirated off, 
forming a tight seal between the 





After incubation the coverslip, was inverted over the chamber ensuring the pipette 
loading bays are exposed. A filter paper was used to aspirate any excess fluid from 
the chamber. Chemoattractant (80µl) was loaded onto the chamber via the loading 
bays. The chamber was then visualised immediately using the Zeiss Primovert 
microscope at x20 magnification. The software used for collecting images using the 
‘movie’ tab was Q Imaging Retiga 2000R camera. An image was captured every 30 
seconds for 20 minutes.  
For analysing the videos, Manual tracking Plugin software and Image J software 
(Rasband, W.S., ImageJ, U.S. National Institutes of Health, Bethesda, Maryland, USA) 
was used. For the videos, there were 20 slides altogether and a reference point was 
put on the top left of the image. Tracking points were added for the cells that had 
directional movement towards the chemoattractant. Usually, 15 cells were chosen as 
previously determined by Roberts et al., (HM Roberts thesis 2016 entitled neutrophil 
function in chronic inflammatory disease states) and the data points were exported to 
an Excel table. The images were also saved as an animated graphics interchange 
format (GIF) file.  
The exported data were analysed using an established method provided by Muinonen-
Martin et al., 2010. From the spreadsheet, a spider diagram was made to see the 
measurement of cells movement towards the chemoattractant. Measurement of 
velocity, speed and chemotactic index was also obtained from the spreadsheet. 
Velocity is the µm/minutes cells move towards the chemoattractant where positive 
measurement shows a movement towards the chemoattractant, meanwhile, negative 
measurement shows a movement away from the chemoattractant. Average speed of 
a cell in any direction over the time course is known as cell speed (Roberts et al., 
2015). Chemotactic index is measure of the accuracy of chemotaxis that was 
calculated by taking the cosine of the angle between a line directly up the gradient and 
one that connects a cell's start point to its end point. A value of 1 is directly up the 
gradient. The average of velocity, speed and chemotactic index was used in Graph 
Pad Prism (GraphPad software, San Diego, United States of America (USA)) software 






3.2.3 ChemoTx chamber (Neuroprobe) 
ChemoTx Chamber (Neuro Probe, Warwick, United Kingdom) is an example of a 
single use Boyden Chamber assay. The manufacturer provided a membrane in a 
metal frame for ease of handling with selectively coated hydrophobic masks around 
each of the test sites (figure 3.3). The method was based on manufacturer’s protocol. 
Neutrophils (1 x 105 per ml) were suspended in RPMI. The lower chamber of this assay 
was filled with chemoattractant in gPBS (308µl) per well. The membrane filter was 
placed above the lower chamber and neutrophils (50µl) were pipetted onto the 
individual hydrophobic masked test areas. This plate A was incubated for 90 minutes 
at 37°C.  
 
A second plate (Plate B) was prepared with cell detachment solution (308µl, 0.1uM 
Versene) per well and then, prewarmed to 37°C. After 90min liquid from the top of the 
membrane filter was removed and washed once with gPBS (110µl). The filter was 
removed and placed onto the second plate. Then, it was incubated for 30minutes at 
37°C. gPBS (100µl) from each of the lower chamber (plates A and B) was transferred 
into a black fluorescence plate with clear bottom. The number of cells was measured 
using Cyquant dye (Thermo Fisher, Loughborough, United Kingdom): the preparation 
of the solution was as follows: 24µl stock and 120µl suppressor into 5.8ml gPBS. 
Amount of 50µl CyQuant NF (2x) solution was added to each well. The plate was 
incubated for 30 minutes at 37°C. Fluorescence readings were taken at 485/535nm 
from bottom of the plate. 
  
Figure 3.3: ChemoTx Chemotaxis Chamber from Neuro Probe. The metal mounted 
filter serves as filter and upper chamber onto which drops of cell suspension are 





3.2.4 Forty-eight (48) Micro Chemotaxis Chamber (Neuroprobe) 
The next Boyden type chamber tried was the Micro chemotaxis chamber, also from 
Neuroprobe (figure 3.4). This reusable chamber used replaceable polycarbonate 
track-etch (PCTE) membranes (Neuroprobe) onto which neutrophils became attached 
following chemotaxis. The bottom well or chamber was filled with chemoattractant in 
gPBS (25µl) per well. The PCTE membrane filter was placed above the lower chamber 
and neutrophils (50ul, various concentrations) were pipetted into the top or upper 
chamber. This plate was incubated for 60 minutes at 37°C. The neutrophils were 
stained with Giemsa stain (Sigma-Aldrich). About 20µl of stain were put into the wells. 
Then, the number of neutrophils was then counted using a light microscope.  
 
  
Figure 3.4: Micro Chemotaxis Chamber from Neuro Probe. The upper chamber was 
used for cells and the lower chamber was used for chemoattractant, between the two 








3.3 Results  
3.3.1 Neutrophil cell viability 
Neutrophils were routinely isolated from whole blood from healthy volunteers (methods 
section 2.2). In the first experiments the length of time that the cells could sustain 
viability outside the body was measured. It was necessary to understand the length of 
time that neutrophils could remain viable so that extended experiments examining the 
manipulation of intracellular GSH could be performed before the cells became 
compromised.  
In the first experiments the novel Real-Time Glo (RT Glo, Promega corporation) assay 
was used. Real-Time Glo was used to record neutrophil cell viability in the same 
sample well continuously whilst inside the luminometer. This assay is adenosine 
triphosphate (ATP)-independent and able to identify any changes in cell viability very 
quickly. Isolated neutrophils were plated in RPMI medium or glucose supplemented 
PBS (gPBS) in a 96-well plate.  The plate was then incubated in a luminometer and 
continuously monitored for 12 hours. The results (figure 3.5) demonstrate that 
neutrophils in either RPMI or gPBS lost viability after 4-5h and showed rapid decline 
after this time. Addition of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) to maintain pH diminished this effect. Further addition of foetal bovine serum 
(FBS) in either RPMI or gPBS appeared to increase the viability of the cells. This, in 
other cell types, may indicate a growth of the cells but it was unlikely neutrophils. At 
the end of the 12h experiment it was observed that the liquid evaporated. This factor 
could have changed the mechanism of the assay. In an attempt to mitigate this effect, 
the experiment was repeated but with an adhesive cover with RPMI as this showed 
the most change over the 12h incubation. At the same time the effect of phenol red 
was also explored, by using a non-phenol red containing medium to compare to the 
RPMI originally used. Figure 3.6 shows that while the inclusion of phenol red did not 
alter the response of the cells in the Real Time Glo viability experiment, the restriction 
of evaporation by use of an adhesive lid prevented the cell death and the apparent 
increase in cell viability over 12h. Overall these experiments indicated that either RPMI 





experiments. Subsequent experiments used a simple Trypan blue exclusion count to 
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Figure 3.5: Cell viability of neutrophil cells (1 x 105) over 12h in either (a) RPMI (with phenol red) or (b) gPBS supplemented with 
HEPES and or FBS (0.1-10%). Data represented at percentage of time zero viability (mean +/- SD). Viability was measured using 
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Figure 3.6: Cell viability of neutrophil cells (1 x 105) over 12h in RPMI (with or without 
phenol red) or RPMI (with phenol red) supplemented with HEPES. The experiment 
was either conducted with or without an adhesive lid to prevent evaporation. Data 
represented at percentage of time zero viability (mean +/- SD). Viability was measured 





3.3.2 Neutrophil cell chemotaxis 
There are many ways to measure neutrophil chemotaxis. The purpose of this work 
was to assess a high throughput chemotaxis assay for the chemotactic ability of 
neutrophils. In this section, four different methods were used to measure chemotaxis: 
via video microscopy and the Insall chamber; and via three semi-high through put 
Boyden chamber methods.  
3.3.2.1 Insall chamber analysis of chemotaxis 
The Insall Chamber is a direct visualization chamber and can be used to look at 
neutrophils’ chemotactic behaviour in video micrography. Figure 3.7 movement of all 
tracked cells in a spider diagram format, the cells act in their normal behaviour where 
they move randomly in one place: their path length is short and not in any particular 
direction. As for interleukin-8 (IL8) and N-formylmethionine-leucyl-phenylalanine 
(fMLP) chemoattractant, the neutrophils moved in a directional manner towards the 
chemoattractant. Neutrophils migrating towards fMLP chemoattractant had faster 
movement and stronger migration towards the chemoattractant, in comparison to IL8, 
that is they travelled further, faster. This is quantified by measurement of cell speed 
(average speed of a cell in any direction over the time course), velocity (average speed 
of a cell in its most prominent direction over the time course) and chemotactic index 
(directional accuracy of chemotaxis measurement, calculated as a change in the angle 
of a cell along the Y axis according to the cosine plot) as shown in figures 3.8. 
Statistical analysis by one-way ANOVA demonstrated that there was a significance 
difference for IL8 and fMLP compared to RPMI in terms of speed, velocity and 
chemotactic index. Whilst this assay provides the most information about the 
movement of the neutrophils it was the most laborious and difficult to examine a large 
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Figure 3.8: Box and whiskers graph of average speed, velocity and chemotactic index of neutrophils isolated from healthy blood 
volunteers (n=5). Central line represents the median, lower and upper bounds of boxes represent the 25th and 75th percentile 
respectively, and whiskers represent furthest reaches of the data. Statistical analysis: One-way ANOVA with Tukey’s post-test. *** 






3.3.2.2 ChemoTx chemotaxis chamber 
The first Boyden chamber tried was the ChemoTx chemotaxis chamber from 
Neuroprobe. This device was a made from a metal mounted filter placed above a 96 
well plate. Each experimental test area was defined by hydrophobic masks to prevent 
cross contamination of different areas above different wells. After chemotaxis cells 
were counted in both the chemoattractant well beneath as well as after dislodging any 
cells from the membrane itself. It was found that the membrane was extremely fragile 
and could easily be rupture by a pipette tip. This made it extremely difficult to handle. 
Additionally, any movement of the filter, for example in tapping the bench to place the 
plate, could cause the droplet of cells in the hydrophobic area to be dislodged and flow 
into adjacent areas. For these reasons this chamber was not taken further for 
experimentation. 
 
3.3.2.3 Micro Chemotaxis chamber  
The second Boyden style chamber sued was the Micro chemotaxis chamber, also 
from Neuropore. This chamber had the advantage of being reusable. However, in 
contrast to the other chambers, it was recommended to visually count the number of 
transmigrated neutrophils on the underside of the membrane after use. To do this 
neutrophil were placed in the upper chamber and allowed to move towards the 
chemoattractant for 90min. Following this time, the membrane was removed, and cells 
were visualised by staining. An attempt was then made to count the cells using a light 
microscope. Figure 3.9 shows a typical membrane before and after use. Whilst the 
neutrophils are identifiable it was neither particularly high through put nor easy to 
differentiate between them and the pores in the membrane. As with the ChemoTx 
membrane the membrane was fragile and easily broken. Thus, this device was not 








Figure 3.9: Photographs of the poly carbonate track etched (PCTE) membrane. a. 
shows the membrane before use, the black arrows highlight the pores; b. shows after 









3.3.2.4 QCM chemotaxis 3µm 96-well cell migration assay (Merck Millipore) 
After finding that the ChemoTx Chamber and 48 Well Micro Chemotaxis Chamber do 
not work well, the QCM chemotaxis 3µm 96-well cell migration assay from Merck 
Millipore was tested. It was costly however it was robust, and the manufacturer’s 
protocol gave quantifiable results. Neutrophil cells were plated in an upper chamber 
with attached membrane. This was then placed above a lower chemoattractant 
containing chamber. Cells migrating directly into the lower chamber plus cells 
dislodged from the lower side of the membrane were counted by fluorescent detection 
in a fluorimeter, after incorporation of Cyquant dye. Cyquant dye exhibits strong 
fluorescence when bound to DNA. Neutrophils isolated from healthy donors were used 
in this assay to determine if they resulting data showed similar patterns to that found 
with the Insall chamber. Figure 3.10 shows that neutrophils in this assay migrated 
towards fMLP and IL8 in a similar manner to that observed by video microscopy, that 
is that more cells accumulated beyond the membrane in response to fMLP than IL8 
but that both chemoattractants cause greater accumulation of cells beyond the 
membrane compared to PBS. This suggests that the cells were migrating in the 
direction of the chemoattractants rather than either sedimenting or randomly moving 
through the membrane.  
Due to the ease of use and the results appearing equivalent to the laboratory gold 
standard, Insall chamber chemotaxis, the QCM cell migration assay was used in 
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Figure 3.10: Chemotaxis of neutrophil cells towards chemoattractants fMLP (1μM) and 
IL8 (1μM) as assessed by the QCM chemotaxis 3µm 96-well cell migration assay. n= 
3 healthy donors. Central line represents the median, lower and upper bounds of 
boxes represent the 25th and 75th percentile respectively, and whiskers represent 
furthest reaches of the data. Statistical analysis: One-way ANOVA with Tukey’s post-







3.3.3 Neutrophil cell glutathione 
For neutrophil cell intracellular reduced and oxidised glutathione, the GSH and 
GSH/GSSG Glo assays were used from Promega (UK). The ratio between reduced 
and oxidised forms of glutathione was approximately 10:1 as expected in healthy 
neutrophils (figure 3.11). The assay was straight forward, and no further assays were 
tested for the measurement of reduced and oxidised glutathione. 
 
Figure 3.11: Standard graph of glutathione (GSH) and oxidised glutathione (GSSG) 





3.3.4 Effect of manipulation of intracellular glutathione on neutrophil chemotaxis 
On completion of a selection of semi high throughput assays for assessment of 
neutrophil chemotaxis and glutathione measurement the main aim of this chapter was 
explored. Neutrophils were isolated from healthy volunteers and the intracellular 
glutathione content was altered by using glutathione modulating compounds which 
were BSO, BCNU and CDNB. The effect of these on chemotaxis was measured by 
using the QCM cell migration assay.   
For neutrophils with glutathione modulating compounds, over the course of the 
experiment, cell viability, as measured by trypan blue exclusion, gradually declined 
across all treatments (figure 3.12). Additionally, no change to viability was found to be 
caused by the glutathione modulating compounds themselves. Therefore, the 
compounds do not affect the viability of neutrophils when compared to the vehicle 
control.  
For the glutathione modulating compounds, it was found that CDNB, a depleter of 
glutathione through thioester conjugation, and BCNU, an inhibitor of glutathione 
reductase as well as BSO, an inhibitor of rate limiting gamma-glutathione cysteine 
synthetase all decreased both neutrophil intracellular gluthathione compared to PBS 
(figure 3.13) and chemotaxis relative to PBS treated cells responding to both fMLP 
and IL8 in figure 3.14. However, NAC did not appear to have an effect on glutathione 







Figure 3.12: Neutrophil cell viability change with glutathione modulating compounds 
(GSH) compounds. Isolated neutrophils were incubated with BSO (10µM), NAC 
(5mM), BCNU (5µM) or CDNB (10µM) for 4 or 8h prior to determination of cell viability 
by trypan blue exclusion. n=4, mean and standard deviation shown. 
 
Figure 3.13: Changes in glutathione (GSH) levels of neutrophil cells with glutathione 
modulating compounds: BSO (10µM), NAC (5mM), BCNU (5µM) and CDNB (10µM) 
from GSH-Glo glutathione assay. * p<0.0001, comparisons are to PBS treatment for 
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Figure 3.14: Neutrophil cell chemotaxis with glutathione modulating compounds 
(GSH) compounds. Isolated neutrophils were incubated with BSO (10µM), NAC 
(5mM), BCNU (5µM) or CDNB (10µM) for 4 h prior to distribution in to 96 well QCM 
migration assay plate. Cells 1x105 per ml were then allowed to respond to 
chemoattractants FMLP (1uM) or IL-8 (1uM) for a further 4h before measurement of 
the number of cells that had migrated. Data are represented as mean +/- standard 
deviation (n= 4 donors). Significance was measured by One-way ANOVA with Tukey’s 
post-test * p<0.0001, $ p<0.001 (comparisons are to PBS treatment for each 











3.4 Discussion  
The ultimate aim of the work presented in this chapter was to be able to modulate the 
intracellular glutathione of neutrophils isolated from healthy donors. To do this the 
neutrophils would need to be exposed to compounds that could alter the intracellular 
glutathione. This first incubation would take 4h and then the setup of the chemotaxis 
would take up to another 4h. Thus, it was vital to understand if neutrophils could 
survive for this length of time. A new assay was tested as it could monitor in real time 
the viability of neutrophils over a long period of time. This assay, Real Time Glo from 
Promega, was set up with a number of conditions. The assay mechanism is based 
upon the provision of a proprietary luciferase reagent that is cell permeant. This 
reagent enters viably cells where it is reduced and can then diffuse out of the cell 
again. The reduced version is then a substrate for extracellular luciferase which 
catalyses the production of light which can be detected by a luminometer.   
Once the initial teething issues of evaporation were sorted out it was possible to 
assess the use of different additives to either a rich medium such as RPMI or minimal 
medium such as gPBS could aid in neutrophil viability. It was found that RPMI alone 
would sustain the cells if evaporation was limited. Various concentrations of foetal 
bovine serum (FBS) were added to the cell culture medium because FBS can enhance 
length of survival and contains a high content of growth promoting factors. Additionally, 
HEPES was added as a buffering agent as the incubation was without carbon dioxide 
(CO2). Thus, in subsequent experiments the cells were maintained in RPMI during 
incubation. Additionally, subsequent assays used Trypan blue exclusion for analysis 
of cell viability as this was quicker and cheaper long term.  
The first chemotaxis assay tested was the ChemoTx chemotaxis chamber from 
Neuroprobe. This assay has been successfully utilised by, for example, Williams et 
al., (2017) and Simard (2009). However, here this membrane was found to be very 
fragile and difficult to handle, it was not even possible to generate any robust data. 
The second assay tested was the Micro chemotaxis chamber, also from Neuroprobe. 
This was a reusable chamber that had wells into which neutrophil suspension could 
be pipetted. This made for a much more stable system, though the membrane was 





previously for neutrophil migration studies (Barber et al., 1999). The tricky aspect with 
this assay was the visualisation of the neutrophils on the membrane. The membrane 
contained many track etched pores which were easier to visualise then the migrated 
neutrophils themselves. Whist either of these two approaches might have benefited 
from further fine tuning, the availability of third chamber was tested at the same time 
to isolate a more robust assay. This final assay was the QCM assay from Merck 
Millipore, which had also been previously reported for use with chicken heterophils 
(Larson 2008). This assay incorporated the robust nature of the wells above the 
membrane and an integrated membrane to the upper wells. This made for much easier 
handling. Additionally, the manufacturer’s protocol suggested the use of a DNA 
binding fluorescent dye that allowed for rapid quantitation of the migrating cells. 
Comparison of migration of human neutrophils towards fMLP or IL8 demonstrated 
similar patterns to those seen in the Insall chamber. Thus, this assay was chosen for 
subsequent analysis of neutrophil chemotaxis.  
In this study, one of the aims was to perturb the redox balance with glutathione 
modulating compounds to alter the glutathione level and determine if this perturbed 
the chemotactic ability of neutrophils. In a study by Harlan et al. (1984), the glutathione 
redox cycle was perturbed at several points using BCNU, CDNB and BSO. Therefore, 
the same glutathione modulating compounds used in this study with the addition of 
NAC as a method to potentially increase glutathione concentrations as well.   
Across the length of the experiment the treatment of the neutrophils did not appear to 
alter cell viability as measured by trypan blue exclusion. The use of this reagent not 
only was rapid and in expensive but also allowed for analysis without the complication 
of trying to understand the interaction of the modulating compounds with the enzyme 
systems in the RT Glo assay.  
The compounds altered the glutathione level: BCNU, CDNB or BSO decreased the 
glutathione level, meanwhile, NAC maintained the glutathione level. NAC delivers 
cysteine to the cells, but also work as an antioxidant itself. The maintenance of cell 
viability when intracellular GSH appeared to plummet is of interest. Decreased of GSH 
is an early event of cell death progression (Henze et al., 2000, Franco and Cidlowski 
2009, Chiang et al., 2011). GSH depletion occurs before rupture of plasma membrane 





Finally, it was possible to assess the effect of altering intracellular glutathione 
concentration on neutrophil migration or chemotaxis. Previously this could be inferred 
from the analysis by Dias et al., (2013) and of Roberts et al., (2015) who separately 
measured each activity on neutrophils isolated from patients with periodontitis. Data 
presented here (figure 3.13 and 3.14) demonstrates that a decrease in glutathione 
causes a decrease in chemotaxis in neutrophils isolated form health donors. 
Chemotaxis is a highly regulated and complex set of events that involve the detection 
of a chemoattractant, mobilisation of the intracellular cytoskeleton and the movement 
of the whole cell through interaction with the extracellular matrix.  One key player in 
the cytoskeleton is the protein actin which forms rod like structures to propel forward 
the cell body. It exists in two states: either free actin so called G-actin or globular actin 
or actin in a filament structure so called F-actin or filamentous actin. It has previously 
been reported that changes to G-actin, such as protein glutathionylation, can prevent 
it from forming F-actin (Dalle-Donne et al., 2003; Lassing et al., 2007; Shelton et al., 
2005; Wang et al., 2001). Protein glutathionylation is a post translational modification 
that occurs within cells to protect thiol active cysteines. Their formation may be 
reverted at the expense of glutathione. The decrease in glutathione within the 
neutrophils may have prevented this. Alternatively, chemotaxis requires the production 
of limited quantities of hydrogen peroxide (Ball et al., 2017) which also need to be 
controlled by redox regulation and buffering by glutathione. Decreases in available 
glutathione may prevent many cellular processes including chemotaxis. Interestingly 
hydrogen peroxide may also serve as a chemoattractant (Klyubin et al., 1996, Yoo et 
al., 2011). In the results of the NAC it was seen that this compound also decreased 
the amount of chemotaxis. It may be that the antioxidant nature of this compound 
decreased any extracellular hydrogen peroxide preventing key signalling events at the 







3.5 Conclusion  
When the redox balance was perturbed with glutathione modulating compounds, the 
glutathione antioxidant was decreased as well as the chemotactic ability of neutrophils 
decreased in healthy volunteers. It can be concluded that BCNU, CDNB or BSO 
decreased intracellular glutathione in primary neutrophils. BCNU, CDNB or BSO 





























CHAPTER 4 – Optimisation of neutrophil sample preparation and 







Optimisation of neutrophil sample preparation and separation for 
proteomics and detection of glutathionylated proteins 
4.1 Introduction 
To maximise the output from mass spectrometry based proteomics it is important to 
decrease sample complexity as it flows into the mass spectrometer. This improves the 
value of peptide identification in the mass spectrometer: this is due to the selection of 
the top 10-20 peptides in each ion packet isolated for fragmentation. If more than this 
number of peptides is present, then the lower abundance peptides will not be 
fragmented and hence not identified later in the work flow.  By using two dimensional 
techniques, such as two dimensional chromatography, an increase the number of 
peptides and ultimately proteins has been demonstrated (eg Batth et al 2014). 
Similarly, by targeting or isolating peptides with a desired characteristic, eg post 
translational modification, then the identification of these peptides can also be 
improved. The data presented in this chapter explores the identification of the best 
methods to isolate proteins from neutrophils and to separate them by two dimensional 
chromatography, and additionally to isolate glutathionylated proteins for identification.  
For the development of two dimensional chromatography two different methods were 
compared in the first dimension: strong cation exchange chromatography (SCX), 
which had been established in the laboratory for a long time; and high pH reverse 
phase chromatography (C18) which was developed in the lab following a publication 
by another group at the beginning of these studies (Batth et al., 2014). One potential 
advantage of the C18 column was that the buffers used might decrease the amount 
of sample clean up required, and hence decrease sample loss in multiple stages. For 
both the second dimension was the C18 reverse phase column attached to the mass 
spectrometer. For the detection of glutathionylated proteins an antibody based 







Proteomics information can provide proteins that are expressed from neutrophils in 
either healthy people or periodontitis patients. Use of proteomic methods allows for 
various approach to understand and explore the role proteins play in neutrophil cells. 
Neutrophil primary granules can be found in granulocytes which contain 
myeloperoxidase, acid hydrolases and defensins. Myeloperoxidase (MPO) is a 
microbial enzyme which produces hyperchlorous acid from hydrogen peroxide and 
chloride ions (Hughes et al., 2003). Proteolytic and bactericidal proteins are stored by 
azurophilic granules (Borregaard et al., 1993). The shape of these granules is 
described as spherical or football shaped. Secretory vesicles are rich in receptors. 
Many neutrophil functions are regulated such as adhesion, phagocytosis, killing of 
bacteria and interaction with endothelial cells during exocytosis of cytoplasmic 


















4.2 Materials and methods 
An overview of the workflows used in this chapter are shown in figure 4.1. In HPLC, 
strong cation exchange column (SCX) and High-pH reverse phase column (C18) were 
used. The SCX column separates peptides from negative to positive charge ions. 
Meanwhile, the C18 column separates peptides from hydrophilic to hydrophobic 
phase. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to 














Figure 4.1: Proteomics workflow for detection of whole proteins and glutathionylated 
proteins in neutrophil cells. 
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4.2.1 Neutrophil lysis buffer 
Various of neutrophil lysis buffer were used to lyse cells which are; 
1. 10% SDS with 100 mM TEAB with protease inhibitor (protease mini, Roche) 
2. Radioimmunoprecipitation assay buffer (RIPA buffer) with protease inhibitor 
(protease mini, Roche) 
3. M-PER mammalian protein extraction reagent (M-PER buffer) with protease 
inhibitor (protease mini, Roche) 
4. Laemlli buffer  
Isolated neutrophils (1 x 105 cell per ml) were lysed in any of the buffers described 
above. For buffers 1-3 the cell suspension was then sonicated (10s, 5Hz) on ice. Any 
cell debris was pellet by centrifugation (1min, 4000g). Protein content was measured 
and 20µg was then prepared with Laemlli buffer. For samples prepared directly in 
Laemlli buffer isolated neutrophils (1 x 105 cells) were lysed directly in Laemlli buffer. 
Samples in Laemlli buffer were heated at 95°C for 5min.  
20µl prepared neutrophil protein (from methods 1-4) was loaded onto a 12% sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) gel (Bio-Rad) and 
electrophoresed at 150V for approximately 90min until the dye front reached the 
bottom of the gel. . Then, Coomassie blue protein stain (refer methods section 2.15.3) 
was used to stain the proteins and allow bands to be viewed directly in the gel. 
4.2.2 Strong Cation Exchange (SCX) column fractionation 
The method was based on Batth et al 2014. Briefly:  
The SCX chromatography was done on a polysulfethyl A column (100 mm ×2.1 mm, 
5 μm particle size. PolyLC, Columbia, MD) with a javelin guard cartridge (10 mm × 2.1 
mm, 5 μm particle size, 200 Åpore size. PolyLC, Columbia, MD). Two mobile phase 
buffers (A and B) were prepared. Buffer A: potassium dihydrogen orthophosphate (10 





dihydrogen orthophosphate (10 mM) and potassium chloride (500 mM, pH 3) was 
dissolved in water and 20% ACN was added. The flow rate was set at 0.2ml/minutes 
to accommodate pressure for the system below 20MPa. Gradient for liquid 
chromatography ran from 0 % mobile phase B for 15min, 0-70% B over 65min, 70-
100% B over 20min. The column was washed and re-equilibrated in buffer A over 
10min. 
4.2.3 High pH Reverse Phase (HpH) Fractionation 
In this study, HpH was done on either a XBridge Shield RP18 (5µm particle size, 2.1 
mm internal diameter x 100 mm long column, Waters, UK) or a Hypersil Gold C8 
column (5µm particle size, 2.1 mm internal diameter x 50 mm long column, Thermo 
Fisher, UK) on the ETTAN LC system, a HPLC operating system at 500 mL/min for 
peptide separation. 100µl of sample was injected on to the column in each experiment. 
For experiments, buffer A consisted of 1000mL of water added with 10mM ammonium 
hydroxide and buffer B consisted of 90% acetonitrile in with 10mM ammonium 
hydroxide. Both buffers were adjusted to pH 10 with ammonium hydroxide. All of the 
peptide fractions were collected using a collector (fraction collector F9-R) at 2 min 
intervals. Samples were loaded onto the column at 500 mL/min for 2min after the 
fractionation gradient commenced as follows: 1% to 25% B in 50 min, 60% B in 4 min, 
and ramped to 70% B in 2 min. At this point, fraction collection was halted, and the 
gradient was held at 70% B for 5 min before being ramped back to 1% B, during which 
time the column was washed and re-equilibrated. The number of fractions that were 
concatenated was set to 10 fractions and 4 fractions throughout the experiment. Prior 
to concatenation, ammonium hydroxide was evaporated in a Speed Vacuum operating 
at 45°C.  
Column storage 
All columns were washed and equilibrated into 100 % acetonitrile and were stored at 






4.3.1 Lysis of neutrophil cell 
In previous studies, various methods have been used to lyse cells: here four methods 
were compared. The lysis buffers used were: 10% SDS with 100 mM TEAB with 
protease inhibitor; radioimmunoprecipitation assay buffer (RIPA buffer) with protease 
inhibitor; M-PER mammalian protein extraction reagent (M-PER buffer) with protease 
inhibitor; and Laemlli buffer without protease inhibitor (reference methods section 
4.2.1). From the Coomassie protein stain in figure 4.2, neutrophil cells in all three lysis 
buffers showed a ladder of protein bands between predominantly between 70 kDa to 
40 kDa. Meanwhile, the proteins prepared directly in Laemlli buffer appear to show a 
different pattern: the predominant bands between 70-40kDa are absent and there 
appear to be a larger quantity of low molecular weight protein bands; there appear to 
be more higher molecular weight bands. 
          
Figure 4.2: Representative SDS-PAGE gel of coomassie blue protein stain for 
neutrophil cells in four different lysis buffer: 10% SDS with 100 mM TEAB with 
protease inhibitor, RIPA buffer with protease inhibitor, M-PER buffer with protease 
inhibitor and Laemlli buffer without protease inhibitor. (see general methodology 
section 2.15 for western blot protocol). 

























4.3.2 High performance liquid chromatography (HPLC)  
To start with investigating the efficacy of the different types of chromatography that 
could be used a BSA digest was prepared as this was rapid, inexpensive and did not 
require donation of neutrophils. Although a relatively simple mixture, in comparison to 
a digest prepared from a complex mixture of proteins, this was able to show a range 
of results for the three columns. Representative chromatograms from the separation 
of BSA digests on the three columns are shown in figure 4.3, 4.4 and 4.5.  Table 4.1 
shows the number of proteins detected for digested neutrophil extracts without 
fractionation and after separation by SCX of HpH reverse phase columns.  
 










120+/-18 (n=3) 4 86+/-13 
(n=3) 












Table 4.1: Number of proteins detected from a digest prepared from neutrophil cell 
extracts either without fractionation or with fractionation by three chromatography set 
ups. Total numbers of proteins identified by using either 4 or 10 concatenated fractions 
form these separations are also shown. Number of proteins detected by mass 








Figure 4.3: Representative separation of digested BSA on A, strong cation exchange 
(SCX) polyLC polysulfethyl column, B High-pH reverse phase (C8) Hypersil Gold 
column and C High-pH reverse phase (C18) Waters XBridge column. 22 fractions 
were collected from each separation. Pink represents injection, continuous blue line 
shows peptide profile, green line shows gradient B concentration. 
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4.3.3 Coverage and peptide spectrum matches (PSM’s) in neutrophil separations 
The data obtained from the separation of neutrophil digests was examined for protein 
coverage and numbers of peptide spectral matches (PSMs) to ascertain further 
information about the proteins detected. Coverage is the percentage of the protein 
sequence covered by identified peptides. Proteins coverage depends on factors such 
as protein size and abundance. The number of PSMs is the total number of identified 
peptide spectra matched for the protein and included multiple identifications of the 
same peptide sequence so gives a qualitative indication of the abundance of the 
protein.  
Coverage of proteins extracted from neutrophil cells and separated by either SCX or 
C18 HpH reverse phase in the first dimension are shown in figure 4.4. Percentage of 
protein coverage for neutrophil cells on both columns are similar in terms of coverage. 
A higher coverage may be of use when trying to gain deeper insights into the proteome 
for not merely detection of proteins but analysis of isoforms or splice variants. As the 
latter was not a major focus of this thesis the coverage was adequate for the aims 
presented here. 
The number of PSMs per protein discovered in digested neutrophil extracts, separated 
by either SCX or C18 HpH reverse phase in the first dimension, are shown in figure 
4.5. It can be seen that the number of PSMs detected per protein increases with 





















































































Figure 4.4: Protein coverage of fractions collected after separation of neutrophil 
samples separated by either SCX or HpH C18 column in the first dimension. n=3 







































































































Figure 4.5: Number of PSMs detected per protein from detected in fractions collected 
after separation of neutrophil samples separated by either SCX or HpH C18 column 








4.3.4 Protein class in neutrophil separations 
Exploration of the proteins detected revealed proteins expected to be of neutrophil or 
cellular origin eg actin, but also proteins indicative of the matrix from which they were 
isolated: blood. The most abundant contaminating protein was haemoglobin. Whilst 
red blood cells are lysed on purpose during the neutrophil isolation procedure to allow 
for their removal haemoglobin was a persistent contaminant.  Its presence however 
can be excluded by filtering and identification as a contaminant in Proteome 
Discoverer. However, if present in high quantities it would decrease the opportunity to 
detect less abundant proteins. Thus, cell washing was done meticulously during 
neutrophil isolation.   
The detected proteins by either chromatography method were analysed by 
bioinformatics tool Panther to understand if there was any difference in the protein 
function, or class. The analysis, shown in figure 4.6, demonstrated that it appeared 
that similar protein classes were returned for either separation type, suggesting that 
similar proteins were being detected. The Venn diagram in figure 4.7 analysed by 
bioinformatics tool Venny 2.1 shown that there are similar proteins detected in both 
chromatography method. (For the list of proteins detected by SCX and C18, refer to 






Figure 4.6: Percentage of proteins binned into different protein classes by Panther for 























































































































































Figure 4.7: Numbers of similar proteins detected by Venny 2.1 for neutrophil cell 





4.3.5 Detection of glutathionylated proteins via Western blotting 
To stimulate the chemotactic phenotype of neutrophils, cells were stimulated with 
fMLP (10nM) or IL8 (200ng/ml) for up to 60min. Examination of Coomassie stained 
gels of stimulated cells (figure 4.8) showed that there was a remarkable difference in 
the protein profile between FMLP and IL8 stimulated cells. The approximately 72kDa 
highly abundant proteins was excised from the gels and trypsin digested. Analysis by 
LC-MS/MS identified the protein as myeloperoxidase (MPO). MPO is a primary or 
azurophilic granule protein. Primary granules are exocytosed rapidly in response to 











Figure 4.8: Coomassie stained SDS-PAGE gel showing separation of neutrophil 
extracts. Cells were stimulated with either IL8 or fMLP for up to 60min. ‘m’ represents 
the molecular weight markers. (see general methodology section 2.15.3 for 








In preliminary experiments to detect glutathionylated proteins or actin neutrophil 
extracts from three separate donors were used with an antibody against 
glutathionylated proteins (PSSG) and then the same membranes were stripped and 
reprobed with an antibody against actin. The output of these experiments is seen in 
figure 4.9. In two of the donors glutathionylated proteins are visible as a small number 
of bands from high to low molecular weight but with a larger number in the low end.  
Neutrophil extracts from one donor did not reveal any glutathionylated proteins. All 
three donors, however, showed very similar quantities of actin. 
Next neutrophil cells were stimulated with either fMLP or IL8 and the same proteins 
detected. Figure 4.10 shows that for both proteins the stimulation appears to make 







Figure 4.9: Western blots of neutrophil extracts from three different healthy donors 
(label 1,2 & 3). Proteins of interest were detected by A.  anti-glutathionylated (PSSG) 
antibody or B anti-actin antibody. ‘m’ represents the molecular weight markers. 
Representative of n=3 experiments. (see general methodology section 2.15 for 
western blot protocol).  
 
Figure 4.10: Western blots of neutrophil extracts. Cells were stimulated with either IL8 
or FMLP for 60min. Proteins of interest were detected by A.  anti-glutathionylated 
(PSSG) antibody or B anti-actin antibody. ‘m’ represents the molecular weight 







In this chapter methods were developed and refined in our laboratories for the 
optimisation of neutrophil sample preparation and separation for proteomics and 
detection of glutathionylated proteins. First an off-line high-pH reverse-phase 
fractionation was developed using off-line basic reverse-phase fractionation technique 
from a publication by Batth et al (2014). Batth et al (2014) had developed their protocol 
for in-depth phosphoproteome studies which detected multiphosphorylated peptides. 
For lysis of neutrophil cells, protein inhibitors were used to stop the action of a broad 
range of proteases that could degrade proteins present in the neutrophil samples. 
Neutrophils contain a large amount of proteases and it is vital to keep proteins intact 
to allow for identification of peptides later in the proteomics work flow and to allow for 
comparison by SDS-PAGE. No protease inhibitors were added to the Laemlli buffer 
because this buffer denatures proteins rapidly preventing protease activity anyway. 
Once cells had been lysed and homogenised the extracted proteins were separated 
by SDS-PAGE. The gels were stained with Coomasie blue and compared visually. 
The reason for these lower molecular weight proteins was not investigated further but 
could be due to more efficient lysis of granules containing lower molecular weight 
species or possibly degraded proteins, though this is unlikely due to the processing of 
the cells to proteins rapidly in a denaturing solution The higher molecular weight 
species could the release of  membrane-bound proteins by this method, that are 
perhaps not as abundant in the other preparations.  Since the interest of this study 
was to look at which proteins are glutathionylated in the cytosol of neutrophils, it was 
concluded to continue the use of 10% SDS with 100 mM TEAB with protease inhibitor 
as the lysis buffer for neutrophil cells as this was the simplest buffer that could 
generate potentially the best preparation of cytosolic proteins. 
High performance liquid chromatography (HPLC) was used to fractionate samples 
before submitting for mass spectrometry analysis. In this research, three columns 
were used: strong cation exchange column (SCX) and two high-pH reverse phase 
column (C8 and C18). The SCX column separates peptides based on their charge 
whereas the HpH reverse phase used peptide hydrophobicity as the separating factor. 





peptide mixture interacted with the negatively charged polysulfethyl functional groups 
on the polymer beads. Peptides with a negative charge will move faster and elute 
earlier from the column in comparison to the positively charged peptides that elute 
later. The high-pH reverse phase column separates peptides based on hydrophobic 
interactions. This has been shown to be more efficient in fractionation compared to 
that of charge-based separations like SCX (Batth et al., 2014).  
Of all three column types it was immediately apparent that the Hypersil Gold C8 
column showed much less separation of the peptides in comparison to both the SCX 
and Waters XBridge columns may be because this matrix is more commonly used to 
separated proteins rather than peptides. Additionally, the Waters XBridge column 
showed very good resolution of the peptides, by returning to the base line, and seemed 
to limit a large number of peptides coming through very rapidly in the initially wash, 
where negatively charged peptides do not bind appear to the SCX column. Thus, the 
Waters XBridge column was selected for the main work in this thesis. This was 
pleasing as it out performed the established method in our laboratory. All the methods 
seemed to produce similar results in terms of the protein classes detected. 
 To verify that this was the correct choice digested neutrophil lysates were also 
separated by the three columns and fraction collected. The fractions were then 
concatenated and pooled to either 4 or 10 fractions for analysis by mass spectrometry. 
From table 4.1, the highest quantity of proteins was detected using the C18 Waters 
XBridge column compared to the C8 Hypersil Gold and SCX column. This confirmed 
the choice of using the Waters XBridge column in further studies.  
In a study by Rørvig et al (2013) a larger number of proteins were detected than 
presented here. However, these authors were looking to study all the granule proteins 
within neutrophils. They used a nitrogen cavitation technique to effectively breakdown 
all the granule membranes after subcellular fractionation. This was not a technique 
available nor was the release of all the granule proteins desired as this may have 
clouded the results of the chemotactic machinery found in the cytosol.  
Proteins extracted from neutrophils were separated by SDS-PAGE and the proteins 
transferred to nitrocellulose membranes by electroblotting. The membranes were then 





Western blotting. Of particular interest in this study was the detection of 
glutathionylated proteins in general and actin specifically. The latter was of interest 
because of the discovery by Sakai et al (2012) that demonstrated that glutathionylated 
actin prevented efficient chemotaxis of neutrophils.  
Actin is an abundant protein in cytoskeleton of neutrophils and used during cell 
movement (Kuhns et al., 2019). Actin is the protein that would be of interest to see in 
this study. Thus, it was readily detected by western blotting. Glutathionylated proteins 
appeared to be more elusive and were not consistently detected in neutrophils extracts 
from different donors. An attempt was made to purify glutathionylated proteins using 
the BioGEE system. BioGEE utilises a biotinylated glutathione ethyl ester that can be 
introduced in to cells during a pre-incubation with cells, or during culturing in longer 
lived cells. The biotin conjugate can then be purified by use of streptavidin beads to 
pull down proteins with biotinylated glutathione covalently attached. A method was 
reported by Brenan et al., (2006) who demonstrated low concentrations of 
glutathionylated proteins from neutrophils.   Further optimisation may be required, or 
many more neutrophils cells need to be used as input to these experiments. An 
alternative might also be to use the ‘redox array’ technology to identify glutathionylated 
protein irrespective of its relative abundance (Mullen et al., 2015). This technique was 
developed to work with secreted proteins rather than cytosolic ones and can detect 
proteins 100x lower in concentration than those found by mass spectrometry. 
However, an antibody array is also part of the set up meaning that this is a targeted 
approach rather than a discovery based approach.  
4.5 Conclusion 
Work presented here supports the choice of using HpH reverse phase 
chromatography for increasing the numbers of proteins detected in neutrophil cell 
extracts. Detection of glutathionylated proteins by western blotting was possible but 
may be inconsistent in detection or the quantity of glutathionylation between neutrophil 
donors may be inconsistent. Detection of actin however was consistent by western 
blotting. The discrepancy in glutathionylated protein detection may be due to low 






























Detection of protein glutathionylation in model protein haemoglobin  
5.1 Introduction 
In this thesis, one of the aims was to detect protein glutathionylation. Therefore, a 
model glutathionylated protein was examined first to establish if current 
instrumentation available could identify this modification. The protein used was human 
haemoglobin (Thermo Fisher Scientific, Paisley, United Kingdom) as previously 
described by (Regazzoni et al., 2009). Mass spectrometry was used as a platform to 
characterise the modified and unmodified forms of the protein. Two methods were 
used: direct infusion mass spectrometry and LC-MS/MS. Through direct infusion, 
samples were injected directly into the instrument and thus, everything in the sample 
was detected simultaneously. Through the LC-MS/MS method, sample first went 
through reverse phased column (C18) and then, through Orbitrap-based mass 
spectrometer, allowing for a separation of proteoforms or peptides. Proteoforms are 
the narrowest view of a particular protein which means that it is the same protein but 
in different proteoforms, for example modified and unmodified haemoglobin may be 
thought of as different proteoforms.   
Glutathionylation is a process to protect protein thiols from irreversible oxidation and 
also to prevent loss of GSH under oxidative stress. Previous study mentioned that 
significant redox disturbances occur in neutrophils of periodontitis patients associated 
with deregulation of anti-inflammatory transcription factor Nrf2 pathway producing 
neutrophil hyperactivity (Dias et al., 2013). There are studies that have shown linkage 
of cigarette smoking and nicotine toxicity to glutathione depletion in periodontal tissues 
(Chapple and Matthews., 2007). There are also studies that reported areca nut 
alkaloid, arecoline-induced thiol depletion in periodontal ligament fibroblasts may 
make them more vulnerable to the effects of nicotine (Jr et al., 2007) and periodontal 
ligament fibroblast glutathione levels were decreased in a dose-dependent means by 






5.2 Materials and methods 
5.2.1 Direct infusion analysis: 
A 10µL sample of 10mM haemoglobin solution in 0.1% formic acid  was introduced to 
the mass spectrometer at a gas pressure of 0.3 pound-force per square inch (PSI) and 
1.8 kV. The aqueous solution was injected directly into the mass spectrometry 
equipped with a TriVersa Nanomate chip-based electrospray device (Advion, Ithaca, 
New York), the electrospray ionization (ESI) source. The optimized parameters were 
as follows: gas pressure 0.3 psi, a tip voltage of 1.55 kV for direct infusion electrospray 
and a capillary temperature of 250 °C. Each analysis required about 5 minutes. Mass 
spectra were acquired by scanning over the 100-1000 m/z range. Xcalibur Analyst 
internal software (v2.0.7, Thermo Fisher Scientific) was used for instrumentation 
control and data acquisition.   
5.2.2 Haemoglobin glutathionylation 
Method for haemoglobin glutathionylation was adapted from a study done by Woodi 
et al. (2009). For preparation of glutathionyl haemoglobin, commercial haemoglobin 
(Thermo Fisher Scientific) was used with large excess of oxidized glutathione (GSSG) 
(Thermo Fisher Scientific) at a concentration of 67 mM in 0.5 M ammonium 
bicarbonate buffer (pH 8) for 12 hours at 37°C. A sephadex G-10 column (GE 
Healthcare, Buckinghamshire, United Kingdom) was used to remove any excess 








5.3  Results  
5.3.1 Haemoglobin mass list  
To accurately identify glutathionylated proteoforms, Protein Prospector 
(http://prospector.ucsf.edu/prospector/mshome.htm) was used to generate lists of 
mass to charge ratio for proteins. The original source of the human haemoglobin 
protein sequences were UniProt (accession numbers: haemoglobin alpha P69905 and 
haemoglobin beta P68871).The resulting mass lists are shown in table 5.1 and were 
used to identify the haemoglobin proteins and glutathionylation modification of 
haemoglobin beta.   
From the results (figure 5.1, 5.2, 5.3 and 5.4), protein glutathionylation was observed 
in haemoglobin through direct infusion using whole protein and in LC-MS/MS using 
whole protein and digested protein. Glutathionylation was observed in beta subunit of 
haemoglobin only, maybe because of an accessible cysteine residue indicated by a 
mass increment of 305 Da. A previous study by Woodi et al (2009) suggested a mass 
increment of 305 Da for glutathionylation because addition of one glutathione molecule 










15248.93 15989.30 NA 
M 15125.92 15866.28 16171.30 
M+H 15126.93 15867.29 16172.31 
(M+2H)/2 7563.97 7934.15 8086.66 
(M+3H)/3 5042.98 5289.77 5391.44 
(M+4H)/4 3782.49 3967.58 4043.83 
(M+5H)/5 3026.19 3174.26 3235.27 
(M+6H)/6 2521.99 2645.39 2696.22 
(M+7H)/7 2161.85 2267.62 2311.19 
(M+8H)/8 1891.75 1984.29 2022.42 
(M+9H)/9 1681.67 1763.93 1797.82 
(M+10H)/10 1513.60 1587.64 1618.14 
(M+11H)11 1376.09 1443.40 1471.13 
(M+12H)/12 1261.50 1323.20 1348.62 
(M+13H)/13 1164.54 1221.49 1244.95 
(M+14H)/14 1081.43 1134.31 1156.10 
(M+15H)/15 1009.40 1058.76 1079.09 
(M+16H)/16 946.38 992.65 1011.71 
(M+17H)/17 890.77 934.32 952.26 
(M+18H)/18 841.34 882.47 899.41 
(M+19H)/19 797.11 836.08 852.13 
(M+20H)/20 757.30 794.32 809.57 
(M+21H)/21 721.29 756.55 771.07 
(M+22H)/22 688.55 722.20 736.07 
(M+23H)/23 658.66 690.85 704.11 
(M+24H)/24 631.25 662.10 674.81 
(M+25H)/25 606.04 635.66 647.86 
(M+26H)/26 582.77 611.25 622.98 
Table 5.1: Haemoglobin mass list used to search for haemoglobin glutathionylation 
detected by mass spectrometry. These data were generated using in silico digestion 
by Protein Prosepctor. ‘M’ refers to mass of the proteoform, meanwhile ‘M+xH/x’ refers 
to mass with x proton charges and subsequent mass to charge ratio. Bold text 
indicates mass to charge ratio that were detected during mass spectrometry 






5.3.2 Direct infusion method 
In this study, direct infusion electrospray ionization mass spectrometry (ESI-MS) was 
used to identify protein glutathionylation in haemoglobin. Haemoglobin samples with 
and without incubation with GSSG were injected directly into the mass spectrometer. 
By using direct infusion, all proteins present were observed at the same time. In the 
haemoglobin sample, the masses of haemoglobin were detected according to the 
mass list in table 5.1 and a representative mass spectrum is shown in figure 5.1. This 
was also the same for glutathionylated haemoglobin (figure 5.2) where the 
glutathionylated protein masses were detected in the β subunit. Tandem mass spectra 
of intact proteins can be complex, therefore spectral deconvolution was used to group 
all mass to charge ratios, or isotopomer envelopes, together to examine the entire 
mass of the protein subunits. Deconvolution takes into account of mass to charge ratio 
and converts it to one species. The deconvoluted mass spectra of unmodified 
haemoglobin for the alpha subunit was centred at 15125 Da and the haemoglobin beta 
subunit at 15866 Da. Modified haemoglobin beta subunit centred at 16171 Da 
confirming a mass shift of 305 Da suggesting that the subunit was glutathionylated as 








Figure 5.1: Mass spectrum of whole haemoglobin protein generated by direct infusion mass spectrometry. The top panel depicts 
deconvoluted peaks for alpha and beta subunits with masses of 15125 Da and 15866 Da respectively. The bottom panel depicts the 






Figure 5.2: Mass spectrum of whole glutathionylated haemoglobin protein by direct infusion mass spectrometry showing alpha and 
glutathionylated beta peaks of masses 15125 Da and 16171 Da respectively in the top panel. The bottom panel depicts the mass 






                                                                                                                                                                                                                 
5.3.3 Liquid Chromatography – tandem Mass Spectrometry (LC-MS/MS) analysis of 
Hb and modified Hb. 
Native and glutathionylated haemoglobin samples were separated by HPLC (reverse 
phase C18) coupled to Orbitrap-based mass spectrometry. Haemoglobin was diluted 
50-fold before it was analysed by LC-MS/MS for intact haemoglobin α and β chain. 
The alpha and beta chains eluted at different retention times allowing for separation 
of the overlapping spectra previously seen by direct infusion MS (figures 5.3 and 5.4). 
Also, as seen with direct infusion MS, glutathionylation was observed on the beta 
chain. The deconvoluted spectra again showed masses of 15125 Da, 15866 Da and 
16171 Da for the alpha, beta and glutathionylated beta chains respectively. In figure 
5.3, different isoforms of haemoglobin can also be seen (unannotated peaks by the 








Figure 5.3: Mass spectrum haemoglobin analysed by LC-MS/MS. The upper panel depicts mass spectra of haemoglobin along with 
the charge distribution for alpha subunits of Hb. Meanwhile, the lower panel depicts mass spectra of haemoglobin along with the 







Figure 5.4: Mass spectrum of glutathionylated haemoglobin analysed by LC-MS/MS. The upper panel depicts mass spectra of 
haemoglobin along with the charge distribution for alpha subunits of Hb. Meanwhile, the lower panel depicts mass spectra of 






5.3.4 Haemoglobin digested samples and LC-MS/MS method  
Haemoglobin and glutathionylated haemoglobin samples were digested with trypsin 
overnight. These samples were then desalted using Ziptips to purify and concentrate 
the samples. Following this, they were analysed by mass spectrometry using LC-
MS/MS. Haemoglobin was found with a coverage of 80% Hb and 96% Hb-SSG when 
compared to the human database. About 80% of PSMs came from Hb and any 
remainder may be small quantities of contaminants in the Hb purchased (tables 5.2 
and 5.3). For the Hb-SSG, about 91% of PSMs came from Hb and the other remainder 
could be contaminants in the Hb purchased. Digested Hb beta analysed by LC-MS/MS 
also yielded identification of modified peptides (figure 5.5). 





GTFATLSELHcDK (4 PSMs) 
VLGAFSDGLAHLDnLKGTFATLSELHcDK (4 PSMs) 
GTFATLSELHcDKLHVDPENFR (1 PSM) 
LLGNVLVcVLAHHFGK (5 PSMs) 
LLGnVLVcVLAHHFGK (4 PSMs) 
 
Figure 5.5: Sequence of human Hb beta (accession P68871) showing the location of 
glutathionylated cysteine (green) and the individual peptides identified below. c 
denotes modified cysteine and n denotes deamidated asparagine. Number of PSMs 







Accession Description PSMs 
P68871 Haemoglobin subunit beta 209 
P02042 Haemoglobin subunit delta 108 
P69905 Haemoglobin subunit alpha  99 
P00915 Carbonic anhydrase 1  65 
P69891 Haemoglobin subunit gamma-1  43 
P69892 Haemoglobin subunit gamma-2  43 
P00918 Carbonic anhydrase 2  14 
P02768 Serum albumin  11 
P30041 Peroxiredoxin-6  6 
P0CG48 Polyubiquitin-C  3 
Table 5.2: Protein profiling of digested haemoglobin with trypsin. The table shows the 
protein accession number, protein description and number of PSMs.  
Accession Description PSMs 
P68871 Haemoglobin subunit beta  437 
P69905 Haemoglobin subunit alpha  353 
P02042 Haemoglobin subunit delta 82 
P00915 Carbonic anhydrase 1  35 
P69892 Haemoglobin subunit gamma-2  29 
P00918 Carbonic anhydrase 2  17 
P30041 Peroxiredoxin-6  8 
P60174 Triosephosphate isomerase  4 
Table 5.3: Protein profiling of digested glutathionylated haemoglobin with trypsin. The 








In this chapter, methods were established to demonstrate that protein glutathionylation 
could be detected by instruments available. The haemoglobin sample preparation 
method published by Woodi et al., (2009) and Regazzoni et al (2009) was followed but 
different mass spectrometry instrument used. In this study, various methods of mass 
spectrometry were tested, for example direct infusion and LC-MS/MS methods of 
intact protein and LC-MS/MS of digested protein, to identify the modification. In Woodi 
et al., (2009) study, haemoglobin was used to look for glutathionylation using single 
quadrupole mass spectrometry, whereas here the orbitrap mass spectrometer was 
used. In Regazzoni et al., (2009) study, the mass spectrometry used was LTQ-
Orbitrap Hybrid mass spectrometer that used a linear ion trap for fragmentation, 
whereas here used LTQ-Orbitrap Elite ETD mass spectrometer that used the electron-
transfer dissociation (ETD) ion trap mass analyser for fragmentation.  
Glutathionylation is a posttranslational modification of protein cysteine residues by the 
addition of glutathione. Glutathionylation is often involved in protection of protein 
cysteines from irreversible oxidation and also in protein regulation (Cooper et al., 2011, 
Zhiyou & Liang-Jun 2013, Liang-Jun 2014). This modification alters protein mass 
charge, structure, function and prevents degradation due thiol over oxidation. 
Formation of protein glutathionylation involves the formation of a mixed disulphide 
between a free thiol group on a protein and molecule of GSH, It can occur through 
oxidation of a protein thiol group in response to reactive oxygen species (ROS) and 
reaction with GSH. A study by Regazzoni et al., (2009) indicated that glutathionylated 
haemoglobin as biomarker of oxidative stress through its ability of GSSG to form into 
Hb-SSG. In this study, glutathionylation of intact haemoglobin could be observed using 
the direct infusion and LC-MS/MS methods. This study was similar to Regazzoni et 
al., (2009) study that used mass spectrometry method of direct infusion and digested 
haemoglobin samples, thus, was able to look at haemoglobin glutathionylation. The 
modification could only be observed at the beta-chain with an absence of modification 
on the alpha-chain. This was similar to the Woodi et al., (2009) and Regazzoni et al., 
(2009) study that observed the modification only in the beta-chain due to the addition 





Incidentally, during this study it was the first time haemoglobin intact protein sample 
directly analysed by technique reversed-phase liquid chromatography tandem mass 
spectrometry (LC-MS/MS). Particularly, if the objective is identification, intact proteins 
of < 30kDa can be analysed intact through LC-MS/MS or otherwise protein digestion 
is necessary (Udeshi et al., 2008). Human haemoglobin is a protein of 64.5kDa 
consists of two α-chains and two β-chains that are noncovalent associated (Perutz et 
al., 1960). Detection of intact haemoglobin by mass spectrometry is challenging 
because of its noncovalent association of the 4 Hb subunits (Peng et al., 2005). 
Previous study developed technique nano electrospray ionization tandem mass 
spectrometry (nanoESI MS/MS) for detection of intact haemoglobin protein interaction 
with platinum drug (oxaliplatin) (Peng et al., 2005). Another previous study did a liquid 
chromatography (LC) separation of blood samples intact protein using reverse-phase 
(RP) chromatography as a first step, then the fractions collected that were of interest 
was digested with trypsin for mass spectrometry analysis by top-down and bottom-up 
technique for protein separation as a second step allowing identification of Hb 
sequences as well as glutathione modification using this approach (Huttenhain & Hess 
2010).  
It was demonstrated that the instruments in the laboratory could pick up 
glutathionylation using intact preparations of haemoglobin. This would be beneficial in 
the future to use this model protein to look for glutathionylation modification using the 
mass spectrometer instrument available in the laboratory.  
5.5 Conclusion 
Glutathionylation modification could be observed in haemoglobin samples through 
direct infusion mass spectrometry and LC-MS/MS methods in LTQ-Orbitrap Elite ETD 















CHAPTER 6 – Assessment of neutrophils role in periodontitis 






Assessment of neutrophils role in periodontitis patients 
6.1 Introduction 
In this chapter, a clinical study is described that was set up to investigate the role of 
periodontitis on alterations to peripheral blood neutrophils: periodontitis patients were 
compared to healthy controls and also before and after periodontal therapy. In this 
study, neutrophils were isolated from whole blood to assess glutathionylated proteins, 
neutrophil chemotaxis and further understand redox balance of neutrophils.  
Neutrophils are important for periodontal health because: they can respond to 
inflammatory mediators and enter the periodontal tissues towards chemoattractant 
signals produced by bacteria in the gingiva (Scott and Krauss, 2011); they are able to 
mount an antimicrobial attack on dental plaque via reactive oxygen species (ROS) and 
other species; they are able to phagocytize bacteria and thereby remove them; they 
have neutrophil extracellular traps (NETs). Findings from (Bhansali et al., 2013) have 
shown that neutrophils from localized aggressive periodontitis (LAP) patients failed to 
generate the products of the respiratory burst. This is because elevated superoxide 
generation in LAP neutrophils is associated with increase in diacylglycerol and 
reduced levels of diacylglycerol kinase in LAP patients. LAP patients usually exhibit 
abnormal neutrophil functions to a variety of environment and host stimuli (Bhansali et 
al., 2013). The hyperactivity and reactivity of blood neutrophils from periodontitis 
patients is a constitutive characteristic of the host in relation to the elaboration of 










There was aberrant chemotaxis in periodontitis patients compared to healthy people. 
(Roberts et al., 2015). Following periodontal treatment, it was found out that speed 
reduced in response to both chemoattractants meanwhile velocity and accuracy were 
normalized for Interleukin-8 which is a weak chemoattractant and remained 
significantly reduced for fMLP (Roberts et al., 2015). Another study was done using 
Boyden Chamber reported impairment of neutrophil movement in chronic periodontitis 
relative to control subjects (Prakash and Kumar, 2012). The study also showed that 
chemotactic response altered in neutrophils after periodontal treatment suggested that 
periodontal treatment does have an effect although it was at a lesser degree. 
Tandem mass tag (TMT) is quantitative proteomics. There are labelled isobaric tags 
for peptide identification and quantification. Each neutrophil sample gets a different 
TMT tag. This quantitative proteomics can give information on identification and 
number of peptides in the neutrophil sample. In the mass spectrometry, measurement 
of peptides fragment and tags were done which give relative quantification that 
measure relative to how much there is of a different part of sample. There are other 
ways to measure quantitative proteomics such as label-free technique and SILAC. 
Label-free technique was not done in this experiment as it is more expensive to use 
label-free than labelled tags as how the mass spectrometry service was set up in the 
laboratory. SILAC was not done also because its purpose is for growing cells in 
incorporate amino acid in proteins as it introduces heavy and light form of amino acid 
in proteins in the cell culture. Neutrophils are not growing cells; therefore, it is not 












6.2 Materials and methods 
6.2.1 Study participants  
Periodontitis patients (n=4) were recruited from periodontitis new patient clinics at the 
University of Birmingham’s School of Dentistry and Birmingham Dental Hospital. Age 
(+/- 5 years) and gender matched healthy controls (n=4) were recruited from staff of 
the University of Birmingham’s School of Dentistry. Volunteers gave written informed 
consent and medical history including age, gender, ethnicity and smoking status at 
recruitment. They donated approximately 25ml blood for this study from which 
neutrophils were isolated as described in general methodology section 2.2. 
Periodontitis patients made one donation before non-surgical treatment began and 
one two months post treatment. Healthy volunteers gave one donation only. 
Periodontitis patients underwent standard non-surgical periodontal treatment of 5 
treatments for 5 weeks as one treatment per week, carried out by one hygienist. 
Thereafter they were given 2 months for healing and were then called back for post 
treatment review. Out of the 4 patients recruited only 2 patients that came back for the 
post treatment visit at the 2 month review despite recall letters being sent. The cause 
was not known. The patient flow diagram is shown in Figure 6.1. Measurements that 
were recorded in this clinical study were percentage of sites of bleeding on probing (% 
bleeding) and presence of plaque percentage (plaque index (PI) %). Periodontal 
disease was classified as severe periodontitis are based on Page et al (2012) case 
definitions (severe periodontitis: > 2 interproximal sites with PPD > 5mm). Controls 
were not examined for periodontal health, merely asked for their latest classification 
by their general dental practitioner. Thus, they may have had some level of gingivitis.     
The recruitment of periodontal patients was based on inclusion and exclusion criteria. 
The inclusion criteria were patients with periodontitis defined as having 2 or more sites 
with PPD of 5-9mm, loss of attachment and bleeding on probing. The exclusion criteria 
were patients lacking capacity to consent, smokers and those with other chronic 



























Recruitment (via new patient clinic by clinical staff) 
Study visit 1: Sampling day – Baseline 
- Informed consent and medical history (age, gender, ethnicity, 
smoking/non-smoker) 
- Blood sampling: 4 green top tubes, tubes with lithium heparin 
- Clinical measures: Plaque index, pocket depth, bleeding on 
probing  
 
3 months for treatment and review 
Treatment: 
Patients underwent periodontology treatment by a single 
hygienist, each patient received 5 appointments for 5 weeks, with 
one appointment per week  
 
Study visit 2: Sampling day – Post treatment 
2 months after the date of the 5th appointment, patients were 
recalled for review  
- Blood sampling: 4 green top tubes, tubes with lithium heparin 







6.2.2 Quantitative Proteomics 
For detection of all protein including potentially glutathionylated proteins, neutrophils 
were lysed with lysis buffer and protease inhibitor (section 4.3.1) and then stored at    
-20°C until all samples had been prepared. Protein content of each preparation was 
measured by BCA assay (section 2.9).  
Extracted proteins (100µg) isolated from neutrophil samples were reduced, alkylated 
and digested overnight (as described in section 2.10). The TMT Label Reagents 
(Thermo Fisher Scientific) from the kit was equilibrated to room temperature before 
use. Anhydrous acetonitrile (4µl) was added to each tube containing individual TMT 
labels (0.8mg). The reagent was vortexed for 5 minutes to allow it to dissolve. Then, 
the tube was briefly centrifuged. 
Then, one of the TMT label reagent (41µl) was added to one peptide preparation to 
create ten differently labelled peptide preparations. The reactions were incubated for 
1 hour at room temperature. To quench the reaction, hydroxylamine (8µl, 5% in 
100mM TEAB) was added to the reactions and they were incubated for 15 minutes at 
room temperature. All labelled samples were combined and dried by vacuum 
centrifugation. The sample was then cleaned up using macrotrap desalting method 
(method section 2.11). After this, the samples were sent to be analysed through the 
mass spectrometry (Q Exactive HF hybrid quadrupole-Orbitrap mass spectrometer, 

























Figure 6.2: Work flow for preparation of TMT labelled peptides and their analysis.  
 
Neutrophil cells 
Proteins extracted from samples. 
Proteins reduced, alkylated and digested overnight. 
Peptides labelled with TMT tags  
Peptides combined and fractionated by high pH reversed phase HPLC to 
reduce complexity. 
Peptides analyzed by LC-MS/MS mass spectrometry. 






6.3.1 Clinical study outcomes of treatment 
Four volunteers were enrolled into this study with severe periodontitis. Four healthy 
controls were then recruited as gender and age-matched (+/- 5 years) for comparison. 
Periodontitis patients received standard non-surgical periodontal therapy for 2 months. 
Out of the 4 patients recruited, only 2 patients that came back for review and post 
treatment sampling. The cause was not known, and efforts were made to recall them, 
to no avail. Figure 6.3 shows an approximate consolidated standards of reporting trials  
(CONSORT) diagram for the patient pathway with numbers at each stage.  
The demographic profiles of the patients and controls are shown in table 6.1. From the 
change in baseline, it can be seen that, there were improvements in percentage of 
bleeding site, clinical attachment loss (CAL),  mean periodontal pocket depth (PPD) 
and of teeth with PPD> 4mm for periodontitis patients returning after treatment. These 
data indicate the treatment for patients N002 and N005, who returned for the review 
visit, was successful. It can be seen in table 6.2 that there is more clinical attachment 
loss (CAL) than periodontal pocket depth (PPD) which means patients had some 
recession as well. For local bleeding, the percentage of bleeding on probing (BOP) 
should be less than 30%, otherwise if it is > 30%, is considered as general BOP (Lang 
et al., 1986). In table 6.2, patient N001, N002, N003 and N005 have percentage of 
bleeding more than 10% at recruitment, before treatment, but after treatment for 
patients N002 and N005 the percentage of bleeding on probing improved and was 
then at less than 10%. Patient N002 had more percentage plaque surfaces after 
treatment compared to before treatment, it could be speculated that this may be due 
to consumption of plaque inducing foods prior to that day of sampling or a relapse to 
poor cleaning practises. One of the limitations of this clinical study is that patient N004 







 Control group Periodontitis group 
Number 4 4 
Mean age (range) 40.5 +/- 4.5 years old 40.75 +/- 2.5 years old  
Gender (% female) 50% 50% 





Figure 6.3: CONSORT diagram representing the flow of the clinical study starting from 
recruitment of periodontitis patients until exit from the study after follow up review 
following treatment. This diagram also indicates the number of periodontitis patients 





Table 6.2: The table represents the periodontal profile of the patients before V1 periodontal treatment (pre-treatment); V2 after 
periodontal treatment (post-treatment); PPD-, periodontal pocket depth; CAL-, clinical attachment loss. 
ID patient N001 N002 N003 N005 
Visit V1 V2 V1 V2  V1 V2 V1 V2 
Number of 
teeth 
31 - 28 28 31 - 29 29 
Percentage 
bleeding 








2.6 +/- 1.8  
(0-8) 
- 3.0 +/- 2.8  
(0-14) 
2.7 +/- 2.4  
(0-12) 
4.0 +/- 2.5  
(1-9) 
- 2.0 +/- 1.5  
(0-8) 
1.8 +/- 1.8  
(0-10) 
Teeth>4mm 15 - 16 15 24 - 10 9 
CAL Mean 
+/- SD 
2.6 +/- 1.8 - 3.1 +/- 2.8 2.8 +/- 2.4 4.0 +/- 2.5 - 2.7 +/- 2.4 2.5 +/- 2.8 
% sites1-
2mm 
59.1 - 57.1 61.3 41.9 - 62.1 55.7 
% sites3-
4mm 
23.1 - 9.1 12.9 18.8 - 14.5 15.6 
% sites 
>4mm 





6.3.2 Neutrophil cell viability 
To verify the viability of neutrophils isolated from periodontitis patients pre and post 
treatment and healthy controls cell viability determined by trypan blue exclusion assay 
using the automated Luna cell counter (as described in section 2.4.2). Figure 6.4 
represents the cell viability for periodontitis patients before and after treatment and 
control at time point of 0 and 4 hours. Neutrophil cells were at least 87% viable with 
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Figure 6.4: Neutrophil cell viability for periodontitis patients before and after 
periodontal treatment and healthy controls at 0, after isolation and after four hours. 
Cell viability was measured by trypan blue exclusion assay (section 2.4.2) using the 






6.3.3 Chemotaxis of neutrophil cells 
Chemotactic ability of the neutrophil cells was measured from periodontitis patients 
and controls and results are shown in figure 6.5. The controls had higher chemotactic 
ability compared to the pre-treatment patients. It is also shown in figures 6.5 and 6.6 
that after periodontal treatment, two review patients had improvement in their 
chemotactic ability towards the chemoattractant fMLP. However, these changes were 
small, and the movement of the neutrophils does not reach the same level as control 
donors. Looking at the effect of IL8 shows that there is not as simple a relationship 
with a variable effect of treatment of neutrophil movement towards IL8. While the pre 
and post results could not be examined statistically due to too few remaining in the 
study the comparison between pre-treatment chemotaxis and healthy controls showed 














































1 0 0 0 0
2 0 0 0 0
3 0 0 0 0
4 0 0 0 0

















F M L P
p = 0 .1 2 5 0
p = 0 .3 7 5 0
p = 0 .1 2 5 0
 
Figure 6.5: Periodontitis patient pre-treatment and post-treatment as well as clinical 
study control chemotactic ability of neutrophil cells in Phosphate buffered saline (PBS), 
Interleukin 8 (IL8) and N-Formylmethionine-leucyl-phenylalanine (fMLP) 






p re  tre a tm e n t p o s t tre a tm e n t 
0
5 0 0 0
1 0 0 0 0
1 5 0 0 0
2 0 0 0 0

















N 0 0 2
N 0 0 5
p re  tre a tm e n t p o s t tre a tm e n t 
0
1 0 0 0 0
2 0 0 0 0
3 0 0 0 0

















N 0 0 2
N 0 0 5
p re  tre a tm e n t p o s t tre a tm e n t 
0
1 0 0 0 0
2 0 0 0 0
3 0 0 0 0
4 0 0 0 0
















N 0 0 2
N 0 0 5
 
Figure 6.6: Direction of change for patients N002 and N005 for chemotactic ability of 
neutrophil cells towards Phosphate buffered saline (PBS), Interleukin 8 (IL8) and N-





6.3.4 Measurement of total glutathione (GSH) and oxidized glutathione (GSSG)  
The amount of glutathione was measured as well as the ratio of total 
glutathione/oxidized glutathione in periodontitis patients (pre- and post- treatment) and 
controls. Figure 6.7 shows the amount of total glutathione and oxidized glutathione. 
The control donors had a higher quantity of glutathione compared to periodontitis 
patient’s pre-treatment. However, one patient post-treatment nearly had the same 
amount of glutathione with the matched control. Figure 6.8 shows that there was no 
significant difference between GSH/GSSG ratio of control and pre-treatment 














































2 .01 0 6
4 .01 0 6
6 .01 0 6
0
1 0 0 0 0 0
2 0 0 0 0 0
3 0 0 0 0 0
G lu ta th io n e













to ta l G S H
G S S G
 
Figure 6.7: Control and periodontitis patient pre-treatment and post-treatment total 
glutathione (GSH) and oxidized glutathione (GSSG). GSH and GSSG were measured 
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Figure 6.8: Periodontitis patient pre-treatment and post-treatment total glutathione 
(GSH) and oxidized glutathione (GSSG) showing change after treatment. GSH and 







6.3.5 Detection of glutathionylated proteins  
This part of the study aimed to detect glutathionylated proteins in the controls and 
periodontitis patients by use of quantitative proteomics based mass spectrometry 
using tandem mass tag (TMT) labels and western blotting for glutathionylated proteins.  
Neutrophil cell extracts were reduced, alkylated and digested with trypsin overnight. 
The resulting peptides from each extract were then labelled with individual TMT 
reagents and mixed together.  This pooled sample was the fractionated by high pH 
reverse phase HPLC in 10 fractions and the new Q Exactive mass spectrometer as it 
was much more sensitive, and more information could be gained by using it. Each 
fraction was analysed in triplicate technical repeats. Use of the principal component 
analysis (PCA) tool within Proteome Discoverer (v2.2) illustrated that the triplicate 
repeats clustered together (figure 6.9). It appears that the post treatment samples 
cluster more closely together than the pre-treatment samples, however this is a small 








Figure 6.9: Principle component analysis (PCA) of data from the proteomic analysis of 
extracted neutrophil samples from periodontal patients (pre and post treatment) and 
controls. Graph was drawn in Proteome Discoverer (version 2.2). Each sample is 
represented by a different colour as denoted at the bottom of the graph. The label 







Using all the data the clustering of the different samples was also explored and 
visualised using hierarchical clustering (using maximum distance and average 
linkage) with the online R based tool ClustVis. Figure 6.10 shows the generated 
heatmap. To create this representation, mean averages were determined for all 
proteins from all control samples and the ratio of these proteins to all the control and 
patients’ samples was determined. These were then compared.  It can be seen that 
the majority of the proteins show a relatively pale colour highlighting that most proteins 
do not change greatly in abundance between the different samples. In patients 1 and 
2 there are darker colours (particularly at the top of the columns) indicating that there 
were greater changes between these proteins and the average control value. These 
have been identified as haemoglobins. Examining the pattern of clustering it can be 
seen that the different types of samples, i.e. control or patient pre-treatment or patient 
post treatment, appear to cluster together with the exception of control 5. This perhaps 
indicates similarities in the underlying protein profile of these different neutrophil 









Figure 6.10: Heatmap showing ratio to mean of all controls for all samples from periodontal patients (pre and post treatment) and 
controls. No scaling was applied to rows. Both rows and columns are clustered using maximum distance and average linkage. 495 
rows, 10 columns. Heatmap was generated by using ClustVis R based online tool. Colours show fold change for individual proteins 





To explore the TMT data, volcano plots were drawn (figure 6.11) for individual pairs of 
patients and controls, patients before and after therapy and for an overall change 
between health and periodontitis (figure 6.12). Many proteins did not change. 
Following generally accepted rules a 2 fold cut off and p value of less than 0.05 was 
used to identify proteins of potential interest. The colours on the volcano plots highlight 
proteins with significant and twofold change. The proteins highlighted by the individual 
volcano plots in figure 6.11 are detailed in appendix 8.5 and 8.6. The proteins 
highlighted in the overall volcano plot in figure 6.12 are discussed further later and are 







Figure 6.11: Volcano plots of individual periodontal patients versus controls. Red dots 
represent data where both greater than two fold and less than 0.05 significance are 
found. C represents controls and P periodontitis patients. Tx represents samples from 






Figure 6.12: Volcano plot of all periodontal patients versus controls. Mean changes 
between age and gender matched pairs were calculated and assessed. The colours 
represent changes that are either more than 2 fold changed (blue and violet) or have 
significance less than 0.05 (orange or green) or that are both greater than two fold and 












6.3.6 Western blotting for PSSG and actin   
For detection of total glutathionylated proteins (PSSG) and actin protein, each sample 
was separated by SDS-PAGE, electroblotted on to membranes, which were then 
probed for these antigens. Patient samples and matched controls were run on the 
same gels to aid comparison. Figure 6.13 shows the scans of the membranes.  In the 
images visible bands can been seen for glutathionylated protein and actin in some 
lanes. Due to the different quantities of actin detected it suggests that even though 
similar quantities of protein were added to each well there was unequal loading. The 
quantity of actin was then used to normalise the amount of PSSG detected. Figure 
6.14 shows that there appears to be more PSSG in the patient samples than controls, 
however this difference did not reach statistical significance and there are no data for 

















Figure 6.13: Western blots of PSSG and actin protein detected in patient and control neutrophil extracts. Figure A; Blot of PSSG, B; 
Blot of PSSG, C; Blot of actin and D; Blot of actin. The symbol for the lanes on the blot represents: M; molecular weight protein ladder, 
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Figure 6.14: Densitometry analysis of the quantity of PSSG and Actin detected by 
Western blotting in control samples and patient samples pretreatment. Software Gel 
Analyzer was used to measure the darkness and volume of the bands found in figure 
6.13. Middle bar represents the mean and the outer bars represent the standard 
deviation. Bands were not detected in sample C2 or in either of the post treatment 








In this chapter, a pilot clinical study was done to examine the effect of periodontal 
therapy on neutrophil function and proteome, which were compared to age and gender 
matched control (ie non-periodontitis) donors. Various clinical measures were used to 
determine the periodontal status of the patient donors. A single dental clinician 
completed the periodontal disease diagnosis and a single dental hygienist provided 
therapy and monitored the periodontal condition of the four clinical subjects. A full 
mouth examination was conducted on mesial and medio buccal sites per tooth on the 
maxilla and mandible. Probing pocket depth (PPD, mm) and bleeding on probing 
(BOP, dichotomous absence or presence) were done using a dental probe and 
charted. For the definition of BOP, if the accumulated percentage of bleeding was less 
than 30%, it was defined as local bleeding. However, if the percentage was 30% or 
higher, it can be considered as general BOP (Lang et al., 1986). For examination of 
each individual’s oral hygiene, presence of plaque at each tooth was recorded to 
determine the percentage of plaque surface. Table 6.2 shows that the two patients 
(N002 and N005) who came for pre-treatment and post-treatment visits had 
improvements in percentage BOP, PPD and CAL. Therefore, suggesting that the non-
surgical periodontal treatment was successful for these two patients.  
In this pilot clinical study, 5 patients were recruited, one patient withdrew leaving 4 
patients at the start of the study; two patients completed the second recall visit. Using 
the data in chapter 6, a power calculation was done to determine the sample study. If 
the data in figure 6.14 was taken and expected that there is a difference between the 
controls and patients for statistical significance, the power calculation determines that 
it is expected to be 6 people (n=6) in this study sample. Therefore, if this study was to 
be done in the future, about 12 people need to be recruited accounting for any 
dropouts as well. As for this study, the dropout rates were quite high as the aim was 
for 5 people from clinic that is the pragmatic number for a small study. Unfortunately, 







From each donor, neutrophils were isolated and the viability of these cells was 
determined at time of isolation and 4h later. These experiments illustrated (figure 6.4) 
that the cells had comparable viability both at time of isolation and after the duration 
of the experiments used for both patient and healthy donors.  
The first experiment to compare neutrophil properties between patients and healthy 
controls and between pre and post treatment of patients was neutrophil chemotaxis 
(figure 6.5). The number of donors was small and this may have impacted on the level 
of statistical significance reached when comparing the patients pre-treatment to 
healthy controls, however there was a trend towards there being fewer neutrophils 
migrated in patient isolations than controls suggesting that they were slower. This is 
in agreement with video microscopy analysis of neutrophil isolated from periodontitis 
patients using the Insall chamber in our laboratory (Roberts et al., 2015) and also 
similar, though less high throughput, Boyden chamber analysis of neutrophil 
movement by Kumar and Prakash, 2012). It is not possible to draw out conclusions 
from the two patients who returned after treatment as the numbers were very small 
and there was variability in response to the different chemoattractants (figure 6.6): 
improvements were seen for PBS and fMLP but one patient had decreased 
chemotaxis to IL8 whilst thither remained unchanged. Previously Roberts et al (2015) 
had found that there was a persistent reduction in speed (movement in any direction) 
though an improvement in velocity (movement towards the chemoattractant) for IL8 in 
periodontal disease patients compared to controls even after therapy. The Boyden 
chamber cannot give this level of information about movement but gives a more rapid 
answer that could be used to gain insight in greater numbers of patients more rapidly.    
Next the intracellular total and oxidised glutathione levels were measured in isolated 
neutrophils. Previous studies have demonstrated that GSH is lower in periodontitis 
patients compared to controls (Dias et al., 2013, Bains & Bains 2015). Data in figure 
6.7 suggests that the donors used in this study may also follow this trend however 
there is a large amount of variability between the donors and no significant difference 







appear to be no other studies that have attempted to measure this. Changes in 
glutathione in gingival crevicular fluid do show changes towards a more reducing 
environment after periodontal therapy however (Grant et al., 2010).  
One of the main aims of this thesis was to explore if there was a change in glutathione 
status within neutrophils from periodontitis patients and if this was associated with 
changes in their chemotaxis. Glutathione may adduct reactive cysteines and thereby 
protect them from oxidation. To explore the potential for this cell lysates were created 
and the protein composition and glutathionylation status of the identified proteins was 
explored by quantitative mass spectrometry. In the first instance protein content was 
explored: visualisation of this can be seen in figure 6.10 as a heat map. This 
visualisation and clustering demonstrated some heterogeneity of the samples but 
generally clustered patient neutrophil profiles or control neutrophil protein profiles 
together.  
Volcano plots were used to explore the data either as individuals (figure 6.11) or as 
the mean comparing pretreatment with controls (figure 6.12). The latter revealed a 
number of proteins of interest that were consistently altered between the donors. 
Three proteins that are part of the glutathione cycle were identified: glutaredoxin-1 
(Grx-1) was increased significantly in a small quantity; GST was decreased over 2 fold 
but non-significantly, suggesting that less GSH was leaving the cell; and glutathione 
reductase was significantly decreased but less than 2 fold, perhaps indicating that the 
GSH cycle was perturbed and more GSSG may be present in the neutrophil cell. 
Future work could be to increase the amount of data in the volcano plot via an 
increased number of patients and to increase number of proteins for detection through 
greater off line separation.    
Haemoglobin was identified as being significantly and over 2 fold decreased. In the 
neutrophil isolation procedure, erythrocytes ware lysed. However, there may be still a 
small contamination of red blood cells in the neutrophils, which may be caused by 







Other proteins of interest that were highlighted (refer to appendix 8.3), either because 
they showed the most significant change in the analysis included glutathione 
reductase; DNA-apurinic or apyrimidinic site lyase; Cdc42; glycogen phosphorylase; 
Alcohol dehydrogenase class-3; or highest fold change was eosinophil peroxidase. 
These are discussed below.  
In the glutathione redox cycle, oxidation of reduced glutathione by hydrogen peroxide 
is catalysed by glutathione peroxidase. It is then reconverted by glutathione reductase 
to form reduced glutathione. Therefore, glutathione reductase is important in the 
production of glutathione itself as the glutathione regeneration is catalysed by 
glutathione reductase. In neutrophils, glutathione reductase plays an important role in 
regulation of the respiratory burst and cell signalling. Glutathione reductase was 
significantly but slightly decreased (p=0.004, fold change 0.69; appendix 8.3). 
Decreases in this enzyme may contribute to the neutrophil status observed in 
periodontitis. 
DNA-apurinic or apyrimidinic site lyase was altered in expression: mild decrease at 
fold change 0.87, p=0.007. DNA-apurinic or apyrimidinic site lyase plays a role to 
repair oxidative damage to DNA bases as it is a DNA repair enzyme. From the action 
of DNA glycosylases, this enzyme catalyses the excision of ribose residues at apurinic 
and apyrimidinic DNA sites. In neutrophils, it plays a role in repair of oxidative DNA 
damage. This is important as previous studies have shown that periodontitis patients 
have excess production of reactive oxygen species (ROS) (Dahiya et al., 2013) and 
this enzyme could help to repair the neutrophils DNA damage. DNA-apurinic or 
apyrimidinic site lyase deficient cells have been shown to have increased ROS, which 
is a hallmark of periodontal neutrophil phenotype and thus this may be a novel 
mechanism in these cells requiring further study. 
Cell division control protein 42 homolog, or Cdc42, regulates signalling pathways that 
control diverse cellular functions including cell morphology, migration, endocytosis, 







processes that are dependent on actin cytoskeleton, such as phagocytosis, cell 
migration and chemotaxis. In actin cytoskeleton, Cdc42 regulates membrane 
receptors in the signal transduction pathway to form filopodia. Filopodia are membrane 
protrusions that extend from the plasma membrane in migratory cells that contain actin 
filaments and are able to function as sensory probes into the cellular surroundings. In 
neutrophils, Cdc42 are also involved in chemotaxis: an increase in Cdc42 activity can 
stimulate migration speed, such as seen in neutrophils isolated from knockout mice 
(Szczur et al., 2006). 
Glycogen is accumulated in the liver and glycogen phosphorylase is one that plays an 
important role in carbohydrate metabolism. In this study, glycogen phosphorylase was 
found to be mildly but significantly increased (1.2 fold change, p=0.009). This protein 
catalyses the reaction initiating glycogen degradation, to generate glucose-1-
phosphate the main source of glucose in the neutrophil. This suggests energy 
requirement in neutrophils in circulation in periodontitis patients.    
Alcohol dehydrogenase class-3 (ADH3) catalyses the oxidation of long-chain primary 
alcohols by oxidation of glutathione. ADH3 acts as an S-hydroxymethyl glutathione 
dehydrogenase and as a glutathione-dependent formaldehyde dehydrogenase it can 
detoxify formaldehyde. Every cell in the human body produces formaldehyde and it is 
metabolized quickly to prevent accumulation. The reaction occurs at the expense of 
glutathione and therefore could be a source of glutathione loss within neutrophils. The 
change is ADH3 was fold change 1.23, p=0.0001. 
Eosinophil peroxidase was increased by 2.57 fold change (p=0.23). It is found in the 
primary granules in innate immune cells in humans, including neutrophils. This 
enzyme catalyses the peroxidase reaction and shares some similarities with 
myeloperoxidase, wherein its products can disrupt bacterial cell walls. Eosinophil 
peroxidase is also found in eosinophils, which are the most common, but of low 
abundance, contaminant in neutrophil isolations. Previous studies (Thomas et al., 







centrifugation isolated neutrophils and found that the portion of eosinophil transcripts 
is very low. Although eosinophils were not quantified in these studies previous 
experience within the lab from examining cytospins suggests eosinophil contamination 
to be low (Roberts et al., 2016). 
Taken together there is a picture of altered glutathione regulation through changes of 
proteins recycling glutathione within neutrophils of periodontitis patients. 
Unfortunately, it was not possible to identify any glutathionylated protein targets, one 
of the desired aims of the study. This is most likely due to low abundance that was 
then diluted further by addition of the TMT tags for quantitation. Future studies could 
make use of iodo-TMT tags that could isolate glutathionylated proteins only. This 
approach has been used by a small number of groups (for example Pan et al., 2014). 
There are a number of controlled steps required to ensure that glutathionylated 
proteins are isolated instead of other cysteine modifications or oxidations. 
6.5 Conclusion 
In periodontitis patients prior to treatment, glutathione quantity was decreased and 
chemotactic ability was impaired compared to controls. The two review periodontitis 
patients showed improvement in clinical measures and also showed a slight (non-
significant) increase in chemotaxis and increment of ratio GSH:GSSG. The redox 
balance in periodontitis patients was perturbed and appeared to affect the glutathione 
antioxidant and chemotactic ability of neutrophils. On top of this the glutathione 
enzyme systems also appeared to be perturbed within these neutrophils, perhaps 





























Neutrophil cells are important leucocytes however can cause bystander damage to 
host tissues through ROS production. In normal cellular function glutathione is used 
to protect intracellular mechanisms from ROS mediated damage, and to maintain 
cellular homeostasis for example chemotaxis (Sakai et al., 2012). However, in 
periodontitis patients, neutrophils have lower intracellular glutathione level (Dias et al., 
2013) and display aberrant chemotactic behaviour (Roberts et al., 2015). Therefore, 
this thesis comprises methods developed for exploring neutrophil function; particularly 
by exploration of neutrophils healthy volunteers and periodontitis patients to look at 
modulation of glutathione, the ability of neutrophils to chemotax and changes to the 
proteome. Biological experiments to assess and optimize functional assays of 
neutrophils for chemotaxis were made and measurement of intracellular glutathione. 
Proteomics workflows were produced for detection of glutathionylated proteins from 
neutrophils. Finally, a clinical study was done to look at these aspects in periodontitis 
patients. 
The first novel finding of the work presented here was that manipulation of intracellular 
glutathione did result in changes in chemotaxis as hypothesised. This is in agreement  
with Sakai et al (2012) and provides a mechanistic view of changes in periodontitis 
patients, where our group and others have previously demonstrated decreases in 
chemotaxis. A summary of the results is shown in figure 7.1. Inflammatory reactions 
in periodontal tissues causes oxidative stress induces hydrogen peroxide (H202) 
product. (Kiyoshima et al., 2012). For chemotaxis, hydrogen peroxide (H202) is a 
second messenger that is produced at the leading edge of chemotaxis cells (Lennicke 
et al., 2015). Motile cells generate H202 and initiate cofilin activity oxidation at 








it is inside the membrane can allow H20 to pass through and activates protein tyrosine 
phosphatase thus activates the migration pathway (Tamma et al., 2018). Leucocyte 
migration at Fish’s eyes in T-cells undergoes chemokinesis as it goes in any direction 













Figure 7.1: Glutathione depleting compounds decrease neutrophil chemotaxis. 
The second novel aspect of this work was the establishment of the High-pH reverse 
phase methodology for two dimensional chromatography in our laboratories. At the 
commencement of these studies this method had just been published (Batth et al., 
2014) and it allowed an increase in protein detection. Therefore, in this study, 2D off 
line HPLC-MS/MS technique was evaluated and implemented that increased the 
number of proteins discovered. When a new instrument arrived in the laboratory which 
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was the Q Exactive mass spectrometer (Thermo Fisher), more proteins were 
discovered as the system was much more sensitive and more information was 
obtained. 
Advances in laboratory mass spectrometry capabilities by this thesis also 
encompassed detection of glutathionylated proteins and peptides.  The results 
presented herein describe direct infusion ESI-MS and liquid chromatography-mass 
spectrometry LC-MS/MS can recognize protein glutathionylation in haemoglobin 
samples. Haemoglobin was used in this study as a model protein to test the system 
and glutathionylation was successfully detected at the whole protein and peptide level 
for the b chain as previously described. However, when using the neutrophil digested 
sample, it was not possible to find the modification. This may have been to do with low 
abundance or sample complexity (Chandramouli et al., 2009).  Enrichment of 
glutathionylated peptides may be of interest. There are several ways to extract 
glutathionylated proteins such as BioGee and redox array technology (Mullen et al., 
2015). Whilst the Bio-GEE technique was piloted in these studies it was never 
successful.  
Finally, a clinical study utilized the methods developed and allowed for in depth 
analysis of the neutrophil proteome from periodontitis patients. This appears to be the 
first time that quantitative proteomics has been used to examine the neutrophil 
proteome of periodontitis patients. It could be seen that there was difference between 
patients and controls: and for one of the patients that underwent periodontal therapy, 
the change in the proteome after treatment made the overall protein profile more 
similar to neutrophils from healthy donors. Future work could involve analysis for 
proteins that were discovered from neutrophils in periodontitis patients, whether the 









7.1 Major limitations 
7.1.1 Recruitment of patients 
In this study, only 5 patients were recruited, and 1 patient withdrew during the 1st 
sampling visit. The limitation of the study is on the number of periodontitis patients 
recruited within the limited time period of the PhD study. However, in the future, this 
study could be expanded to recruit more patients for the sampling to obtain a larger 
data.  
In this pilot clinical study, 5 patients were recruited, one patient withdrew leaving 4 
patients at the start of the study; two patients completed the second recall visit. Using 
the data in chapter 6, a power calculation was done to determine the sample study. If 
the data in figure 6.14 was taken and expected that there is a difference between the 
controls and patients for statistical significance, the power calculation determines that 
it is expected to be 6 people (n=6) in this study sample. Therefore, if this study was to 
be done in the future, about 12 people needs to be recruited including criteria for any 
dropout rates. As for this study, the dropout rates were quite high as the aim was for 
5 people from clinic that is the pragmatic number for a small study. Unfortunately, 
some people did not come back.  
7.1.2 Glutathionylated proteins 
Glutathionylated proteins could not be identified in periodontitis patients, therefore 
various things need to be changed and new discoveries in the future. It is 
recommended to do N, N-biotinyl glutathione disulphide (bio-GEE) to study protein S-
glutathionylation to detect glutathionylated proteins in proteomics. This treatment of 








7.1.3 High performance liquid chromatography (HPLC) 
The HPLC that was used in this study was damaged, therefore new HPLC equipment 
was bought by the laboratory, however, it did not work in the same way, in that 
peptides could not be detected. Hence, for future recommendation, a replicate 
procedure of the High-pH reverse phase HPLC could be coupled offline to the Q 
Exactive mass spectrometer. Q Exactive mass spectrometer is the newest mass 
spectrometer equipment in the laboratory and is much faster, has increased sensitivity, 
increased resolution and less ion loss. Hence, Q Exactive mass spectrometer was 
much better compared to the Orbitrap mass spectrometer as it detected increased 
number of proteins. 
7.2 Recommendations for future research  
The results outlined in this thesis point to glutathionylated proteins in neutrophil cells, 
which could improve neutrophil chemotactic behaviour and redox balance with 
periodontal treatment. However, this study had a limitation in the numbers of 
periodontal patients recruited. Therefore, it is recommended to do a similar study to 
recruit more patients for the sampling. A better technique could also be developed for 
detecting glutathionylated proteins in proteomics such as N, N-biotinyl glutathione 
disulphide (bio-GEE) to study protein S-glutathionylation. Further analysis could be 
done on the proteins that were discovered in the heatmap to pick up any proteins and 
looked at individual proteins. Therefore, by understanding the role of redox balance in 
neutrophils to the inflammation, more strategies could be applied to perturb the redox 
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Appendix 8.1: List of proteins from all fractions pooled from high-pH reverse phase (C18) Waters Bridge column and analysed by 
mass spectrometry (LC-MS/MS). n=3 
Protein ID 
Gene name Description of gene 
P06702 S100A9  Protein S100A9  
P05109 S100A8  Protein S100A8  
P07737 PFN1  Profilin1  
P62937 PPIA  Peptidylprolyl cistrans isomerase A  
P60660 MYL6  Myosin light polypeptide 6  
P69905 HBA1  Hemoglobin subunit alpha  
P60709 ACTB  Actin, cytoplasmic 1 Actin 
P04083 ANXA1  Annexin A1  
P61626 LYZ  Lysozyme C  
P12429 ANXA3  Annexin A3  
P02788 LTF  Lactotransferrin  
P02768 ALB  Serum albumin  
P08311 CTSG  Cathepsin G  
P05164 MPO  Myeloperoxidase  
P06733 ENO1  Alphaenolase  
P47756 CAPZB  Factincapping protein subunit beta  
P04040 CAT  Catalase  
P08107 HSPA1A  Heat shock 70 kDa protein 1A/1B  






P26038 MSN  Moesin  
P14780 MMP9  Matrix metalloproteinase9  
Q9Y490 TLN1  Talin1  
P21333 FLNA  FilaminA  
P80511 S100A12  Protein S100A12  
P59665 DEFA1  Neutrophil defensin 1  
P02042 HBD  Hemoglobin subunit delta  
P04075 ALDOA  Fructosebisphosphate aldolase A  
P60174 TPI1  Triosephosphate isomerase  
P0C0S5 H2AFZ  Histone H2A.Z  
P32119 PRDX2  Peroxiredoxin2  
P16401 HIST1H1B  Histone H1.5  
P08670 VIM  Vimentin  
P06396 GSN  Gelsolin  
P35579 MYH9  Myosin9  
P68871 HBB  Hemoglobin subunit beta  
Q9HD89 RETN  Resistin  
P62805 HIST1H4A  Histone H4  
O60814 HIST1H2BK  Histone H2B type 1K  
P31949 S100A11  Protein S100A11  
P04406 GAPDH  Glyceraldehyde3phosphate dehydrogenase  
P12724 RNASE3  Eosinophil cationic protein  
P16403 HIST1H1C  Histone H1.2  
P24158 PRTN3  Myeloblastin  






P04264 KRT1  Keratin, type II cytoskeletal 1  
P06744 GPI  Glucose6phosphate isomerase  
P11488 GNAT1  Guanine nucleotidebinding protein G(t) subunit alpha1  
P52209 PGD  6phosphogluconate dehydrogenase, decarboxylating  
K4DIE0 NUMA1  Nuclear mitotic apparatus protein 1 (Fragment)   
P12814 ACTN1  Alphaactinin1  
P07996 THBS1   Thrombospondin1  
H0YL80 TPM1   Tropomyosin alpha1 chain (Fragment)  
H0YFX9 H2AFJ  Histone H2A (Fragment)  
G3V1N2 HBA2  HCG1745306, isoform CRA_a  
P23528 CFL1  Cofilin1  
H3BUH7 ALDOA  Fructosebisphosphate aldolase A (Fragment)  
P02775 PPBP  Platelet basic protein  
P14174 MIF  Macrophage migration inhibitory factor  
Q9Y536 PPIAL4A  Peptidylprolyl cistrans isomerase Alike 4A/B/C  
P09211 GSTP1  Glutathione Stransferase P  
O75594 PGLYRP1  Peptidoglycan recognition protein 1  
P49913 CAMP  Cathelicidin antimicrobial peptide  
P15153 RAC2  Rasrelated C3 botulinum toxin substrate 2  
P19105 MYL12A  Myosin regulatory light chain 12A  
Q6NXT2 H3F3C  Histone H3.3C  
P20160 AZU1  Azurocidin  
P06733-2 ENO1  Isoform MBP1 of Alphaenolase  
B0YJC5 VIM  Vimentin  






P11142 HSPA8  Heat shock cognate 71 kDa protein  
P37837 TALDO1  Transaldolase  
P29401 TKT  Transketolase  
P11215 ITGAM  Integrin alphaM  
Q9UM07 PADI4  Proteinarginine deiminase type4  
P08514 ITGA2B  Integrin alphaIIb  
Q9NU22 MDN1  Midasin  
D6RCN3 ANXA5  Annexin A5  
P62328 TMSB4X  Thymosin beta4  
C9JTX5 ACTB  Actin, cytoplasmic 1 (Fragment)  
K7EJ44 PFN1  Profilin 1, isoform CRA_b  
F5H2R5 ARHGDIB  Rho GDPdissociation inhibitor 2 (Fragment)  
J3KS60 ARHGDIA  Rho GDPdissociation inhibitor 1  
H0YLF3 B2M  Beta2microglobulin form pI 5.3 (Fragment)  
D6RFM2 TPM3  Tropomyosin alpha3 chain  
C9JTV5 ARPC2  Actinrelated protein 2/3 complex subunit 2 (Fragment)  
P26447 S100A4  Protein S100A4  
H7C1S1 NCF1  Neutrophil cytosol factor 1 (Fragment)  
P80723 BASP1  Brain acid soluble protein 1  
O60361 NME2P1  Putative nucleoside diphosphate kinase  
P10153 RNASE2  Nonsecretory ribonuclease  
O95626 ANP32D  Acidic leucinerich nuclear phosphoprotein 32 family member D  
B1AK87 CAPZB  Capping protein (Actin filament) muscle Zline, beta, isoform CRA_a  
P26583 HMGB2  High mobility group protein B2  






Q5T3N1 ANXA1  Annexin (Fragment)  
B2RPK0 HMGB1P1  Putative high mobility group protein B1like 1  
P52565 ARHGDIA  Rho GDPdissociation inhibitor 1  
P01036 CST4  CystatinS  
P08133 ANXA6  Annexin A6  
Q96KK5 HIST1H2AH  Histone H2A type 1H  
H3BT25 PKM  Pyruvate kinase PKM (Fragment)  
P01037 CST1  CystatinSN  
Q06830 PRDX1  Peroxiredoxin1  
P15531 NME1  Nucleoside diphosphate kinase A  
P23284 PPIB  Peptidylprolyl cistrans isomerase B  
Q13231 CHIT1  Chitotriosidase1  
P00738 HP  Haptoglobin  
P67936 TPM4  Tropomyosin alpha4 chain  
C9JKM9 XPO1  Exportin1 (Fragment)  
C9J0S5 LTF  Kaliocin1 (Fragment)  
P18669 PGAM1  Phosphoglycerate mutase 1  
P30101 PDIA3  Protein disulfideisomerase A3  
P52566 ARHGDIB  Rho GDPdissociation inhibitor 2  
O75015 FCGR3B  Low affinity immunoglobulin gamma Fc region receptor IIIB  
P50395-2 GDI2  Isoform 2 of Rab GDP dissociation inhibitor beta  
C9J155 NCF1  Neutrophil cytosol factor 1 (Fragment)  
P23381 WARS  TryptophantRNA ligase, cytoplasmic  
O15143 ARPC1B  Actinrelated protein 2/3 complex subunit 1B  






O00299 CLIC1  Chloride intracellular channel protein 1  
U3KPS2 PRTN3  Myeloblastin  
P17213 BPI  Bactericidal permeabilityincreasing protein  
P09525 ANXA4  Annexin A4  
O14745 SLC9A3R1  Na(+)/H(+) exchange regulatory cofactor NHERF1  
Q15942 ZYX  Zyxin  
P63104 YWHAZ  1433 protein zeta/delta  
P00338 LDHA  Llactate dehydrogenase A chain  
Q8WUT4 LRRN4  Leucinerich repeat neuronal protein 4  
P19878-2 NCF2  Isoform 2 of Neutrophil cytosol factor 2  
P48595 SERPINB10  Serpin B10  
P50552 VASP  Vasodilatorstimulated phosphoprotein  
P07900 HSP90AA1  Heat shock protein HSP 90alpha  
P26641 EEF1G  Elongation factor 1gamma  
P11413 G6PD  Glucose6phosphate 1dehydrogenase  
P30520 ADSS  Adenylosuccinate synthetase isozyme 2  
P13796 LCP1  Plastin2  
P07237 P4HB  Protein disulfideisomerase  
P40121 CAPG  Macrophagecapping protein  
C9JKR2 ALB  Albumin, isoform CRA_k  
P47755 CAPZA2  Factincapping protein subunit alpha2  
P08238 HSP90AB1  Heat shock protein HSP 90beta  
O43707 ACTN4  Alphaactinin4  
F8VSC5 SCYL2  SCY1like protein 2 (Fragment)  






P68104 EF1A1  Elongation factor 1-alpha 1  
P51589 CYP2J2  Cytochrome P450 2J2  
Q5HY54 FLNA  FilaminA  
C9K0F3 TPST1  Proteintyrosine sulfotransferase 1 (Fragment)  
D6R904 TPM3  Tropomyosin alpha3 chain  
E9PMP4 CCDC67  Deuterosome protein 1  
F5H0N6 OLR1  Oxidized low-density lipoprotein receptor 1, soluble form (Fragment)  
E5RGE1 YWHAZ  1433 protein zeta/delta (Fragment)  
F8WBC0 RAP1B  Rasrelated protein Rap1b (Fragment)  
E9PGV1 GSTM2  Glutathione Stransferase Mu 2  
F8WEE7 F8WEE7 SEC14-like protein 2  
E5RG49 ATP6V1H  Vtype proton ATPase subunit H (Fragment)  
H0YK21 ZFAND6  AN1type zinc finger protein 6 (Fragment)  
B0AZS9 BNIP3L  BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like  
D6RJB2 APBB3  Amyloid beta A4 precursor proteinbinding family B member 3  
F6XY72 NME1NME2  Nucleoside diphosphate kinase  
H3BT58 COTL1  Coactosinlike protein  
Q4VY20 YWHAB  1433 protein beta/alpha (Fragment)  
Q5T123 SH3BGRL3  SH3 domainbinding glutamic acidrichlike protein 3  
E9PLV4 PHF21A  PHD finger protein 21A (Fragment)  
Q96T52 IMMP2L  Mitochondrial inner membrane protease subunit 2  
R4GN98 S100A6  Protein S100-A6 (Fragment)  
P80723-2 BASP1  Isoform 2 of Brain acid soluble protein 1  
K7EQF2 PLCD3  1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-3 (Fragment)  






B1AH77 RAC2  Ras-related C3 botulinum toxin substrate 2  
Q9NP64 ZCCHC17  Nucleolar protein of 40 kDa  
F5H4M0 VPS37B  Vacuolar protein sortingassociated protein 37B (Fragment)  
P25815 S100P  Protein S100P  
Q499Y3 2 SV Putative uncharacterized protein C10orf88like  
H0YAH8 TGFBI  Transforming growth factorbetainduced protein igh3 (Fragment)  
P49842-4 STK19  Isoform 4 of Serine/threonineprotein kinase 19  
Q96MC5-
2 C16orf45  Isoform 2 of Uncharacterized protein C16orf45  
D6RCA8 ANXA3  Annexin (Fragment)  
Q9UHG0-
2 DCDC2  Isoform 2 of Doublecortin domaincontaining protein 2  
P06748-3 NPM1  Isoform 3 of Nucleophosmin  
J3QSA3 UBB  Ubiquitin (Fragment)  
M0R2W4 STAP2  Signaltransducing adaptor protein 2 (Fragment)  
Q6ZSX4 EPB41L2  Band 4.1like protein 2  
P68431 HIST1H3A  Histone H3.1  
Q86Y82 STX12  Syntaxin12  
K7ERT7 VAT1  Synaptic vesicle membrane protein VAT-1 homolog (Fragment)  
M0QY96 HNRNPM  Heterogeneous nuclear ribonucleoprotein M (Fragment)  
G3V1A4 CFL1  Cofilin 1 (Nonmuscle), isoform CRA_a  
J3QRP4 CNDP2  Cytosolic nonspecific dipeptidase  
H3BU13 PKM  Pyruvate kinase PKM (Fragment)  
J3KMY5 NPC2  Epididymal secretory protein E1  






H0YA76 CNOT6L  CCR4NOT transcription complex subunit 6like (Fragment)  
B1APY9 ELAVL4  ELAVlike protein 4  
C9IZ41 ZYX  Zyxin (Fragment)  
F8VUA8 C14orf79  Uncharacterized protein C14orf79  
K7ESA3 K7ESA3 Synaptic vesicle membrane protein VAT-1 homolog (Fragment)  
Q9H299 SH3BGRL3  SH3 domainbinding glutamic acidrichlike protein 3  
P62158 CALM1  Calmodulin  
P08579 SNRPB2  U2 small nuclear ribonucleoprotein B''  
V9GYJ7 GDI2  Rab GDP dissociation inhibitor beta (Fragment)  
O60884 DNAJA2  DnaJ homolog subfamily A member 2  
Q5T7C4 HMGB1  High mobility group protein B1  
E9PF05 SUMF1  Sulfatasemodifying factor 1  
E9PJB2 C11orf73  Protein Hikeshi  
Q7Z6M3-
2 0 Isoform 2 of Allergin-1  
F5H450 FZD10  Frizzled10  
K7ELW0 PARK7  Protein DJ1  
P01877 IGHA2  Ig alpha2 chain C region  
P16949 STMN1  Stathmin  
C9J386 H2AFV  Histone H2A  
P04080 CSTB  CystatinB  
H7BZJ3 H7BZJ3 Thioredoxin (Fragment)  
K7EQR1 UBN1  Ubinuclein1 (Fragment)  
K7EM16 VASP  Vasodilator-stimulated phosphoprotein (Fragment)  






H0YKH0 TLE3  Transducinlike enhancer protein 3  
P02774-2 GC  Isoform 2 of Vitamin Dbinding protein  
Q13316-2 DMP1   Isoform 2 of Dentin matrix acidic phosphoprotein 1  
B4DXJ9 PSMA6  Proteasome (Prosome, macropain) subunit, alpha type, 6, isoform CRA_a  
O15400-2 STX7  Isoform 2 of Syntaxin7  
H0Y7A0 EMILIN1  EMILIN1 (Fragment)  
M0R042 TUBB4A  Tubulin beta4A chain (Fragment)  
B0YJC4 VIM  Vimentin  
Q5JVS8 VIM  Vimentin (Fragment)  
B7Z4N8 USP14  Ubiquitin carboxylterminal hydrolase  
F5GXH2 LDHA  Llactate dehydrogenase A chain (Fragment)  
P60174-4 TPI1  Isoform 4 of Triosephosphate isomerase  
Q86VE9-3 SERINC5   Isoform 3 of Serine incorporator 5  
Q9H098 FAM107B  Protein FAM107B  
P80188 LCN2  Neutrophil gelatinase-associated lipocalin  
Q15428 SF3A2  Splicing factor 3A subunit 2  
E9PHT9 ANXA5  Annexin  
O43439-2 CBFA2T2   Isoform 2 of Protein CBFA2T2  
M0R149 PRAM1  PMLRARAregulated adapter molecule 1 (Fragment)  
K7EJH8 ACTN4  Alpha-actinin-4 (Fragment)  
Q9BTT0 ANP32E  Acidic leucine-rich nuclear phosphoprotein 32 family member E  
P37802 TAGLN2  Transgelin2  
H0YF68 TAOK3  Serine/threonineprotein kinase TAO3 (Fragment)  
Q5JRS1 UBA1  Ubiquitin-like modifier-activating enzyme 1 (Fragment)  






G3V4U0 FBLN5  Fibulin-5  
Q92930 RAB8B Ras-related protein Rab-8B  
A8K8G0 HDGF  Hepatomaderived growth factor  
G3V2W4 ACTN1  Alphaactinin1 (Fragment)  
D6RG15 TWF2  Twinfilin2  
P31946 YWHAB  1433 protein beta/alpha  
Q04917 YWHAH  1433 protein eta  
P10412 HIST1H1E  Histone H1.4  
Q5VU63 TPM3  Tropomyosin alpha3 chain  
F8W835 PRPH  Peripherin (Fragment)  
C9JBC2 HDAC7  Histone deacetylase 7 (Fragment)  
P51858 HDGF  Hepatoma-derived growth factor  
Q14002-2 CEACAM7  Isoform 2b of Carcinoembryonic antigenrelated cell adhesion molecule 7  
P09417 QDPR  Dihydropteridine reductase  
K7EMN2 PGD  6phosphogluconate dehydrogenase, decarboxylating (Fragment)  
A8MYZ5 IQCF6  IQ domaincontaining protein F6  
Q5T8M8 ACTA1  Actin, alpha skeletal muscle  
Q9NUQ9 FAM49B  Protein FAM49B  
P15259 PGAM2 Phosphoglycerate mutase 2  
H0Y9Z7 H0Y9Z7 Kinesin-like protein KIF13A (Fragment)  
Q8WVY7 UBLCP1  Ubiquitinlike domaincontaining CTD phosphatase 1  
P54108 CRISP3  Cysteinerich secretory protein 3  
P30044 PRDX5  Peroxiredoxin5, mitochondrial  
P40925 MDH1  Malate dehydrogenase, cytoplasmic  






P28676 GCA  Grancalcin  
P04350 TUBB4A  Tubulin beta4A chain  
Q99536 VAT1  Synaptic vesicle membrane protein VAT1 homolog  
B4DDF9 ANXA4  Annexin  
Q9Y4D8-
3 HECTD4  Isoform 3 of Probable E3 ubiquitinprotein ligase HECTD4  
Q9Y266 NUDC  Nuclear migration protein nudC  
P17066 HSPA6  Heat shock 70 kDa protein 6  
P22626-2 HNRNPA2B1  Isoform A2 of Heterogeneous nuclear ribonucleoproteins A2/B1  
Q5T2D2 TREML2  Tremlike transcript 2 protein  
Q86X10-4 RALGAPB Isoform 4 of Ral GTPaseactivating protein subunit beta  
P22626 HNRNPA2B1  Heterogeneous nuclear ribonucleoproteins A2/B1  
H0YHL7 CORO1C  Coronin-1C (Fragment)  
B7Z817 DHCR24  Delta(24)sterol reductase  
P23526-2 AHCY  Isoform 2 of Adenosylhomocysteinase  
V9GYF0 V9GYF0 Rho guanine nucleotide exchange factor 2 (Fragment)  
Q8IX06 REXO1L1P  Putative exonuclease GOR  
F8WDB9 CAP2  Adenylyl cyclaseassociated protein  
P02675 FGB  Fibrinogen beta chain  
H3BS21 HP  Haptoglobin (Fragment)  
B1AKP8 MTOR  Serine/threonine-protein kinase mTOR  
E9PEI0 CDCA2  Cell division cycleassociated protein 2  
Q5SVZ7 ZMYM1  Zinc finger MYM-type protein 1 (Fragment)  
P23381-2 WARS  Isoform 2 of TryptophantRNA ligase, cytoplasmic  






C9JB56 ARHGAP25  Rho GTPaseactivating protein 25  
P08246 ELANE  Neutrophil elastase  
P46020-3 PHKA1  Isoform 3 of Phosphorylase b kinase regulatory subunit alpha, skeletal muscle isoform  
P78417 GSTO1  Glutathione Stransferase omega1  
Q7L0X0 TRIL  TLR4 interactor with leucine rich repeats  
Q8TCJ2 STT3B  Dolichyldiphosphooligosaccharideprotein glycosyltransferase subunit STT3B  
K7EQ48 GPI  Glucose6phosphate isomerase  
Q9Y2J2-3 EPB41L3  Isoform C of Band 4.1-like protein 3  
Q9ULH4 LRFN2 Leucine-rich repeat and fibronectin type-III domain-containing protein 2  
B4DKG1 NAB1  NGFIAbinding protein 1  
F2Z393 TALDO1  Transaldolase  
Q9NYL9 TMOD3  Tropomodulin3  
B4E2V5 STOM  Erythrocyte band 7 integral membrane protein  
P0C874 SPATA31D3  Putative spermatogenesisassociated protein 31D3  
P98168 ZXDA  Zinc finger Xlinked protein ZXDA  
O43488 AKR7A2  Aflatoxin B1 aldehyde reductase member 2  
Q8N7B1 HORMAD2  HORMA domaincontaining protein 2  
O95718-3 ESRRB   Isoform 3 of Steroid hormone receptor ERR2  
H7C144 ACTN4  Alpha-actinin-4 (Fragment)  
E9PN89 HSPA8  Heat shock cognate 71 kDa protein (Fragment)  
P18206-3 VCL   Isoform 3 of Vinculin  
F5H3K3 F5H3K3 Spermatogenesis-associated protein 2  
O95025 SEMA3D  Semaphorin3D  
P50395 GDI2  Rab GDP dissociation inhibitor beta  






Q96JG8-4 MAGED4  Isoform 4 of Melanoma-associated antigen D4  
P43246 MSH2  DNA mismatch repair protein Msh2  
K7EM23 K7EM23 Uncharacterized protein C17orf66  
P13688-3 CEACAM1  Isoform 3 of Carcinoembryonic antigen-related cell adhesion molecule 1  
P61160 ACTR2  Actinrelated protein 2  
D6REY1 CHIT1  Chitotriosidase-1  
P11021 HSPA5  78 kDa glucoseregulated protein  
J3QLC9 HP  Haptoglobin (Fragment)  
Q4VNC0 ATP13A5  Probable cation-transporting ATPase 13A5  
P02788-2 LTF  Isoform DeltaLf of Lactotransferrin  
H0YI72 ANKS1B  Ankyrin repeat and sterile alpha motif domaincontaining protein 1B (Fragment)  
P03905 MT-ND4  NADH-ubiquinone oxidoreductase chain 4  
P31997 CEACAM8  Carcinoembryonic antigenrelated cell adhesion molecule 8  
P35527 KRT9  Keratin, type I cytoskeletal 9  
Q8WUH2 TGFBRAP1  Transforming growth factorbeta receptorassociated protein 1  
Q9UJU6 DBNL Drebrin-like protein  
B7WPN9 ATP13A4  Probable cationtransporting ATPase 13A4  
Q96P15 SERPINB11  Serpin B11  
Q9NQH7-
3 XPNPEP3  Isoform 3 of Probable XaaPro aminopeptidase 3  
Q13591 SEMA5A  Semaphorin5A  
Q58FF3 HSP90B2P  Putative endoplasminlike protein  
Q9UBW7 ZMYM2  Zinc finger MYM-type protein 2  
A8MVU1 NCF1C  Putative neutrophil cytosol factor 1C  






P43246-2 MSH2  Isoform 2 of DNA mismatch repair protein Msh2  
Q9HDC9 APMAP  Adipocyte plasma membraneassociated protein  
P31146 CORO1A  Coronin1A  
Q01518 CAP1  Adenylyl cyclaseassociated protein 1  
V9GZ37  Heat shock 70 kDa protein 1A/1B  
P00739 HPR  Haptoglobinrelated protein  
B4E022 TKT  Transketolase  
E7EVW7 HCLS1  Hematopoietic lineage cellspecific protein  
O95171 SCEL  Sciellin  
Q5H9M0 MUM1L1  PWWP domaincontaining protein MUM1L1  
Q01518-2 CAP1  Isoform 2 of Adenylyl cyclaseassociated protein 1  
O15042-3 U2SURP  Isoform 3 of U2 snRNPassociated SURP motifcontaining protein  
P04839 CYBB  Cytochrome b245 heavy chain  
P61158 ACTR3  Actinrelated protein 3  
G5EA52 PDIA3  Protein disulfide isomerase family A, member 3, isoform CRA_b  
Q15070 OXA1L Mitochondrial inner membrane protein OXA1L  
Q9HAW4-
2 CLSPN  Isoform 2 of Claspin  
Q9Y2Q0 ATP8A1  Probable phospholipidtransporting ATPase IA  
J3KP11 CACNA1E  Voltagedependent Rtype calcium channel subunit alpha1E  
Q52LW3 ARHGAP29  Rho GTPaseactivating protein 29  
Q8TF30 WHAMM  WASP homologassociated protein with actin, membranes and microtubules  
H7C022 WDR60  WD repeatcontaining protein 60 (Fragment)  
O75083 WDR1  WD repeatcontaining protein 1  






Q8N3C0 ASCC3  Activating signal cointegrator 1 complex subunit 3  
H9KV75 ACTN1  Alphaactinin1  
E9PDY4 CR1  Complement receptor type 1  
Q05655 PRKCD  Protein kinase C delta type  
P35609 ACTN2  Alphaactinin2  
Q8NDG6 TDRD9 Putative ATP-dependent RNA helicase TDRD9  
P19021 PAM  Peptidylglycine alphaamidating monooxygenase  
Q5T2X4 CEP350  Centrosomeassociated protein 350 (Fragment)  
Q9NQH7 XPNPEP3  Probable Xaa-Pro aminopeptidase 3  
Q99715-4 COL12A1  Isoform 4 of Collagen alpha1(XII) chain  
A8MYE6 ITGB2  Integrin beta  
Q1MSJ5-
1 CSPP1  Isoform 1 of Centrosome and spindle poleassociated protein 1  
Q9P2E3-2 ZNFX1  Isoform 2 of NFX1-type zinc finger-containing protein 1  
Q06203 PPAT  Amidophosphoribosyltransferase  
F5H228 TRIO  Triple functional domain protein  
P08514-3 0 Isoform 3 of Integrin alpha-IIb  
Q01082-3 0 Isoform 2 of Spectrin beta chain, non-erythrocytic 1  
Q9P2N6 KANSL3  KAT8 regulatory NSL complex subunit 3  
O60486 PLXNC1  PlexinC1  
Q9UHB6 LIMA1  LIM domain and actinbinding protein 1  
Q9Y4B4 RAD54L2  Helicase ARIP4  
Q8N655 C10orf12  Uncharacterized protein C10orf12  
Q5TCU6 TLN1  Talin-1  






Q05707-3 COL14A1   Isoform 3 of Collagen alpha1(XIV) chain  
Q9BYW2 SETD2 Histone-lysine N-methyltransferase SETD2  
P16157 ANK1  Ankyrin1  
O75339 CILP  Cartilage intermediate layer protein 1  
E9PBV1 NWD1  NACHT and WD repeat domaincontaining protein 1  
Q9P273 TENM3  Teneurin3  
P11277 SPTB  Spectrin beta chain, erythrocytic  
Q9BY89 KIAA1671  Uncharacterized protein KIAA1671  
Q01082 SPTBN1  Spectrin beta chain, nonerythrocytic 1  
P53804 TTC3  E3 ubiquitinprotein ligase TTC3  
Q5VT06 CEP350  Centrosome-associated protein 350  













Gene name Description of gene 
A0M8Q6 IGLC7 Ig lambda-7 chain C region 
A6NEQ6 COL9A1 Collagen alpha-1(IX) chain 
A8K2U0 A2ML1  Alpha-2-macroglobulin-like protein 1 
P62937 PPIA  Peptidylprolyl cistrans isomerase A  
P60660 MYL6  Myosin light polypeptide 6  
P69905 HBA1  Hemoglobin subunit alpha  
P60709 ACTB  Actin, cytoplasmic 1 Actin 
P04083 ANXA1  Annexin A1  
P61626 LYZ  Lysozyme C  
P12429 ANXA3  Annexin A3  
P02788 LTF  Lactotransferrin  
P02768 ALB  Serum albumin  
P08311 CTSG  Cathepsin G  
P05164 MPO  Myeloperoxidase  
P06733 ENO1  Alphaenolase  
P47756 CAPZB  Factincapping protein subunit beta  
P04040 CAT  Catalase  






P14618 PKM  Pyruvate kinase PKM  
P26038 MSN  Moesin  
P14780 MMP9  Matrix metalloproteinase9  
Q9Y490 TLN1  Talin1  
P21333 FLNA  FilaminA  
P80511 S100A12  Protein S100A12  
P59665 DEFA1  Neutrophil defensin 1  
P02042 HBD  Hemoglobin subunit delta  
P04075 ALDOA  Fructosebisphosphate aldolase A  
P60174 TPI1  Triosephosphate isomerase  
P0C0S5 H2AFZ  Histone H2A.Z  
P32119 PRDX2  Peroxiredoxin2  
P16401 HIST1H1B  Histone H1.5  
P08670 VIM  Vimentin  
P06396 GSN  Gelsolin  
P35579 MYH9  Myosin9  
P68871 HBB  Hemoglobin subunit beta  
Q9HD89 RETN  Resistin  
P62805 HIST1H4A  Histone H4  
O60814 HIST1H2BK  Histone H2B type 1K  
P31949 S100A11  Protein S100A11  
P04406 GAPDH  Glyceraldehyde3phosphate dehydrogenase  
P12724 RNASE3  Eosinophil cationic protein  
P16403 HIST1H1C  Histone H1.2  






P13645 KRT10  Keratin, type I cytoskeletal 10  
P04264 KRT1  Keratin, type II cytoskeletal 1  
P06744 GPI  Glucose6phosphate isomerase  
P11488 GNAT1  Guanine nucleotidebinding protein G(t) subunit alpha1  
P52209 PGD  6phosphogluconate dehydrogenase, decarboxylating  
K4DIE0 NUMA1  Nuclear mitotic apparatus protein 1 (Fragment)   
P12814 ACTN1  Alphaactinin1  
P07996 THBS1   Thrombospondin1  
H0YL80 TPM1   Tropomyosin alpha1 chain (Fragment)  
H0YFX9 H2AFJ  Histone H2A (Fragment)  
G3V1N2 HBA2  HCG1745306, isoform CRA_a  
P23528 CFL1  Cofilin1  
H3BUH7 ALDOA  Fructosebisphosphate aldolase A (Fragment)  
P02775 PPBP  Platelet basic protein  
P14174 MIF  Macrophage migration inhibitory factor  
Q9Y536 PPIAL4A  Peptidylprolyl cistrans isomerase Alike 4A/B/C  
P09211 GSTP1  Glutathione Stransferase P  
O75594 PGLYRP1  Peptidoglycan recognition protein 1  
P49913 CAMP  Cathelicidin antimicrobial peptide  
P15153 RAC2  Rasrelated C3 botulinum toxin substrate 2  
P19105 MYL12A  Myosin regulatory light chain 12A  
Q6NXT2 H3F3C  Histone H3.3C  
P20160 AZU1  Azurocidin  
P06733-






B0YJC5 VIM  Vimentin  
P00558 PGK1  Phosphoglycerate kinase 1  
P11142 HSPA8  Heat shock cognate 71 kDa protein  
P37837 TALDO1  Transaldolase  
P29401 TKT  Transketolase  
P11215 ITGAM  Integrin alphaM  
Q9UM07 PADI4  Proteinarginine deiminase type4  
P08514 ITGA2B  Integrin alphaIIb  
Q9NU22 MDN1  Midasin  
D6RCN3 ANXA5  Annexin A5  
P62328 TMSB4X  Thymosin beta4  
C9JTX5 ACTB  Actin, cytoplasmic 1 (Fragment)  
K7EJ44 PFN1  Profilin 1, isoform CRA_b  
F5H2R5 ARHGDIB  Rho GDPdissociation inhibitor 2 (Fragment)  
J3KS60 ARHGDIA  Rho GDPdissociation inhibitor 1  
H0YLF3 B2M  Beta2microglobulin form pI 5.3 (Fragment)  
D6RFM2 TPM3  Tropomyosin alpha3 chain  
C9JTV5 ARPC2  Actinrelated protein 2/3 complex subunit 2 (Fragment)  





B1AMJ5 CDK5RAP2                                CDK5 regulatory subunit-associated protein 2 (Fragment)  






B4E0G6 RBM6                                         RNA-binding protein 6   
C9J0S5  LTF                                             Kaliocin-1 (Fragment)   
C9JUH3  CCM2                                         Malcavernin  
D6RCA8  ANXA3                                        Annexin (Fragment)   
E5RGE1  YWHAZ                                       14-3-3 protein zeta/delta (Fragment)  
E9PEA7  STAC                                           SH3 and cysteine-rich domain-containing protein   
E9PJX3  DCST1                                        DC-STAMP domain-containing protein 1   
F5H228  TRIO                                           Triple functional domain protein   
F5H7B0  SKIV2L                                        Helicase SKI2W  
F8VS53  SOCS2                                         Suppressor of cytokine-signaling 2  
F8VSC5  SCYL2                                          SCY1-like protein 2 (Fragment)   
F8VV57  KRT5                                            Keratin, type II cytoskeletal 5 (Fragment)  
F8VY05  CCDC38                                       Coiled-coil domain-containing protein 38 (Fragment)  
F8W1C8  ZNF606                                        Zinc finger protein 606 (Fragment)  
F8W6P5  HBB                                              LVV-hemorphin-7 (Fragment)  
F8W9B8  EXOC5                                          Exocyst complex component 5  
F8WBA9  SELENBP1                                    Selenium-binding protein 1  
G3V1N2  HBA2                                             HCG1745306, isoform CRA_a  
G3V3H7  AKAP6                                           A-kinase anchor protein 6  
G8JLD3  ERC1                                             ELKS/Rab6-interacting/CAST family member 1  
H0YBM4  ASAP1                                           Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 (Fragment)  
H0YJ97 TRIP11                                           Thyroid receptor-interacting protein 11 (Fragment)  
H0YL80 TPM1                                              Tropomyosin alpha-1 chain (Fragment)  
H3BSI0 GOLGA8O                                      Golgin subfamily A member 8O (Fragment)  






H7BZ69 BBS9                                               Protein PTHB1 (Fragment)  
H7BZJ3 PDIA3                                             Thioredoxin (Fragment)  
H7BZJ8 AZGP1                                             Zinc-alpha-2-glycoprotein (Fragment)  
H7C013 ALB                                                  Serum albumin (Fragment)  
H7C1M1 PPP2R3A                                        Serine/threonine-protein phosphatase 2A regulatory subunit B'' subunit alpha (Fragment)  
H7C4A0 ANKRD44                                       Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit B (Fragment)  
H7C5G8 RBM28                                            RNA-binding protein 28 (Fragment)  
I3L3P5 P4HB                                               Protein disulfide-isomerase (Fragment)  
I3L428 SMYD4                                            SET and MYND domain-containing protein 4 (Fragment)  
I3L4X5 USP31                                              Ubiquitin carboxyl-terminal hydrolase 31  
I3L520 DNAH2                                            Dynein heavy chain 2, axonemal (Fragment)  
J3KQ37 RGPD8                                             RANBP2-like and GRIP domain-containing protein 8  
J3KRE2 ARHGDIA                                         Rho GDP-dissociation inhibitor 1  
J3QQV3 CEP112                                            Centrosomal protein of 112 kDa (Fragment)  
K7EMD9 KRT13                                              Keratin, type I cytoskeletal 13 (Fragment)  
K7EPY2 TBX4                                                T-box transcription factor TBX4 (Fragment)  
M0QZ61 PIH1D1                                            PIH1 domain-containing protein 1 (Fragment)  
M0R327 ZNF701                                            Zinc finger protein 701 (Fragment)  
O60234 GMFG                                              Glia maturation factor gamma  
O60814 HIST1H2BK                                      Histone H2B type 1-K  
O75594 PGLYRP1                                          Peptidoglycan recognition protein 1  
O94806 PRKD3                                              Serine/threonine-protein kinase D3  
O94885 SASH1                                              SAM and SH3 domain-containing protein 1  
O95104 SCAF4                                               Splicing factor, arginine/serine-rich 15  






P00558 PGK1                                                 Phosphoglycerate kinase 1  
P01034 CST3                                                  Cystatin-C  
P01036 CST4                                                  Cystatin-S  
P01037 CST1                                                  Cystatin-SN  
P01040 CSTA                                                  Cystatin-A  
P01591 IGJ                                                      Immunoglobulin J chain  
P01620                                                            Ig kappa chain V-III region SIE  
P01777                                                            Ig heavy chain V-III region TEI  
P01833 PIGR                                                   Polymeric immunoglobulin receptor  
P01834 IGKC                                                   Ig kappa chain C region  
P01857 IGHG1                                                Ig gamma-1 chain C region  
P01859 IGHG2                                                Ig gamma-2 chain C region  
P01876 IGHA1                                                Ig alpha-1 chain C region  
P01877 IGHA2                                                Ig alpha-2 chain C region  
P02533 KRT14                                                Keratin, type I cytoskeletal 14  
P02538 KRT6A                                                Keratin, type II cytoskeletal 6A  
P02549 SPTA1                                                 Spectrin alpha chain, erythrocytic 1  
P02730 SLC4A1                                               Band 3 anion transport protein  
P02766 TTR                                                     Transthyretin  
P02768 ALB                                                     Serum albumin  
P02775 PPBP                                                   Platelet basic protein  
P02787 TF                                                        Serotransferrin  
P02788 LTF                                                      Lactotransferrin  
P02814 SMR3B                                               Submaxillary gland androgen-regulated protein 3B  






P04080 CSTB                                                   Cystatin-B  
P04083 ANXA1                                                Annexin A1  
P04264 KRT1                                                   Keratin, type II cytoskeletal 1  
P04406 GAPDH                                               Glyceraldehyde-3-phosphate dehydrogenase  
P04745 AMY1A                                               Alpha-amylase 1  
P05109 S100A8                                               Protein S100-A8  
P05164 MPO                                                    Myeloperoxidase  
P05164-2 MPO                                                    Isoform H14 of Myeloperoxidase  
P06396 GSN                                                      Gelsolin  
P06702 S100A9                                               Protein S100-A9  
P06733 ENO1                                                   Alpha-enolase  
P06733-2 ENO1                                                  Isoform MBP-1 of Alpha-enolase  
P06870 KLK1                                                    Kallikrein-1  
P07237 P4HB                                                   Protein disulfide-isomerase  
P07737 PFN1                                                   Profilin-1  
P08246 ELANE                                                 Neutrophil elastase  
P08311 CTSG                                                    Cathepsin G  
P08670 VIM                                                      Vimentin  
P08727 KRT19                                                  Keratin, type I cytoskeletal 19  
P08729 KRT7                                                    Keratin, type II cytoskeletal 7  
P08F94-2 PKHD1                                                 Isoform 2 of Fibrocystin  
P09211 GSTP1                                                  Glutathione S-transferase P  
P09228 CST2                                                     Cystatin-SA  
P0CF51 TRGC1                                                  T-cell receptor gamma chain C region 1  






P0CW71 HSMCR30                                            Putative metaphase chromosome protein 1  
P10243-2 MYBL1                                                  Isoform 2 of Myb-related protein A  
P10599 TXN                                                       Thioredoxin  
P10636 MAPT                                                    Microtubule-associated protein tau  
P10636-3 MAPT                                                    Isoform Tau-A of Microtubule-associated protein tau  
P10745 RBP3                                                      Retinol-binding protein 3  
P11277-3 SPTB                                                       Isoform 3 of Spectrin beta chain, erythrocytic  
P12273 PIP                                                          Prolactin-inducible protein  
P12429 ANXA3                                                    Annexin A3  
P13645 KRT10                                                     Keratin, type I cytoskeletal 10  
P13796 LCP1                                                        Plastin-2  
P13804 ETFA                                                        Electron transfer flavoprotein subunit alpha, mitochondrial  
P14780 MMP9                                                     Matrix metalloproteinase-9  
P14923 JUP                                                           Junction plakoglobin  
P15259 PGAM2                                                    Phosphoglycerate mutase 2  
P15924 DSP                                                           Desmoplakin  
P16403 HIST1H1C                                                 Histone H1.2  
P20061 TCN1                                                         Transcobalamin-1  
P21333 FLNA                                                          Filamin-A  
P22079 LPO                                                            Lactoperoxidase 
P23280 CA6                                                            Carbonic anhydrase 6  
P25311 AZGP1                                                        Zinc-alpha-2-glycoprotein  
P26038 MSN                                                           Moesin  
P27348 YWHAQ                                                     14-3-3 protein theta  






P31025 LCN1                                                          Lipocalin-1  
P32119 PRDX2                                                        Peroxiredoxin-2  
P35527 KRT9                                                           Keratin, type I cytoskeletal 9  
P35579 MYH9                                                         Myosin-9  
P35908 KRT2                                                           Keratin, type II cytoskeletal 2 epidermal  
P36873 PPP1CC                                                      Serine/threonine-protein phosphatase PP1-gamma catalytic subunit  
P37837 TALDO1                                                      Transaldolase  
P46020 PHKA1                                                        Phosphorylase b kinase regulatory subunit alpha, skeletal muscle isoform  
P48147 PREP                                                           Prolyl endopeptidase  
P49639 HOXA1                                                        Homeobox protein Hox-A1  
P52565 ARHGDIA                                                    Rho GDP-dissociation inhibitor 1  
P52566 ARHGDIB                                                    Rho GDP-dissociation inhibitor 2  
P59665 DEFA1                                                         Neutrophil defensin 1  
P60709 ACTB                                                           Actin, cytoplasmic 1  
P61626 LYZ                                                               Lysozyme C  
P61647 ST8SIA6                                                       Alpha-2,8-sialyltransferase 8F  
P62805 HIST1H4A                                                   Histone H4  
P62937 PPIA                                                             Peptidyl-prolyl cis-trans isomerase A  
P68871 HBB                                                              Hemoglobin subunit beta  
P69905 HBA1                                                            Hemoglobin subunit alpha  
Q02040 AKAP17A                                                     A-kinase anchor protein 17A  
Q05707 COL14A1                                                     Collagen alpha-1(XIV) chain  
Q05707-3 COL14A1                                                      Isoform 3 of Collagen alpha-1(XIV) chain  
Q14166 TTLL12                                                          Tubulin--tyrosine ligase-like protein 12  






Q14993 COL19A1                                                      Collagen alpha-1(XIX) chain  
Q15059-2 BRD3                                                             Isoform 2 of Bromodomain-containing protein 3  
Q15078 CDK5R1                                                         Cyclin-dependent kinase 5 activator 1  
Q15477 SKIV2L                                                           Helicase SKI2W  
Q16549 PCSK7                                                            Proprotein convertase subtilisin/kexin type 7  
Q2TBE0 CWF19L2                                                      CWF19-like protein 2  
Q3BBV0 NBPF1                                                           Neuroblastoma breakpoint family member 1  
Q4G112 HSF5                                                              Heat shock factor protein 5  
Q4KWH8-2 PLCH1                                                           Isoform 2 of 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase eta-1  
Q5T085 AMY1B                                                          Alpha-amylase 1 (Fragment)  
Q5T7V8 GORAB                                                          RAB6-interacting golgin  
Q5T8M8 ACTA1                                                            Actin, alpha skeletal muscle  
Q5TAQ9 DCAF8                                                            DDB1- and CUL4-associated factor 8  
Q5VT06 CEP350                                                          Centrosome-associated protein 350  
Q5XKE5 KRT79                                                            Keratin, type II cytoskeletal 79  
Q6NXT2 H3F3C                                                            Histone H3.3C  
Q6P5S2 C6orf58                                                          UPF0762 protein C6orf58  
Q6S8J7-2 POTEA                                                            Isoform 2 of POTE ankyrin domain family member A  
Q6ZU67 BEND4                                                            BEN domain-containing protein 4  
Q7Z3D6 C14orf159                                                      UPF0317 protein C14orf159, mitochondrial  
Q7Z3Z0 KRT25                                                             Keratin, type I cytoskeletal 25  
Q7Z4W1 DCXR                                                               L-xylulose reductase  
Q7Z794 KRT77                                                              Keratin, type II cytoskeletal 1b  
Q86TG7-2 PEG10                                                             Isoform RF1 of Retrotransposon-derived protein PEG10  






Q8N302 AGGF1                                                             Angiogenic factor with G patch and FHA domains 1  
Q8N427 NME8                                                               Thioredoxin domain-containing protein 3  
Q8N4F0 BPIFB2                                                              BPI fold-containing family B member 2  
Q8NGN5 OR10G8                                                           Olfactory receptor 10G8  
Q8TAL5 C9orf43                                                           Uncharacterized protein C9orf43  
Q8TAX7 MUC7                                                              Mucin-7  
Q8WZ55 BSND                                                               Barttin  
Q96DA0 ZG16B                                                              Zymogen granule protein 16 homolog B  
Q96DR5 BPIFA2                                                            BPI fold-containing family A member 2  
Q96EK7-2 FAM120B                                                        Isoform 2 of Constitutive coactivator of peroxisome proliferator-activated 
receptor gamma  
Q96EU7 C1GALT1C1                                                     C1GALT1-specific chaperone 1  
Q96JM2 ZNF462                                                            Zinc finger protein 462  
Q96P15 SERPINB11                                                      Serpin B11  
Q99798 ACO2                                                                Aconitate hydratase, mitochondrial  
Q99848 EBNA1BP2                                                       Probable rRNA-processing protein EBP2  
Q9BQS8 FYCO1                                                               FYVE and coiled-coil domain-containing protein 1  
Q9C029-1 TRIM7                                                               Isoform 4 of Tripartite motif-containing protein 7  
Q9H094-5 NBPF3                                                               Isoform 5 of Neuroblastoma breakpoint family member 3  
Q9H3U1-2 UNC45A                                                            Isoform 2 of Protein unc-45 homolog A  
Q9H4B7 TUBB1                                                               Tubulin beta-1 chain  
Q9H694-2 BICC1                                                                 Isoform 2 of Protein bicaudal C homolog 1  
Q9HC58 SLC24A3                                                            Sodium/potassium/calcium exchanger 3  
Q9HC84 MUC5B                                                              Mucin-5B  






Q9P1Z3 HCN3                                                                 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 
3  
Q9P2D1 CHD7                                                                  Chromodomain-helicase-DNA-binding protein 7  
Q9UBN4-6 TRPC4                                                                 Isoform Zeta of Short transient receptor potential channel 4  
Q9UGM3 DMBT1                                                                Deleted in malignant brain tumors 1 protein  
Q9UNS1-2 TIMELESS                                                            Isoform 2 of Protein timeless homolog  
Q9Y2Q0 ATP8A1 P                                                           Probable phospholipid-transporting ATPase IA  
Q9Y2Q0-2 ATP8A1                                                               Isoform 2 of Probable phospholipid-transporting ATPase IA  
Q9Y2Z9 COQ6                                                                   Ubiquinone biosynthesis monooxygenase COQ6  
Q9Y3B3 TMED7                                                                 Transmembrane emp24 domain-containing protein 7  
Q9Y6M7-5 SLC4A7                                                                 Isoform 5 of Sodium bicarbonate cotransporter 3  
Q9Y6W5 WASF2                                                                 Wiskott-Aldrich syndrome protein family member 2  
R4GN98 S100A6                                                                 Protein S100-A6 (Fragment)  












change Log10 p-value 
P68871 Haemoglobin subunit beta  -1.02 1.55 
P28161 Glutathione S-transferase Mu 2  -1.00 0.45 
P00915 carbonic anhydrase 1  -0.88 1.40 
P02042 Haemoglobin subunit delta  -0.84 1.74 
P69905 Haemoglobin subunit alpha  -0.79 1.49 
P00390 Glutathione reductase, mitochondrial  -0.52 2.44 
P27695 DNA-(apurinic or apyrimidinic site) lyase  -0.20 2.12 
P07339 Cathepsin D  0.11 1.52 
Q07960 rho GTPase-activating protein 1  0.13 1.43 
P35754 Glutaredoxin-1  0.24 1.42 
Q9P2E9-1 Ribosome-binding protein 1  0.24 1.42 
P60953 Cell division control protein 42 homolog  0.26 2.93 
P06737-1 Glycogen phosphorylase, liver form  0.26 2.03 
P11766 alcohol dehydrogenase class-3  0.30 3.91 
P43490 nicotinamide phosphoribosyltransferase  0.33 1.34 
P40227-1 T-complex protein 1 subunit zeta  0.34 1.55 
P28838 cytosol aminopeptidase  0.41 1.44 






P28676 Grancalcin  0.46 1.33 
Q01432-4 Isoform 2 of AMP deaminase 3  0.50 1.43 
O75915 PRA1 family protein 3  0.61 1.55 
Q9UJ70-2 Isoform 2 of N-acetyl-D-glucosamine kinase  0.63 1.69 
P60842 Eukaryotic initiation factor 4A-I  1.01 0.64 
P05164-3 Isoform H7 of Myeloperoxidase  1.06 0.50 
Q6FI13 Histone H2A type 2-A  1.30 0.38 
P08311 Cathepsin G  1.33 0.45 
P11678 Eosinophil peroxidase  1.36 0.58 
P23527 Histone H2B type 1-O  1.45 0.44 
P62805 histone H4  1.46 0.48 
P51858 hepatoma-derived growth factor  -0.75 0.68 
P02769 Serum albumin  -0.73 1.20 
P54819 Adenylate kinase 2, mitochondrial  -0.66 0.31 
Q3SZR3 Alpha-1-acid glycoprotein -0.66 0.69 
P02768-1 Serum albumin  -0.56 0.73 
P62140 Serine/threonine-protein phosphatase PP1-beta catalytic subunit  -0.56 0.48 
P20810-6 Isoform 6 of Calpastatin  -0.56 0.50 
P32119 Peroxiredoxin-2  -0.52 0.79 
Q28194 Thrombospondin-1 (Fragment)  -0.52 0.67 
P16402 Histone H1.3  -0.50 0.29 
Q96HE7 ERO1-like protein alpha  -0.49 0.28 
P14678-3 
Isoform SM-B1 of Small nuclear ribonucleoprotein-associated proteins B 






P54108-3 Isoform 3 of Cysteine-rich secretory protein 3  -0.47 0.53 
P61981 14-3-3 protein gamma  -0.47 1.15 
P10412 Histone H1.4  -0.46 0.20 
O75015 Low affinity immunoglobulin gamma Fc region receptor III-B  -0.46 0.31 
P16104 Histone H2AX  -0.45 0.81 
P40121 Macrophage-capping protein  -0.43 0.83 
P42166 Lamina-associated polypeptide 2, isoform alpha  -0.42 0.98 
Q96E17 ras-related protein Rab-3C  -0.42 0.20 
P32320 cytidine deaminase  -0.41 0.49 
P04264 Keratin, type II cytoskeletal 1  -0.39 0.90 
O75368 SH3 domain-binding glutamic acid-rich-like protein  -0.39 0.47 
P31150 Rab GDP dissociation inhibitor alpha  -0.38 0.39 
P11166 Solute carrier family 2, facilitated glucose transporter member 1  -0.38 0.23 
P02763 Alpha-1-acid glycoprotein 1  -0.37 0.35 
P23526-1 Adenosylhomocysteinase  -0.37 0.60 
P08637 Low affinity immunoglobulin gamma Fc region receptor III-A  -0.37 0.81 
P07910-1 Heterogeneous nuclear ribonucleoproteins C1/C2  -0.37 0.80 
O00232-1 26s proteasome non-atpase regulatory subunit 12  -0.36 0.87 
P50990 T-complex protein 1 subunit theta  -0.35 0.42 
Q9Y2Y8 proteoglycan 3  -0.35 0.22 
P36957 
Dihydrolipoyllysine-residue succinyltransferase component of 2-
oxoglutarate dehydrogenase complex, mitochondrial  -0.34 0.18 
P25787 Proteasome subunit alpha type-2  -0.34 1.02 






P00488 Coagulation factor XIII A chain  -0.33 0.18 
P41218 Myeloid cell nuclear differentiation antigen  -0.33 0.49 
P04179 Superoxide dismutase  -0.33 0.43 
P05204 Non-histone chromosomal protein HMG-17  -0.33 0.11 
P13645 Keratin, type I cytoskeletal 10  -0.33 0.55 
Q5JTV8-3 Isoform 3 of Torsin-1A-interacting protein 1  -0.31 0.51 
Q01518-1 adenylyl cyclase-associated protein 1  -0.31 0.20 
Q92688 Acidic leucine-rich nuclear phosphoprotein 32 family member B  -0.30 0.45 
Q14739 Lamin-B receptor  -0.30 0.14 
P00918 Carbonic anhydrase 2  -0.29 1.06 
P61077-3 Isoform 3 of Ubiquitin-conjugating enzyme E2 D3  -0.28 0.24 
Q9Y2S6 Translation machinery-associated protein 7  -0.28 0.60 
Q9HBI1-2 Isoform 2 of Beta-parvin  -0.28 0.22 
P27348 14-3-3 protein theta  -0.28 0.16 
Q15942 Zyxin  -0.28 0.43 
P0DOX5 immunoglobulin gamma-1 heavy chain  -0.27 0.19 
P49721 proteasome subunit beta type-2  -0.27 0.35 
P22061-2 Isoform 2 of Protein-L-isoaspartate(D-aspartate) O-methyltransferase  -0.27 0.53 
P62937 peptidyl-prolyl cis-trans isomerase A  -0.26 0.81 
Q15257-1 Serine/threonine-protein phosphatase 2A activator  -0.26 0.28 
Q9UBW5-1 Bridging integrator 2  -0.26 0.22 
P10768 S-formylglutathione hydrolase  -0.25 0.50 
P63241-2 Isoform 2 of Eukaryotic translation initiation factor 5A-1  -0.25 0.20 






P52907 F-actin-capping protein subunit alpha-1  -0.23 0.31 
Q15366-2 Isoform 2 of Poly(rC)-binding protein 2  -0.23 0.61 
P31146 Coronin-1A  -0.23 0.349 
Q9NQR4 Omega-amidase NIT2  -0.22 0.16 
P07737 profilin-1  -0.22 0.21 
P14317 Hematopoietic lineage cell-specific protein  -0.22 0.47 
P61970 nuclear transport factor 2  -0.22 0.83 
P16401 Histone H1.5  -0.22 0.16 
Q01518-2 Isoform 2 of Adenylyl cyclase-associated protein 1  -0.21 0.23 
P49189 4-tnimethylaminobutyraldehyde dehydrogenase  -0.21 0.31 
P26583 High mobility group protein B2  -0.20 0.32 
P06703 protein S100-A6  -0.20 0.16 
Q14847-2 Isoform 2 of LIM and SH3 domain protein 1  -0.20 0.16 
Q16698 2,4-dienoyl-CoA reductase, mitochondrial  -0.20 0.77 
P80723 Brain acid soluble protein 1  -0.20 0.27 
P13798 Acylamino-acid-releasing enzyme  -0.20 0.94 
Q9UKM9-1 RNA-binding protein Raly  -0.20 0.94 
P08758 annexin A5  -0.20 0.22 
P12429 annexin A3  -0.20 0.23 
P63313 thymosin beta-10  -0.20 0.78 
Q9UL46 proteasome activator complex subunit 2  -0.20 0.26 
Q14103 heterogeneous nuclear ribonucleoprotein D0  -0.19 0.42 
P13693 Translationally-controlled tumor protein  -0.19 0.39 






P61626 lysozyme c  -0.19 0.18 
Q06830 peroxiredoxin-1  -0.19 0.49 
P02775 Platelet basic protein  -0.19 0.33 
P20061 Transcobalamin-1  -0.19 0.16 
P04083 annexin A1  -0.18 0.15 
P55957-2 Isoform 2 of BH3-interacting domain death agonist  -0.18 0.28 
O75367-1 Core histone macro-H2A.1  -0.18 0.36 
P50502 Hsc70-interacting protein  -0.18 0.20 
P11310-2 
Isoform 2 of Medium-chain specific acyl-CoA dehydrogenase, 
mitochondrial  -0.17 0.24 
Q05315 galectin-10  -0.17 0.13 
Q99497 protein/nucleic acid deglycase DJ-1  -0.17 0.64 
P14780 Matrix metalloproteinase-9  -0.17 0.26 
Q14019 coactosin-like protein  -0.16 0.14 
P30044-1 Peroxiredoxin-5, mitochondrial  -0.15 0.16 
P36871-1 Phosphoglucomutase-1  -0.15 0.50 
P31949 protein S100-A11  -0.15 0.10 
A6NI72 Putative neutrophil cytosol factor 1B  -0.14 0.27 
P51991-1 Heterogeneous nuclear ribonucleoprotein A3  -0.14 0.43 
P04075-2 Isoform 2 of Fructose-bisphosphate aldolase A  -0.14 0.29 
P16403 Histone H1.2  -0.14 0.14 
Q9NYL9 tropomodulin-3  -0.13 0.15 
Q00839 Heterogeneous nuclear ribonucleoprotein U  -0.13 0.50 






O75131 Copine-3  -0.13 0.30 
Q9H299 SH3 domain-binding glutamic acid-rich-like protein 3  -0.13 0.22 
P40197 Platelet glycoprotein V  -0.12 0.14 
Q92522 Histone H1x  -0.12 0.13 
P61088 ubiquitin-conjugating enzyme E2 N  -0.12 0.64 
P02730 Band 3 anion transport protein  -0.12 0.09 
Q9NQC3 Reticulon-4  -0.12 0.18 
P11215-2 Isoform 2 of Integrin alpha-M  -0.13 0.16 
P13489 Ribonuclease inhibitor  -0.12 0.60 
P00491 purine nucleoside phosphorylase  -0.12 0.16 
P61916 Epididymal secretory protein E1  -0.11 0.26 
O00764-1 Pyridoxal kinase  -0.12 0.15 
P04040 catalase  -0.12 0.46 
Q15084-2 Isoform 2 of Protein disulfide-isomerase A6  -0.12 0.23 
P33241-3 Isoform 3 of Lymphocyte-specific protein 1  -0.12 0.13 
P20340-1 Ras-related protein Rab-6A  -0.11 0.22 
P22234 multifunctional protein ADE2  -0.11 0.59 
P00761 Trypsin OS=Sus scrofa PE=1 SV=1 -0.11 0.20 
P54725 UV excision repair protein RAD23 homolog A  -0.11 0.06 
P07305 Histone H1.0  -0.10 0.08 
P80511 Protein S100-A12  -0.10 0.11 
Q1KMD3 heterogeneous nuclear ribonucleoprotein U-like protein 2  -0.10 0.19 
P40926 Malate dehydrogenase, mitochondrial  -0.10 0.44 






P30504 HLA class I histocompatibility antigen, Cw-4 alpha chain  -0.10 0.19 
P14314 Glucosidase 2 subunit beta  -0.10 0.06 
P61604 10 kDa heat shock protein, mitochondrial  -0.09 0.20 
P13796 Plastin-2  -0.08 0.07 
P78417 Glutathione S-transferase omega-1  -0.08 0.09 
P00558 phosphoglycerate kinase 1  -0.08 0.07 
P40925-3 Isoform 3 of Malate dehydrogenase, cytoplasmic  -0.08 0.11 
P51149 ras-related protein Rab-7a  -0.08 0.11 
Q92930 Ras-related protein Rab-8B  -0.08 0.06 
P19338 Nucleolin  -0.07 0.07 
P80188 Neutrophil gelatinase-associated lipocalin  -0.07 0.08 
P37837 Transaldolase  -0.07 0.06 
P10599-1 thioredoxin  -0.07 0.10 
P23528 Cofilin-1  -0.07 0.07 
Q9UM07 Protein-arginine deiminase type-4  -0.07 0.03 
Q9Y5Z4-1 Heme-binding protein 2  -0.07 0.37 
P50552 Vasodilator-stimulated phosphoprotein  -0.07 0.15 
P18669 Phosphoglycerate mutase 1  -0.07 0.13 
Q6JBY9 CapZ-interacting protein  -0.07 0.13 
P52566 Rho GDP-dissociation inhibitor 2  -0.06 0.08 
P09211 Glutathione S-transferase P  -0.06 0.04 
P08567 pleckstrin  -0.06 0.08 
P63104 14-3-3 protein zeta/delta  -0.06 0.05 






Q13011 Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial  -0.06 0.16 
P09917 arachidonate 5-lipoxygenase  -0.06 0.08 
P23368-1 NAD-dependent malic enzyme, mitochondrial  -0.06 0.18 
P25815 Protein S100-P  -0.05 0.04 
P05107 Integrin beta-2  -0.05 0.11 
P02788 Lactotransferrin  -0.05 0.05 
Q969H8 Myeloid-derived growth factor  -0.05 0.12 
P31946 14-3-3 protein beta/alpha  -0.05 0.07 
P26641-2 Isoform 2 of Elongation factor 1-gamma  -0.05 0.11 
Q9BRA2 Thioredoxin domain-containing protein 17  -0.05 0.05 
Q15907 Ras-related protein Rab-11B  -0.05 0.14 
P62258-1 14-3-3 protein epsilon  -0.05 0.26 
Q00325-1 Phosphate carrier protein, mitochondrial  -0.04 0.07 
Q96FJ2 Dynein light chain 2, cytoplasmic  -0.04 0.06 
Q9NZN3 EH domain-containing protein 3  -0.04 0.03 
Q3ZBD7 Glucose-6-phosphate isomerase OS=Bos taurus GN=GPI PE=2 SV=4 -0.04 0.04 
Q12905 Interleukin enhancer-binding factor 2  -0.04 0.13 
P05455 Lupus La protein  -0.04 0.05 
P55008-1 Allograft inflammatory factor 1  -0.04 0.13 
P26599-3 Isoform 3 of Polypyrimidine tract-binding protein 1  -0.04 0.11 
Q6P4A8 Phospholipase B-like 1  -0.04 0.04 
P22894 Neutrophil collagenase  -0.04 0.03 
Q9BRF8-1 Serine/threonine-protein phosphatase CPPED1  -0.03 0.10 






P07741-1 Adenine phosphoribosyltransferase  -0.03 0.17 
P37802-2 Isoform 2 of Transgelin-2  -0.03 0.04 
P60900 Proteasome subunit alpha type-6  -0.03 0.06 
P06744 glucose-6-phosphate isomerase  -0.03 0.03 
Q9HC38 Glyoxalase domain-containing protein 4  -0.03 0.02 
P00738 Haptoglobin  -0.03 0.05 
P00387-3 Isoform 3 of NADH-cytochrome b5 reductase 3  -0.03 0.30 
P04839 Cytochrome b-245 heavy chain  -0.02 0.07 
Q99439 Calponin-2  -0.02 0.03 
P19878 Neutrophil cytosol factor 2  -0.02 0.06 
P30048 Thioredoxin-dependent peroxide reductase, mitochondrial  -0.02 0.03 
P05109 Protein S100-A8  -0.02 0.02 
P30046 D-dopachrome decarboxylase  -0.02 0.04 
Q16881-1 Thioredoxin reductase 1, cytoplasmic  -0.02 0.04 
P08133-1 annexin A6  -0.02 0.02 
P14866 Heterogeneous nuclear ribonucleoprotein L  -0.02 0.08 
Q10588 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2  -0.02 0.04 
P45880-1 Isoform 1 of Voltage-dependent anion-selective channel protein 2  -0.02 0.07 
P46459 Vesicle-fusing ATPase  -0.01 0.02 
Q92882 osteoclast-stimulating factor 1  -0.01 0.03 
P68036-3 Isoform 3 of Ubiquitin-conjugating enzyme E2 L3  -0.01 0.01 
P26447 Protein S100-A4  -0.01 0.01 
P22626 heterogeneous nuclear ribonucleoproteins A2/B1  -0.01 0.01 






P47756-2 Isoform 2 of F-actin-capping protein subunit beta  -0.01 0.02 
P11142-1 Heat shock cognate 71 kDa protein  -0.01 0.03 
P30043 flavin reductase (NADPH)  -0.01 0.02 
P11413-2 Isoform Long of Glucose-6-phosphate 1-dehydrogenase  -0.01 0.01 
P07996 thrombospondin-1  -0.01 0.01 
P29350-4 Isoform 4 of Tyrosine-protein phosphatase non-receptor type 6  -0.01 0.01 
P15144 aminopeptidase N  -0.00 0.00 
P09525 annexin A4  -0.00 0.00 
P09960-1 leukotriene A-4 hydrolase  -0.00 0.00 
P07359 Platelet glycoprotein Ib alpha chain  0.00 0.00 
O43707 Alpha-actinin-4  0.00 0.00 
P02776 Platelet factor 4  0.00 0.00 
P54727 UV excision repair protein RAD23 homolog B  0.00 0.01 
Q6UX06 Olfactomedin-4  0.00 0.00 
P05106 Integrin beta-3  0.01 0.01 
P53004 Biliverdin reductase A  0.01 0.03 
P62328 Thymosin beta-4  0.01 0.02 
P15311 Ezrin  0.01 0.04 
P06702 Protein S100-A9  0.02 0.02 
O75594 peptidoglycan recognition protein 1  0.02 0.02 
P61224-1 Ras-related protein Rap-1b  0.02 0.03 
P31948-2 Isoform 2 of Stress-induced-phosphoprotein 1  0.02 0.04 
P52209-2 Isoform 2 of 6-phosphogluconate dehydrogenase, decarboxylating  0.02 0.03 






Q9Y376 Calcium-binding protein 39  0.02 0.02 
P49748-3 
Isoform 3 of Very long-chain specific acyl-CoA dehydrogenase, 
mitochondrial  0.02 0.04 
Q9ULZ3 apoptosis-associated speck-like protein containing a CARD  0.03 0.02 
P23284 peptidyl-prolyl cis-trans isomerase B  0.03 0.04 
P30405 Peptidyl-prolyl cis-trans isomerase F, mitochondrial  0.03 0.09 
P12814-1 Alpha-actinin-1  0.03 0.07 
P15954 Cytochrome c oxidase subunit 7C, mitochondrial  0.03 0.02 
P22307-1 Non-specific lipid-transfer protein  0.03 0.26 
P04080 Cystatin-B  0.03 0.02 
P29401-2 Isoform 2 of Transketolase  0.03 0.02 
P60174 Triosephosphate isomerase  0.04 0.05 
P24158 Myeloblastin  0.04 0.04 
P06733-1 alpha-enolase  0.04 0.04 
P17213 Bactericidal permeability-increasing protein  0.04 0.03 
P61204 ADP-ribosylation factor 3  0.04 0.03 
P50995 annexin A11  0.04 0.23 
P30040-1 Endoplasmic reticulum resident protein 29  0.04 0.25 
P14550 alcohol dehydrogenase  0.04 0.30 
P62136-2 
Isoform 2 of Serine/threonine-protein phosphatase PP1-alpha catalytic 
subunit  0.04 0.33 
Q12906-7 Isoform 7 of Interleukin enhancer-binding factor 3  0.05 0.19 
P02647 Apolipoprotein A-I  0.05 0.15 
P16949-2 Isoform 2 of Stathmin  0.05 0.05 






P38646 Stress-70 protein, mitochondrial  0.05 0.05 
O75390 citrate synthase, mitochondrial  0.05 0.77 
P22314 Ubiquitin-like modifier-activating enzyme 1  0.05 0.13 
O95336 6-phosphogluconolactonase  0.05 0.08 
Q99536 Synaptic vesicle membrane protein VAT-1 homolog  0.06 0.12 
P11021 78 kDa glucose-regulated protein  0.06 0.39 
O15143 Actin-related protein 2/3 complex subunit 1B  0.06 0.11 
O75340 programmed cell death protein 6  0.06 0.07 
Q9P1F3 Costars family protein ABRACL  0.06 0.05 
Q15833-1 Syntaxin-binding protein 2  0.06 0.12 
P02675 Fibrinogen beta chain  0.06 0.06 
O00194 ras-related protein rab-27b  0.06 0.03 
P30086 phosphatidylethanolamine-binding protein 1  0.06 0.31 
Q96QK1 Vacuolar protein sorting-associated protein 35  0.07 0.12 
P46976-1 Glycogenin-1  0.07 0.15 
O75083 WD repeat-containing protein 1  0.07 0.08 
P10720 Platelet factor 4 variant  0.07 0.06 
P07108-5 Isoform 5 of Acyl-CoA-binding protein  0.07 0.07 
P19367-3 Isoform 3 of Hexokinase-1  0.07 0.12 
Q9Y490 Talin-1  0.07 0.13 
Q9H4A4 aminopeptidase B  0.07 0.08 
P55145 Mesencephalic astrocyte-derived neurotrophic factor  0.08 0.06 
P00492 Hypoxanthine-guanine phosphoribosyltransferase  0.08 0.61 






Q6XQN6-2 Isoform 2 of Nicotinate phosphoribosyltransferase  0.08 0.72 
P06865 Beta-hexosaminidase subunit alpha  0.08 0.23 
P67936 Tropomyosin alpha-4 chain  0.08 0.08 
P48595 serpin B10  0.08 0.20 
P10644 cAMP-dependent protein kinase type I-alpha regulatory subunit  0.08 0.07 
P11234-2 Isoform 2 of Ras-related protein Ral-B  0.08 0.06 
P12956 X-ray repair cross-complementing protein 6  0.08 0.11 
P36222 Chitinase-3-like protein 1  0.08 0.10 
P20073-1 Annexin A7  0.08 0.18 
P49591 Serine--tRNA ligase, cytoplasmic  0.09 0.09 
Q9HDC9 Adipocyte plasma membrane-associated protein  0.09 0.33 
P68104 Elongation factor 1-alpha 1  0.09 0.17 
Q12913-1 Receptor-type tyrosine-protein phosphatase eta  0.09 0.11 
Q04760-1 lactoylglutathione lyase  0.09 0.29 
P61158 actin-related protein 3  0.09 0.11 
O15511-1 Actin-related protein 2/3 complex subunit 5  0.09 0.57 
P31943 Heterogeneous nuclear ribonucleoprotein H  0.09 0.10 
Q13561-2 Isoform 2 of Dynactin subunit 2  0.09 0.15 
P55786 puromycin-sensitive aminopeptidase  0.10 0.18 
P04406 glyceraldehyde-3-phosphate dehydrogenase  0.10 0.08 
Q06323 Proteasome activator complex subunit 1  0.10 0.13 
P39687 Acidic leucine-rich nuclear phosphoprotein 32 family member A  0.10 0.15 
P30041 Peroxiredoxin-6  0.10 0.12 






P13639 Elongation factor 2  0.10 0.12 
O60234 glia maturation factor gamma  0.10 0.12 
Q9ULV4-3 Isoform 3 of Coronin-1C  0.10 0.22 
P08514-1 integrin alpha-IIb  0.10 0.18 
P18206 Vinculin  0.10 0.27 
P21333 Filamin-A  0.11 0.19 
Q96RU3-1 Formin-binding protein 1  0.11 0.23 
Q16851 UTP--glucose-1-phosphate uridylyltransferase  0.11 0.63 
P30520 adenylosuccinate synthetase isozyme 2  0.11 0.30 
P61106 Ras-related protein Rab-14  0.11 1.14 
Q6IBS0 Twinfilin-2  0.11 0.25 
P99999 cytochrome c  0.11 0.11 
Q15691 Microtubule-associated protein RP/EB family member 1  0.12 0.13 
O15144 Actin-related protein 2/3 complex subunit 2  0.12 0.10 
P10809 60 kDa heat shock protein, mitochondrial  0.12 0.25 
Q96G03 Phosphoglucomutase-2  0.12 0.24 
O00151 PDZ and LIM domain protein 1  0.12 0.06 
P15153 Ras-related C3 botulinum toxin substrate 2  0.12 0.37 
Q9H0U4 ras-related protein Rab-1B  0.12 0.16 
P48643 T-complex protein 1 subunit epsilon  0.12 0.19 
Q14974 Importin subunit beta-1  0.12 0.28 
P04899-1 guanine nucleotide-binding protein G(i) subunit alpha-2  0.13 0.19 
P61586 Transforming protein RhoA  0.12 0.43 






Q92820 Gamma-glutamyl hydrolase  0.12 0.24 
P06753-2 Isoform 2 of Tropomyosin alpha-3 chain  0.13 0.19 
P13224-2 Isoform 2 of Platelet glycoprotein Ib beta chain  0.13 0.15 
Q5JWF2-1 Guanine nucleotide-binding protein G(S) subunit alpha isoforms XLas  0.13 0.14 
P52565 rho GDP-dissociation inhibitor 1  0.13 1.09 
P61020 Ras-related protein Rab-5B  0.13 0.78 
P55072 Transitional endoplasmic reticulum ATPase  0.14 0.42 
P27105 erythrocyte band 7 integral membrane protein  0.14 0.23 
P05089-2 Isoform 2 of Arginase-1  0.14 0.18 
P59998-3 Isoform 3 of Actin-related protein 2/3 complex subunit 4  0.15 0.27 
Q96C19 EF-hand domain-containing protein D2  0.15 0.50 
O00299 chloride intracellular channel protein 1  0.15 0.31 
P39019 40S ribosomal protein S19  0.15 0.13 
Q7L1Q6-3 Isoform 3 of Basic leucine zipper and W2 domain-containing protein 1  0.15 0.42 
P48147 prolyl endopeptidase  0.15 0.39 
Q96QH2-2 Isoform 2 of PML-RARA-regulated adapter molecule 1  0.15 0.25 
P00505 Aspartate aminotransferase, mitochondrial  0.16 0.31 
Q99729-1 Heterogeneous nuclear ribonucleoprotein A/B  0.16 0.20 
P04632 Calpain small subunit 1  0.16 0.62 
P13716-2 Isoform 2 of Delta-aminolevulinic acid dehydratase  0.16 0.25 
Q15365 Poly(RC)-binding protein 1  0.16 0.34 
Q13813-2 Isoform 2 of Spectrin alpha chain, non-erythrocytic 1  0.17 0.19 
P62826 GTP-binding nuclear protein RAN  0.17 0.46 






P02671-1 Fibrinogen alpha chain  0.17 0.15 
P22392-2 Isoform 3 of Nucleoside diphosphate kinase B  0.17 0.49 
P07237 Protein disulfide-isomerase  0.18 0.23 
P15586 N-acetylglucosamine-6-sulfatase  0.18 0.29 
O43488 aflatoxin B1 aldehyde reductase member 2  0.18 0.38 
Q8WUM4-2 Isoform 2 of Programmed cell death 6-interacting protein  0.18 0.51 
P27797 Calreticulin  0.18 0.32 
P51159-1 Ras-related protein Rab-27A  0.18 0.61 
P07602-3 Isoform Sap-mu-9 of Prosaposin  0.18 0.36 
P29692-2 Isoform 2 of Elongation factor 1-delta  0.19 0.99 
P09972 Fructose-bisphosphate aldolase C  0.19 0.33 
P62873 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1  0.19 0.13 
P37840-1 Alpha-synuclein  0.19 0.11 
P04908 histone H2A type 1-B/E  0.19 0.07 
P21796 voltage-dependent anion-selective channel protein 1  0.19 0.46 
P61160-2 Isoform 2 of Actin-related protein 2  0.19 0.59 
P46940 Ras GTPase-activating-like protein IQGAP1  0.20 1.03 
Q15080-1 Neutrophil cytosol factor 4  0.20 0.60 
P25786-2 Isoform Long of Proteasome subunit alpha type-1  0.20 0.39 
Q15404-1 Ras suppressor protein 1  0.20 0.23 
O75923-13 Isoform 13 of Dysferlin  0.20 0.22 
P08575-1 Receptor-type tyrosine-protein phosphatase C  0.20 0.51 
Q13201 Multimerin-1  0.20 0.24 






P61026 ras-related protein rab-10  0.21 0.27 
Q8IX19 Mast cell-expressed membrane protein 1  0.21 0.32 
P16671 Platelet glycoprotein 4  0.21 0.58 
Q13185 chromobox protein homolog 3  0.21 0.46 
O14950 Myosin regulatory light chain 12B  0.21 0.17 
P30740 Leukocyte elastase inhibitor  0.21 0.54 
P07195 L-lactate dehydrogenase B chain  0.22 0.18 
P31939 bifunctional purine biosynthesis protein purH  0.22 0.50 
Q9NUQ9 protein FAM49B  0.22 0.77 
O14745 Na(+)/H(+) exchange regulatory cofactor NHE-RF1  0.22 0.14 
P16152 Carbonyl reductase  0.22 0.17 
P48059-3 
Isoform 3 of LIM and senescent cell antigen-like-containing domain 
protein 1  0.22 0.28 
O95810 caveolae-associated protein 2  0.22 0.15 
Q14005-1 Pro-interleukin-16  0.23 0.33 
P07355-2 Isoform 2 of Annexin A2  0.23 0.39 
O75475-1 PC4 and SFRS1-interacting protein  0.24 0.29 
P08238 Heat shock protein HSP 90-beta  0.24 0.49 
P50570-1 Dynamin-2  0.24 0.45 
Q92841 Probable ATP-dependent RNA helicase DDX17  0.24 0.37 
P53396-1 ATP-citrate synthase  0.25 0.25 
P12724 eosinophil cationic protein  0.25 0.12 
Q9ULC4-3 Isoform 3 of Malignant T-cell-amplified sequence 1  0.25 0.71 






P15121 aldose reductase  0.25 0.35 
P19971-2 Isoform 2 of Thymidine phosphorylase  0.25 0.68 
P30101 Protein disulfide-isomerase A3  0.25 0.35 
P51148-2 Isoform 2 of Ras-related protein Rab-5C  0.26 0.35 
P48735 Isocitrate dehydrogenase  0.26 0.55 
Q9UII2-1 ATPase inhibitor, mitochondrial  0.26 0.75 
P53999 Activated RNA polymerase II transcriptional coactivator p15  0.26 0.33 
P18054 Arachidonate 12-lipoxygenase, 12S-type  0.27 0.42 
O75874 Isocitrate dehydrogenase  0.27 0.25 
P09874 Poly  0.27 0.25 
P02679 Fibrinogen gamma chain  0.28 0.22 
P07900-2 Isoform 2 of Heat shock protein HSP 90-alpha  0.29 0.71 
P14625 Endoplasmin  0.29 0.67 
O15145 Actin-related protein 2/3 complex subunit 3  0.29 0.53 
Q13838-2 Isoform 2 of Spliceosome RNA helicase DDX39B  0.29 0.27 
P17931 Galectin-3  0.29 1.15 
Q86UX7 Fermitin family homolog 3  0.29 0.63 
Q3ZCW2 Galectin-related protein  0.30 0.28 
P06396 Gelsolin  0.30 0.86 
P11169 Solute carrier family 2, facilitated glucose transporter member 3  0.30 0.35 
P06748 Nucleophosmin  0.32 0.33 
P10153 Non-secretory ribonuclease  0.32 0.18 







Glutamate dehydrogenase 1, mitochondrial OS=Bos taurus GN=GLUD1 
PE=1 SV=2 0.33 0.41 
P27824-2 Isoform 2 of Calnexin  0.33 0.72 
O43447 peptidyl-prolyl cis-trans isomerase H  0.34 0.44 
P30085 UMP-CMP kinase  0.35 1.01 
O75695 Protein XRP2  0.35 0.81 
P84243 histone H3.3  0.36 0.17 
P14770 Platelet glycoprotein IX  0.36 0.21 
Q05655-2 Isoform 2 of Protein kinase C delta type  0.37 0.79 
P28482 mitogen-activated protein kinase 1  0.37 0.63 
P59665 Neutrophil defensin 1  0.37 0.35 
P62979 Ubiquitin-40S ribosomal protein S27a  0.37 0.60 
Q9H4M9 EH domain-containing protein 1  0.38 0.37 
O60506 Heterogeneous nuclear ribonucleoprotein Q  0.38 0.33 
Q09666-1 Neuroblast differentiation-associated protein AHNAK  0.38 0.31 
P14618 Pyruvate kinase PKM  0.39 0.78 
P06576 ATP synthase subunit beta, mitochondrial  0.40 0.89 
P28070 Proteasome subunit beta type-4  0.40 0.90 
Q9NR31 GTP-binding protein SAR1a  0.40 1.10 
P53634-1 Dipeptidyl peptidase 1  0.40 0.20 
P02656 Apolipoprotein C-III  0.41 0.18 
P24534 Elongation factor 1-beta  0.41 0.51 
P60709 Actin, cytoplasmic 1  0.41 0.66 






O00160 Unconventional myosin-If  0.45 0.40 
P52790 Hexokinase-3  0.46 0.68 
P52272 Heterogeneous nuclear ribonucleoprotein M  0.48 0.32 
Q15102 Platelet-activating factor acetylhydrolase IB subunit gamma  0.49 0.64 
P09651-1 Heterogeneous nuclear ribonucleoprotein A1  0.49 0.94 
P68366 Tubulin alpha-4A chain  0.51 0.39 
P09382 Galectin-1  0.52 0.66 
P20700 Lamin-B1  0.52 0.43 
P50225 Sulfotransferase 1A1  0.53 0.52 
P0C0S5 Histone H2A.Z  0.53 0.37 
P68032 Actin, alpha cardiac muscle 1  0.54 0.70 
P49913 cathelicidin antimicrobial peptide  0.55 0.75 
Q5QNW6-2 Isoform 2 of Histone H2B type 2-F  0.56 0.16 
P43405-1 Tyrosine-protein kinase SYK  0.57 0.77 
P68371 Tubulin beta-4B chain  0.58 0.56 
P60660 Myosin light polypeptide 6  0.62 0.38 
P08246 Neutrophil elastase  0.63 0.38 
P68363 Tubulin alpha-1B chain  0.64 0.54 
P13010 X-ray repair cross-complementing protein 5  0.69 1.00 
P25705-1 ATP synthase subunit alpha, mitochondrial  0.69 0.69 
P35579-1 Myosin-9  0.70 0.37 
Q01469 Fatty acid-binding protein, epidermal  0.75 1.06 
Q13418 Integrin-linked protein kinase  0.77 0.62 






Q9H4B7 tubulin beta-1 chain  0.82 1.20 
P18124 60S ribosomal protein L7  0.87 0.50 
P08670 Vimentin  0.90 0.39 
P68431 Histone H3.1  0.93 0.34 





Appendix 8.4: Upregulated genes from periodontal patients compared to controls analysed by DAVID bioinformatics tool. Gene 
ontology is shown. 
Gene name GO Description Gene symbol combination detected in 
Calmodulin Calcium ion binding CALM1 (130C/128N) 
Patient 5/control 5 
Cystatin-B For cysteine protease inhibitor CSTB (130C/128N) 
Patient 5/control 5 
Cathepsin G For immune response CTSG (131/127N) 
Patient 2/control 2 
Eosinophil peroxidase Peroxidase activity  EPX (129N/126) 
Patient 1/control 1 
(131/127N) 
Patient 2/control 2 
Coagulation factor XIII 
A chain 
For blood coagulation F13A1 (131/127N) 
Patient 2/control 2 
Fibrinogen gamma 
chain 
For receptor binding, cell surface receptor 
signalling pathway 
FGG (130C/127C) 




For GTPase activity, protein binding GNB1 (129C/128C) 






Histone H2A.Z DNA binding H2AFZ (129N/126) 
Patient 1/control 1 
(131/127N) 
Patient 2/control 2 
Histone H3.3 DNA binding H3F3A (129N/126) 
Patient 1/control 1 
(131/127N) 
Patient 2/control 2 
Histone H1.5 DNA binding HIST1H1B (131/127N) 
Patient 2/control 2 
Histone H1.4 DNA binding HIST1H1E (131/127N) 
Patient 2/control 2 
Histone H2B type 1-O DNA binding HIST1H2BO (129N/126) 
Patient 1/control 1 
(131/127N) 
Patient 2/control 2 
(131/130N) 





Histone H4 At the intracellular nuclear chromosome HIST1H4A (131/127N) 
Patient 2/control 2 
Histone H2A type 2-A DNA binding  HIST2H2AA3 (129N/126) 
Patient 1/control 1 
(131/127N) 
Patient 2/control 2 
(131/130N) 





For chromatin binding, nucleic acid binding HMGN2 (131/127N) 
Patient 2/control 2 
Integrin beta-3 Receptor binding  ITGB3 (130C/127C) 





For glycolysis LDHB (130C/128N) 
Patient 5/control 5 
Platelet factor 4 Chemokine PF4 (129N/126) 
Patient 1/control 1 




Patient 5/patient 5 post 
treatment 
Platelet basic protein Chemokine PPBP (130C/127C) 




For GTPase activity, pyrophisphotase activity, 
For phagocytosis 
RAB27B (130C/127C) 
Patient 5/patient 5 post 
treatment 
(130C/128N) 
Patient 5/control 5 
Tubulin alpha-1B chain Nucleotide binding, Structural constituent of 
cytoskeleton 
TUBA1B (129N/126) 
Patient 1/control 1 
(131/127N) 
Patient 2/control 2 
Tubulin beta-4B chain Nucleotide binding, Structural constituent of 
cytoskeleton 
TUBB4B (129N/126) 






Appendix 8.5: Down regulated genes from periodontal patients compared to controls analysed by DAVID bioinformatics tool. Gene 
ontology is shown. 
Gene name GO Description Gene symbol combination detected in 
Annexin A1 Fatty acid metabolic process ANXA1 (129N/126) 




For immune system process BPI (130C/127C) 
Patient 5/patient 5 post 
treatment 
Calmodulin Calcium ion binding, calmodulin binding CALM1 (129N/126) 
Patient 1/control 1 
(131/127N) 
Patient 2/control 2 
(131/130N) 
Patient 2/ patient 2 post 
treatment 
Coagulation factor XIII A 
chain 
For cellular protein modification process F13A1 (130C/127C) 
Patient 5/patient 5 post 
treatment 
(129C/128C) 
Patient 3 /control 3 
(130C/128N) 
Patient 5/control 5 




Patient 5/control 5 
Histone H1.5 DNA binding HIST1H1B (130C/127C) 
Patient 5/patient 5 post 
treatment 
(130C/128N) 
Patient 5/control 5 
Histone H1.3 DNA binding HIST1H1D (130C/127C) 
Patient 5/patient 5 post 
treatment 
(129C/128C) 
Patient 3 /control 3 
(130C/128N) 
Patient 5/control 5 
Histone H1.4 DNA binding HIST1H1E (130C/127C) 
Patient 5/patient 5 post 
treatment 
(129C/128C) 
Patient 3 /control 3 
(130C/128N) 




Histone H2B type 1-O DNA binding HIST1H2BO (129C/128C) 
Patient 3 /control 3 
(130C/128N) 
Patient 5/control 5 
Histone H2A type 2-A DNA binding HIST2H2AA3 (130C/128N) 




Chromatin binding, nucleic acid binding HMGN2 (130C/128N) 
Patient 5/control 5 
Neutrophil gelatinase-
associated lipocalin 
For binding, isomerase activity LCN2 (130C/127C) 
Patient 5/patient 5 post 
treatment 
Lactotransferrin For binding LTF (130C/127C) 
Patient 5/patient 5 post 
treatment 
Platelet factor 4 Chemokine PF4 (129C/128C) 
Patient 3 /control 3 
Profilin-1 Actin binding PFN1 (129N/126) 
Patient 1/control 1 
(131/130N) 




For GTPase activity RAB3C (130C/128N) 
Patient 5/control 5 




Patient 1/control 1 
Protein S100-A8 Calcium ion binding S100A8 (130C/127C) 
Patient 5/patient 5 post 
treatment 
(131/130N) 
Patient 2/ patient 2 post 
treatment 
Protein S100-P Calcium ion binding S100P (129N/126) 
Patient 1/control 1 
Band 3 anion transport 
protein 
Transmembrane transporter activity SLC4A1 (129C/128C) 




Appendix 8.6: Abstract for British Society for Oral and Dental Research Conference, 
September 2015 (poster presentation) 
Title: Neutrophil cell glutathione changes in chemotaxis 
Introduction: Chronic periodontitis is an inflammatory disorder affecting the teeth, connective 
tissues and alveolar bone within the oral cavity. Neutrophils from periodontitis patients have 
decreased intracellular glutathione. Intracellular glutathione is essential for a number of 
homeostatic and cellular processes, including chemotaxis and is the main intracellular redox 
buffer.  
Objectives: To analyse the effect of alteration in glutathione levels on chemotactic behaviour 
of neutrophils 
Methods: Neutrophils were isolated from the peripheral blood of healthy volunteers. Real Time 
Glo was used as a viability assay to determine time course for neutrophil cells experiment. A 
Boyden type chamber was used to assess neutrophil chemotaxis with and without the pre-
incubation of glutathione depletion reagents: BSO, CDNB, BCNU. Chemoattractants used 
were FMLP and IL8. 
Results: CDNB, a deplete of glutathione through thioester conjugation, and BCNU, an inhibitor 
of glutathione reductase both altered neutrophil chemotaxis relative to control treated cells 
responding to both FMLP and IL8. However BSO, an inhibitor of rate limiting gamma-
glutathione cysteine synthetase, did not appear to have an effect.  
Conclusion: Alterations in chemotaxis and intracellular glutathione in periodontits patients are 
already known separately, this study may begin to help in our understanding the mechanism 
by which these two factors may be linked.  
Authors (First Name Initial Last Name): Nurul-Iman B.S, M. M. Grant 
Authors/Institutions: Dentistry, University of Birmingham, Birmingham, United Kingdom, 
Presenter: Nurul Iman  
Presenter (E-mail only): NIB455@bham.ac.uk 
Preferred presentation type: Poster 




Appendix 8.7: Abstract for Society for Redox Biology and Medicine Conference, 
November 2016 
The innate immune system is the first line of defence against invading microorganisms, and 
neutrophils are the most abundant leukocyte and the first to arrive at a site of infection. 
Periodontitis is a highly prevalent chronic non- communicable disease and in its most severe 
form is the sixth most prevalent human disease, affecting 11.2% of the world’s population. It 
has been associated various systemic diseases and conditions, such as diabetes. In periodontitis 
it is known that neutrophils have aberrant chemotactic behaviour (Roberts et al PMID: 
25360483), as well as increased reactive oxygen species production whilst resting (hyper 
activity) and when stimulated (hyper-reactivity) (Matthews et al PMID: 17223966). This 
combination may lead to enhanced tissue damage in the periodontal lesion. We have also 
shown that levels of glutathione in the periodontal lesion (Grant et al PMID: 19968740) and 
within circulating peripheral neutrophils (Dias et al PMID: 23826097) are decreased, 
demonstrating a loss in redox buffering and capacity. Previous studies have shown the 
importance of glutathionylation of actin in chemotactic movement of neutrophils (Sakai et al 
2012 PMID: 23159440). With the long term aim to examine how diminished glutathione levels 
in periodontitis effect chemotaxis, we examined the effect of glutathione modulation by 
buthioninesulfoximine (BSO), N-acetylcysteine (NAC), bis-chloroethylnitrosourea (BCNU) 
and 1-chloro-2,4-dinitrobenzene (CDNB) on neutrophil intracellular glutathione, viability and 
chemotaxis towards interleukin 8 and N-formylmethionyl-leucyl-phenylalanine (fMLP). BSO, 
BCNU and CDNB decreased the chemotaxis and glutathione levels in peripheral neutrophils 
isolated from healthy donors. Future studies will translate this work into a periodontal cohort 
and examine protein glutathionylation by mass spectrometry. 
 
 
 
 
 
 
 
 
 
 
 
 
